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Abstract
Clinical trials play an important role in advancing therapeutic and
preventive care with many current modalities resulting from prior
research.

While prior research has described barriers to participation

in therapeutic clinical trials, much less in known about barriers related
to participation in trials aimed at prevention, prostate cancer
prevention in particular. Physicians have been shown to play a critical
role in access to trials; however, less is known about the individual
and structural factors that influence their participation in prostate
cancer prevention trials. This research provides rich ethnographic
detail within the context of an ongoing trial. Research participants
included physician/investigators who were either directly (serving as a
co-investigator) or peripherally (referring patients for participation)
involved in prostate cancer prevention intervention clinical trial
(PCPICT), as well as those who were considered for participation but
declined. Methods included open ended semi-structured interviews,
participant-observation and a survey. Participants were recruited via
direct inquiry, email and/or letter regarding participation. The results
of this study show that individual and structural factors intersect,
viii

influencing both the willingness and ability of physician/investigators
to participate or refer patients for participation in a prostate cancer
prevention intervention clinical trial. Individual factors such as
explanatory views on prevention, notions of risk and uncertainty,
shared decision-making and duality of roles appear to have a greater
influence on the willingness of physicians to participate while structural
factors such as staffing, other resources and time are more influential
in regards to the ability to participate.

This research served as a

critical first step towards providing an in-depth understanding of the
individual and structural factors that influence a physician’s
participation in this type of trial. It builds from prior work where a
better understanding of barriers and identification of successful
strategies to overcome them was a noted void. The researcher
identifies areas where additional research would be beneficial and
provides applied recommendations for those considering the design of
future cancer prevention intervention projects.

ix

Chapter One:
Introduction
While completing my doctoral studies I was uniquely situated,
also working as a project manager for a multi-site, cancer prevention
intervention trial in the biomedical arena. During this time I often felt
I was in a very liminal space, navigating the “rules” and languages of
two very disparate worlds, wondering if they would ever intersect. My
role as project manager had increased my awareness of the challenges
inherent in the design, implementation and daily work of conducting a
prostate cancer prevention trial. Simultaneously, my doctoral studies
increased my skillset, providing a new perspective and toolkit with
which to examine the world. My aim with this dissertation research
was to show how the two worlds could indeed merge, with each
informing the other.
This chapter will introduce the challenge of recruitment to cancer
prevention clinical trials. The rationale for conducting this study will
be described and the study objectives explained. The research
questions and hypotheses will be introduced. The significance of the
study and benefits of an anthropological perspective will then be
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discussed. Finally the theoretical frame will be presented and an
overview of the dissertation will be provided.
Statement of the Problem
Clinical trials are widely recognized in the medical and research
communities for their role in advancing both therapeutic and
preventative care (Baquet et al. 2009; Orozco 2009; Yates 2003) with
many current modalities resulting from prior research.
Chemoprevention, or the use of drugs, vitamins, or other agents to
reduce the risk of, or delay the development or recurrence of cancer
(National Cancer Institute 2011) is suggested as one of several means
to reduce cancer incidence (Ford 2003).

Enrolling an adequate

number of patients, within a reasonable time period is particularly
critical in chemoprevention trials (Sharp and Pentz 2004).
Unfortunately, poor enrollment is common with less than twenty
percent of subjects identified as eligible for cancer prevention trials
actually recruited (Chlebowski et al. 2010; Kumar et al. 2011; Ruffin
IV and Baron 2000).
Barriers to participation in therapeutic clinical trials have been
well described (Hall et al. 2010); however, it is suggested that unique
barriers present an ongoing challenge in the recruitment of healthy
individuals as well as cancer survivors (Ford et al. 2009; Frayne 2001;
Ott 2006) and overall less is known about the influences of
2

participation in clinical trials aimed at prevention. The identification of
procedural, structural and infrastructural barriers is seen as critically
important in order to evaluate the increasing number of new
chemoprevention agents (Dilts and Sandler 2006). Referring
physicians play a major role in accessibility to trials (Ford 2003,
Kumar et al. 2011, Miller et al. 1998) and genuine commitment and
trust have been identified as two critical components to a successful
primary care/investigator relationship (Frayne 2001); however, less
is known about the individual and structural factors that
influence a referring physician’s participation in cancer
prevention trials compared to therapeutic trials.
Significant challenges in recruitment to cancer prevention
intervention trials exist. The need for studies of physicians’ attitudes
and behaviors regarding clinical trial participation was identified by
Swanson and Ward (1995) and though researchers responded with
studies examining attitudes related to therapeutic clinical trial
participation (Melisko et al. 2005), there remains a paucity of data
specifically related to cancer prevention trials.

Considering the

important role of the physician in recruitment to prevention trials
(Miller et al. 1998) and the status of health care professionals as
gatekeepers for clinical trial participation (Probstfield and Frye 2011),
an exploration of the structural and individual factors influencing their
3

involvement (or lack thereof) in cancer prevention intervention clinical
trials is warranted.
Specifically related to cancer prevention clinical trials, Frayne et
al. (2001) reported three areas of “physician-level” concerns including:
1) the dual role played as advocate for patient and research; 2) the
threat to maintenance of the primary care relationship; and 3) the
general philosophy of the physician towards prevention. Trial
enrollment is likely the product of interactions between physicians’
beliefs and values, support from medical leadership (Somkin et al.
2005), access and other factors which have yet to be reported or
explored. It is also likely that just as in the primary care setting,
competing demands are a factor in recruitment to cancer prevention
intervention clinical trials as well. Nguyen et al. (2005) suggested that
the identification of barriers that prevent physicians from discussing
research participation with their patients is a potential way to improve
enrollment. Tailoring approaches to a specific practice area (academic
vs. nonacademic) (Meropol et al. 2007) and the use of health
maintenance organizations or managed care groups have been
suggested as a ways to optimize participation while utilizing
infrastructure that is already in place (Ruffin IV and Baron 2000).
Similar to the essential nature of physician involvement in the
provision of preventive services, committed physician involvement has
4

been shown to be critical for successful recruitment to an ongoing
prostate cancer chemoprevention trial (Kumar et al. 2011).
Additionally, the researchers recommended a more in-depth
exploration of infrastructural level challenges, which may vary across
research sites, in order to find solutions to current challenges in
recruitment to this type of trial. Effective strategies to improve
participation must consider the multiple competing demands
(individual and structural factors) faced by physicians, as well as
variants in practice area in order to succeed.
Rationale and Significance
This research served as a critical first step towards providing an
in-depth understanding of the individual and structural factors that
influence physician’s participation in a prostate cancer prevention
intervention clinical trial (PCPICT). This timely work provides
ethnographic detail within the context of an ongoing PCPICT. The
results can be used to inform the design of future cancer prevention
intervention trials which require multi-site participants reflective of our
diverse population.
Study Objective/Research Questions and Hypotheses
I was interested in: a) exploring the factors that influence a
physician’s participation in a PCPICT and b) identifying ways to
improve collaboration between researchers and physicians, thus
5

improving the success of future projects. This study was designed to
explore and document the individual provider level factors (such as
notions of risk and shared decision-making, explanatory views on
prevention, and duality of roles) and the structural (organizational and
infrastructural) considerations that influence a physician/investigator’s
participation in a PCPICT. Additionally, it included a consideration of
how practice area (specialty centers, academic centers, Veteran’s (VA)
medical centers, community offices) impacts the feasibility of
participating in such a trial.

The guiding research questions for this

study were:
1) What individual factors influence a physician’s participation in
a PCPICT?
2) What structural factors influence a physician’s participation in
a PCPICT?
3) How do these factors vary depending on the practice site/area
(specialty centers, academic centers, Veteran’s (VA) medical
centers, community offices)?
The primary hypothesis was that both individual and structural
factors intersect and influence both the willingness and the ability of
the physician/investigator to participate or refer patients for
participation in a PCPICT. Figure 1 shows the proposed model that
undergirds the hypothesis tested in this study. Additionally, it was
hypothesized that these factors will vary based on practice site/area

6

and the interactions will both facilitate and deter participation in these
types of trials.

Figure 1. Proposed Model: Individual and structural factors influencing
physician participation in cancer prevention, intervention clinical trials



Dark blue boxes represent individual factors believed to impact the
physician’s participation in cancer prevention intervention clinical trials
Light blue boxes represent structural factors believed to impact the
physician’s participation in cancer prevention intervention clinical trials

Benefits of an Anthropological Perspective
The absence of anthropological contributions in this specific area
suggested a void where further investigation to explore the role of
physician/investigators as gatekeeper in a prostate cancer prevention
intervention trial was warranted. The holistic anthropological
7

perspective can provide a deeper understanding of the issues, linking
disparate views that might not otherwise be seen as influential or
interrelated. Similarly, the proposed model attempts to capture these
disparate factors of influence within this particular context. Lambert
(2002) suggested that an anthropological perspective may facilitate an
examination of the boundaries of a problem and provide useful insights
to health research, particularly when considering the social and
cultural dimensions of health, ill health and medicine. Additionally,
since the knowledge and practice of “experts” is seen as locally
variable, anthropologists in the healthcare setting can offer valuable
insight to encompass the views, ideas and practices of not just lay
participants but of professionals as well (Lambert 2002).
Ethnography, the hallmark methodology used by
anthropologists, engages with others and their practices to better
understand their local worlds (Kleinman 2006). Ethnographic research
provides a rich, textured description of a phenomenon, providing
insight into the views and experiences of a specific group (Abadie
2010). These methods are useful to tease out the data and
information that contributes to deep knowledge and better awareness
within a certain context. Anthropologists have previously used
ethnography to explore community attitudes toward cancer and the
impact of these attitudes on the implementation of messages from the
8

scientific community that were aimed at the adoption of lifestyle
changes thought to reduce cancer risk. The research revealed that
community members’ beliefs regarding cancer prevention were quite
different from those presented by the scientific community and that
community resistance to health messages were purposeful acts in
response to a loss of control in power and social class (Balshem 1991).
In other work, Gregg and Curry (1994) examined cultural
models for breast and cervical cancer among low-income AfricanAmerican women and explored how these models may impact
screening behavior. Their findings suggested that cancer models held
by the patients and physicians differed substantially in regards to
etiology, methods of cancer screening and prevention, as well as
treatments for cancer and the authors suggested that mutual
understanding between physicians and their patients is needed to
improve screening rates (Gregg and Curry 1994).

Though this work

was completed some time ago it highlights the importance of mutual
understanding between physicians and patients in regards to health
care decision-making. Similarly, this reciprocal understanding may be
relevant and influential when considering participation in a PCPICT.
Specifically in regards to the crisis in clinical trials, Hales et al.
(2001) noted that a better understanding of the problem is needed for
resolution of the current challenges. Similar to work by other
9

anthropologists, the use of a novel perspective to address a previously
identified challenge was seen as beneficial in the design of this project.
It was my hope that ethnography would add a new perspective not
previously considered and provide a rich, textured description of the
local context (Abadie 2010) surrounding a PCPICT, as well as insight
into the views and experiences of the physician/investigators that are
directly or are peripherally involved.
When considered as a vantage point to examine the current
challenges of recruitment to clinical trials in general and cancer
prevention intervention trials in particular, anthropology offered a
valuable lens through which to better understand the complex and
interrelated phenomena that influence this issue, particularly focusing
on the critical role of physician/investigator. By using observation,
participation and interviews, ethnography is useful to expand a model
and discover associations between domains or variables (Schensul et
al. 1999). Hemmings (2005) recognized the importance of the
presence of medical anthropology within medicine, yet following an
extensive review of the influence of anthropology on medicine
spanning two decades, he concluded that unfortunately, medical
anthropology continues to make little impact. Further clarifying, he
noted that while medical anthropology has indeed helped to identify
and articulate the problems of medicine, it has failed to provide
10

realistic solutions (Hemmings 2005). As such, with this research an
anthropological perspective allowed for broad examination with an
applied, solutions-oriented focus.
Theoretical Frame
Theory helps to explain, predict and interpret phenomena of
interest and is important to understand potential links, confounding
variables and the context in which a phenomenon does or does not
occur (Bradley 2007).

Thus, theory provides a framework, guiding

the questions asked and ultimately answered in a research study
(Bradley 2007; Creswell and Plano Clark 2011). The process for
developing theory is diverse and depends on several factors including
the topic of study, its context and the experience of the researcher
(Bradley 2007). Schensul et al. (1999) stated that formative theory
includes an issue or problem, in addition to some ideas about the
components of the physical, social or institutional environment that
may be associated with a problem. It may originate from preexisting
information about the research community or topic, a review of the
related literature, the prior experience of the researcher, or the
experience of a local community. Thus, formative theory serves as a
guide for the research and provides the opportunity to generate
hypotheses from which observations can then be compared (Schensul
et al. 1999).

A theoretically informed focus helps ethnographers to
11

concentrate their fieldwork and to organize the information into a
logical framework.
While designing this project, various theories and constructs
were considered for their overall appropriateness in relation to the
research goals.

This included consideration of theories traditionally

used within the field of anthropology as well as those utilized by
researchers in other fields such as such as Political Economy of Health,
Critical Medical Anthropology, the Ethnomedical Model, Explanatory
Models, the Cultural theory of Risk, Notions of Risk, Clinical interaction
and decision-making, Cancer Fatalism, Duality of Roles and the Theory
of Competing Demands. Those theories and constructs that were
determined to be most relevant to this project are expounded upon in
Chapter Two, the Review of Literature within the context of the various
research objectives.

The overall intent was to let theory guide the

methods chosen to answer the research questions, in order to
contribute to a more in-depth understanding and provide applicable
recommendations.
Physician involvement is thought to be essential for the provision
of many services with the physician serving a critical link in the chain
of events leading to the delivery of preventative services including
cancer screening. The theory of competing demands has been used to
recognize the multiplicity of factors that compete with the provision of
12

preventative services and influence their delivery by physicians in the
primary care setting (Jaen et al. 1994). It is suggested that the
primary components (physician, patient, and practice environment)
are further influenced by factors such as attitudes, knowledge,
expectations, practice organization and alternative demands. As a
result, the multiple demands of the medical encounter “compete” with
those related to prevention during the limited time available. The end
result is that some but not all agenda issues may receive attention at
the specific visit (Jaen et al. 1994) with preventative services often
peripheral to other perceived priorities.
Nutting et al. (2001) also used this model to examine factors
influencing physician recommendation for screening mammography.
Interestingly, their findings suggest that the characteristics of the
physicians, patients and the office visit were equally important in
impacting the frequency of recommendation for mammography.
Additionally, the authors suggested that effective strategies to improve
the delivery of preventative services must go beyond physician
education and performance feedback to consider the multiple
competing demands faced by physicians and patients in order to
prioritize services (Nutting et al. 2001). Prior to data collection, it was
proposed that there is likely similar competition in the urologist’s
office, when a patient receives the results of a prostate biopsy that
13

ultimately influences the likelihood that the recommendation is made
to participate in a cancer prevention, intervention clinical trial.
In other related research, a case study by Joseph and Dohan
(2009) was initiated with the expectation that multiple, competing
demands vied for physicians attention and resources specifically as it
relates to clinical trials recruitment. The authors proposed that some
of these demands would encourage the recruitment of diverse patients
while others would distract clinical investigators from these goals.
Their findings suggested that enrollment in therapeutic cancer clinical
trials was shaped by both biomedical and social factors (Joseph and
Dohan 2009). Though focused more specifically on an examination of
diversity in recruitment to treatment trials, there are certainly
important findings that could be applied to a study examining
individual and structural factors influencing a physician’s involvement
in prostate cancer prevention, intervention clinical trial.
Biomedicine, broadly speaking, is a sociocultural system, with its
own unique values, premises, and problems (Hahn and Kleinman
1983). As a part of the biomedical system, the realm of clinical trials
is also a sociocultural system; and the specific arena of cancer
prevention, intervention clinical trials yet another. The concept of
competing demands was a logical and comprehensive starting point for
this project; however, on its own the adequacy to examine all of the
14

potential sociocultural factors of influence at both the individual and
structural levels was questionable. I also felt that it was likely that no
single theoretical frame was adequate in isolation to fully explore the
research questions. For this reason, an adaptation of the theory of
competing demands that included a theoretically-grounded exploration
of individual provider level factors (such as notions of risk and shared
decision-making, explanatory views on prevention, and duality of
roles) as well as structural level factors (such as practice area and
organizational/infrastructural considerations); informed by the
constant comparison of the similarities and differences of concepts that
emerged in the field as suggested by Glaser and Strauss (1967), was
proposed for this project. As previously noted, the theories and
constructs that were thought to be influential and determined to be
the most relevant are expounded upon in Chapter Two, the Review of
Literature within the context of the various research objectives. Within
this comprehensive frame, I was able to draw upon both micro and
macro level factors to provide a more holistic understanding of the
multitude of variables influencing the physician’s participation in a
PCPICT.
Organization of the Dissertation
This research examines the intersection of competing demands,
the individual and structural factors that influence both the willingness
15

and ability of physician/investigators to participate or refer patients for
participation in a PCPICT.

It extends the theory of competing

demands into the anthropological literature and examines its relevance
to a prostate cancer prevention intervention clinical trial. With the
results, I was able to identify key findings useful for funding agencies
and those designing prevention trials in the future. I also discuss
opportunities and directions for future research.
The dissertation is divided into five chapters.
provides a review of relevant literature.

Chapter Two

Chapter Three provides a

brief overview of the setting of the current study in the context of the
currently evolving health care arena in addition to the methods for
data collection and analysis and a discussion of ethical considerations.
Chapter Four contains the results of the dissertation reported
according to the study objectives and research questions noted
previously. Chapter Five is the discussion of the findings and is
similarly organized by the study objectives and research questions. It
also includes a discussion of the contributions to theory, applied
anthropology and biomedicine (with application to future trials
discussed); a consideration of limitations, reflections on familiarity in
the research setting, a presentation of opportunities and discussion of
dissemination and future directions, in addition to a conclusion.

16

Chapter Two:
Literature Review
Introduction
Prevention trials with a specific disease focus, such as cancer,
may aim to prevent disease initially (primary prevention) or to prevent
recurrence (secondary prevention) (National Institutes of Health 2011)
and have been suggested as a sound medical strategy, particularly
when resources are limited (Sharp and Pentz 2004).

A growing body

of research supports the reduction of cancer incidence through primary
prevention (via lifestyle factors), early detection, and interventions
with chemoprevention and vaccines (Ford 2003).

Advances in the

understanding of cancer biology and pathogenesis have identified
molecular pathways that may serve as indicators for cancer risk,
thereby providing the opportunity for prevention and early detection
trials to play an important role in reducing the burden of this disease
(Cox and McGarry 2003; Yates 2003). Well-designed cancer
prevention studies are needed to validate molecular endpoints and
their role in cancer prevention (Hall et al. 2010).
Adequate recruitment is essential for the completion of a clinical
trial, whether preventative or therapeutic in nature (Lovato et al.
17

1997; Probstfield and Frye 2011). Poor accrual limits not only the
advancement of science but the generalizability of cancer research
(Ka'ano'i et al. 2004) and the societal benefit resulting from clinical
trials is currently jeopardized due to declines in timely patient
recruitment in all patient groups (Murthy et al. 2004; Probstfield and
Frye 2011). Different from therapeutic trials, where treatment is for a
disease or other adverse conditions already present, cancer prevention
trials generally seek to enroll healthy, disease-free, asymptomatic
individuals who may be at an increased risk for cancer due to a
personal or family history of cancer or a pre-malignant condition (Hall
et al. 2010; Hudmon et al. 1999). Additionally, the benefits from a
prevention trial may be less readily evident than those of a therapeutic
trial due to the desired outcome of disease prevention (Hudmon
1996). When the population is considered to be healthy, there is also
an increased challenge and ethical responsibility to keep the
participants healthy (Sharp and Pentz 2004). Despite the potential
benefit of a reduction in disease burden, this expansion of medical
research is not without its challenges (Lovato et al. 1997). Unique
barriers are thought to present ongoing challenges to the recruitment
of healthy individuals (Frayne 2001; Hall et al. 2010; Hudmon 1996;
Korde et al. 2009; Lovato et al. 1997; Meropol et al. 2007; Ott 2006;
Sample 2002; Tangrea 1997) and complex interactions between
18

participants, physicians, study designs and characteristics of the U.S.
healthcare system are all suggested as barriers to participation in
cancer prevention and control trials (Comis et al. 2000; Hudmon 1996;
Ruffin IV and Baron 2000; Sample 2002; Tangrea 1997).
Influence of Practice Area
Since most cancer prevention trials are aimed at the general
population, primary care physicians (PCPs) are considered by some to
be the best source of referral for participation in these trials.
However, Crosson et al. (2001) reported that PCPs prefer to defer
cancer treatment to an oncologist and therefore may not discuss
clinical trials opportunities with their patients, even if they are related
to cancer prevention. Hall et al. (2010) found that oncologists were
interested in referring patients to prevention trials, but did not have
access to eligible (i.e., healthy) patients. These findings suggest that
at least some of the variance in referral and participation rates may be
attributed to the area of practice (generalist or specialist).
Meropol et al. (2007) noted that tailoring approaches to a specific
practice area (academic vs. nonacademic) may help to optimize
participation. It is also noted that logistical barriers must be
addressed and infrastructural support improved in order to increase
participation and enrollment (Ford 2008; Ka'ano'i et al. 2004). These

19

notions required further exploration especially as they may relate to
participation in a PCPICT.
Prevention trials also present access issues at the individual as
well as institutional level, further contributing to the challenge of
recruiting at risk populations (Korde et al. 2009).

Clinical research

opportunities are frequently associated with academic centers as
opposed to community and other medical institutions and the
opportunity to participate may not be a reality for all.

Research done

primarily in university or teaching centers may result in unintended
subject bias due to the population seeking care there (Carbone et al.
2005) and increased availability within the community setting has
been encouraged (Baquet et al. 2009). It is suggested that differential
access to research opportunities due to structural or other barriers
may disparately impact certain populations (Azevedo and Payne 2006;
Murthy et al. 2004). Since the standard of care in many medical
treatment regimens is the direct result of clinical research, this has
implications for many conditions, including across the spectrum of
cancer care from screening and prevention through diagnosis and
treatment to survivorship.
Sharp and Pentz (2004) noted that a study must be
representative of the population that the intervention would be applied
to if proven efficacious. Thus, equitable access to trials is
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important in order to reduce sample selection bias. This is a clear
challenge when most recruitment occurs at academic medical centers
and not within the community. Meropol et al. (2007) recommended
increased accessibility within the community setting as one solution.
This would likely be beneficial for a PCPICT as well, since potential
healthy subjects are less likely to receive care at a specialty center.
By improving accessibility within the community (via collaborations
with physicians in private practice) such projects would be available to
a greater number of individuals including those that are not receiving
their care at academic or specialty centers. Hales et al. (2001) also
reported that it may be less disruptive to enroll patients at their usual
site of healthcare delivery then to refer them elsewhere. The literature
from these sections informed the elaboration of the first study
objective:
Consider how practice area (specialty centers, academic centers,
Veteran’s (VA) medical centers, community offices) impacts the
feasibility of participating in a PCPICT.
Structural Considerations
Organizational support and other health care system related
factors are noted as predictors of enrollment as well as barriers to
participation in treatment trials, with infrastructural support (including
support staff) noted as critical (Roberts 2002; Ruffin IV and Baron
2000; Somkin et al. 2005). The development of systems that ease the
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participation of the healthcare provider are suggested as opportunities
to improve enrollment (Ford 2008). Infrastructure, realignment of
incentives and compensation, and improved patient and physician
navigation systems have all been suggested by surgeons as ways to
improve their engagement in clinical trials (Al Refaie 2011). Though
this research was with treatment trials, these factors likely affect
enrollment for a PCPICT and were worthy of further examination.
Little research has been done to explore barriers in nonacademic
environments (Nguyen et al. 2005); however, these settings have the
potential to recruit a larger and more representative sample (Somkin
et al. 2005) and the exploration of the structural dimensions that may
impact the provision of trials in such settings has been identified as a
research need (Baquet et al. 2008). Increased access to clinical trials
via collaborations between non-academic, community settings and
academic centers is suggested as a way to improve physician and
health provider awareness about available trials and presumably a way
to impact participation (Baquet et al. 2008; Colon-Otero et al. 2008).
Ford et al. (2003) suggested that research results will come faster if
clinicians and researchers can collaborate and promote studies.
Frayne et al. (2001) suggested that recruitment to prevention trials
may require a combined effort between oncology researchers,
oncologists and primary care providers, and while the number of
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cancer-prevention trials has increased, very little research has been
done to explore how investigators and primary care physicians may
coordinate efforts to recruit as well as retain subjects. Additionally,
Ruffin IV and Baron (2000) recommended further research to not only
better understand barriers unique to prevention trials but to identify
successful strategies to overcome them.

The literature in these

sections informed the elaboration of the second study objective:
Explore and document structural (organizational and infrastructural)
considerations that influence participation in a PCPICT (with a
comparison of factors across types of sites).
Individual Considerations
Notions of risk/shared decision-making.
Risk is characterized by various disciplines in diverse ways, with
anthropologists traditionally viewing it as a cultural phenomenon
(Althaus 2005). Anthropologists Douglas and Wildavsky (1982)
consider risk perception to be beliefs, attitudes, judgments and
feelings as well as the socio-cultural disposition that people adapt
towards both hazards and their benefits. The significance for this
project is that in the context of health-related risks, views about
expertise, scientific integrity, professional reliability and integrity and
the credibility of health-related messages are likely to be influenced by
the context in which judgments are made (Tansey 1999). While risk
may have varied meanings to different groups, all risk must be
23

understood within the larger social, cultural and economic context that
it occurs (Douglas and Wildavsky 1982).
Hunt et al. (2006) reported that risk and “risk status” are
complex notions that have multiple meanings and are understood
differently by clinicians and patients. Their research highlighted the
important (and often neglected) differences between epidemiological
(the statistical associations within a population), clinical (the
probability of the occurrence of a particular disease or outcome for an
individual) and lay (signifying current or future illness) notions of risk
and how these important differences may be ignored or treated as
equivalent when they in fact are not (Hunt et al. 2006). Clinicians
often discuss risk in clinically meaningful terms while patients must
translate risk into terms that are personally meaningful and applicable
to their unique circumstance. The authors explore how notions of risk
impact patient’s decisions about prenatal genetic testing and suggest
that failure to acknowledge the varied and often contrasting meanings
of risk may impact communication and the ability of patients to make
autonomous and informed choices about their care (Hunt et al. 2006).
Though not directly related, this research has the potential to
inform when applied to a different context- the role of physicians in
cancer prevention, intervention clinical trials. A consideration of the
various meanings of risk and how they may be used by clinicians and
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patients is important when examining the individual factors influencing
a physician’s recommendation related to participation in a PCPICT.

As

observed by Hunt et al. (2006), risk may have multiple meanings
which influence the evaluation of what is at stake as well as treatment
options, and this may be an individual factor of influence when a
patient has an abnormal yet non-cancerous biopsy result, ultimately
influencing the likelihood that participation in a PCPICT is offered by
the physician. Additionally, Hunt et al. (2005) found that when
clinicians and patients have disparate starting points related to a
perceived problem this greatly influences the options considered in
regards to prevention or control and a shared decision making
approach is recommended to arrive at the ideal decision for each
individual situation. Since physicians are often recognized as a trusted
source of health information (Crosson et al. 2001) and their input is
frequently a key consideration in patient healthcare decision making
(Roberts 2002), a better understanding of notions of risk and risk
status and how this impacts physician recommendations and decision
making for their patients was thought to be potentially relevant in
regards to the decision to participate or refer to a PCPICT and further
exploration was warranted. Attention to the varied meanings of risk
may help both physicians and patients make truly informed decisions
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about managing individual risk, specifically as it pertains to prostate
cancer prevention and the opportunity to participate in a PCPICT.
Explanatory views on prevention.
Prior research has explored physician’s attitudes to the delivery
of preventative interventions with a wide range of variance in
importance seen, depending on the screening measure noted (cancer
screening vs. blood pressure control) (Cornuz et al. 2000). This may
have direct implications for interventions aimed at cancer prevention
as well.

Tangrea (1997) noted that physicians often play a critical

role in deciding if a patient should enter into a trial and since they play
an important role in the delivery of preventative services, it is possible
that the gatekeeper role extends beyond preventative interventions to
providing information about PCPICTs as well.
Interestingly, Hall et al. (2010) reported that the majority of
oncologists (79.4%) were “not at all” or “a little” interested in offering
cancer prevention trials to their patients, noting that medical training
was focused on treatment of active disease and reducing its further
burden, making it challenging to incorporate prevention trials into their
practice. Chavez et al. (1995) noted the importance of including
physicians in the analysis of the social and cultural construction of
biomedical disease concepts since along with patients; they are
considered actors in the ethnomedical belief system warranting an
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analysis of their beliefs. The culture of biomedicine also determines
how physicians make decisions within a certain context. For the
purpose of this project and context, a consideration of the physician’s
social and cultural construction of the concept of disease (cancer)
prevention was thought to be important and further investigation of
these concepts within the specific context of a PCPICT was included.
Duality of roles.
It is suggested that the varied and separate roles of
physician/clinician and investigator may contribute to conflict related
to the ultimate goals and populations targeted (Frayne 2001; Hales et
al. 2001; Orozco 2009) and may be particularly salient in regards to
cancer prevention intervention trials. Ka'ano'i et al. (2004) identified
interference with the doctor/patient relationship, as well as conflict
between the roles of clinician and research advocate as physicianrelated barriers to participation in cancer prevention clinical trials. The
literature in these sections informed the elaboration of the third study
objective:
Explore and document individual provider level factors (such as
notions of risk and shared decision-making, explanatory views
on prevention, and duality of roles) that influence participation in
a cancer prevention intervention clinical trial.
The anthropological voice has been present in discussions and
research in the area of cancer as well as that of clinical trials. The
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literature reviewed for the initial stages of this project identified gaps
in the research to date, particularly in regards to PCPICTs. These
gaps, in addition to the lived experience that will be further detailed in
the next chapter provided the impetus and direction for this research,
to examine if prior findings resonated beyond those groups previously
studied. Specifically, the limited anthropological contributions in this
area provided the groundwork for an exploration of the role of
physicians as gatekeeper and how various individual and structural
factors intersect creating unique challenges for those investigators
conducting PCPICTs.
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Chapter Three:
Methods
Setting the Stage
There are several factors believed to be important to set the
stage for this research project. While pursuing my doctorate, I also
served as a co-investigator and project manager working at a National
Cancer Institute (NCI) Comprehensive Cancer Center in Tampa, FL.
Observations and challenges noted throughout the daily participation
in this work were in large part, the impetus for the design of this
dissertation research. More specifically, after appropriate channels for
institutional approval were navigated, this project was considered a
supplement or ancillary project to a currently ongoing prostate cancer
chemoprevention clinical trial, Phase II, Randomized, Double-blind,
Multi-centered Study of Polyphenon E in Men with High-grade Prostatic
Intraepithelial Neoplasia (HGPIN) and Atypical Small Acinar
Proliferation (ASAP) (IRB 105730). As such, resources, including
access to the faculty and research sites participating in the parent
study were available and helped to successfully facilitate the
completion of this project. Funding for the time and travel to complete
the data collection also allowed for completion without the need to
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secure additional financial support.

My experience conducting

research in a familiar setting will be more fully discussed in Chapter
Five.
The sample chosen for this study was physician/investigators
who had been either directly (serving as a co-investigator) or
peripherally (referring patients for participation) involved in the
previously mentioned prostate cancer chemoprevention clinical trial, as
well as those who have been considered for participation but declined.
By considering the views of those that had been directly or
peripherally involved (participants) as well as those that had not (nonparticipants), a better and more comprehensive understanding of the
factors influencing the actors within their local context was sought.
The research took place at current sites (n=8) of the prostate cancer
chemoprevention clinical trial in the states of Florida, Illinois,
Louisiana, and Minnesota. Participants in this PCPICT were thought to
present a unique and important vantage point from which to obtain
timely and relevant information about their current study participation
and access was considered to be strength in the design of this
research.
In order to reach a broader audience of physicians and elicit the
opinions and experience of participants as well as non-participants in
the PCPICT, I also sought to conduct research with urologists working
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in private practice in the greater Tampa Bay area. The potential key
personnel (n=21) from these sites had either inquired about
participating in the trial or been asked to participate or refer subjects
for participation but had not. The reasons for this were not well
understood or documented, stimulating the interest in obtaining the
views from this subset in addition to that of those who were currently
participating in the clinical trial. Documentation of the lived experience
via the methodologies that will be described more fully in the later part
of this chapter helped me to explore in-depth the factors that influence
the physician’s participation (or lack thereof) in the PCPICT, as well as
factors that may influence possible future participation.

It is the

sincere hope that the findings from this exploratory research will
directly contribute not only to the successful completion of the ongoing
PCPICT but will also inform the design, development and
implementation of future chemoprevention trials and with its applied
focus help to address the bigger challenge of recruitment to clinical
trials.
Also relevant to the results and discussion that will follow is the
mention of an historical event and ongoing controversy, mention of
both which was noted during data collection: 1) the passing of the
Patient Protection and Affordable Care Act (PPACA) in March 2010
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(Harrington 2010) and 2) the lack of uniformity in prostate cancer
screening guidelines in the United States (Gomella et al 2011).
PPACA.
The Patient Protection and Affordable Care Act (PPACA) is
considered the most significant social legislation passed in the United
States since Medicare and Medicaid were enacted in 1965 (Harrington
2010) with the goals of expanding coverage, controlling health care
costs, and improving the health care delivery system (Kaiser 2012).
Changes related to expanded health insurance coverage will become
effective in 2014 so the full effects have not been seen at the time of
this writing.

The market reform changes went into effect beginning in

2010, the possible impacts of which are already being noted by
participants in this project.
Prostate cancer screening.
Prostate cancer has been said to present a public health dilemma
with screening guidelines varying not only between countries but also
within various medical organizations within countries such as the
United States and a recent literature review by Gomella et al. (2011)
suggested that there is indeed no standard of care for prostate cancer
screening. As such, the lack of agreement in guidelines for prostate
cancer screening is an issue that remains contested among
practitioners in the field. This was noted during data collection and
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clearly has implications for future prostate cancer chemoprevention
studies since screening leads to the identification of those who may be
eligible for participation in such a trial.
As previously noted, with this research the investigator was
interested in: a) exploring the factors that influenced a physician’s
participation in a PCPICT and b) identifying ways to improve
collaboration between researchers and physicians, to improve the
success of future projects. The research questions guiding this study
were:
1) What individual factors influence a physician’s participation in
a PCPICT?
2) What structural factors influence a physician’s participation in
a PCPICT?
3) How do these factors vary depending on the practice site/area
(specialty centers, academic center, VA medical centers,
community offices)?
The primary hypothesis was that both individual factors such as
notions of risk and shared decision-making, explanatory views on
prevention, and duality of roles and structural factors such as
institutional support and requirements, resources, time and patient
pool intersect and influence both the willingness and the ability of the
physician/investigator to participate or refer patients for participation
in a PCPICT. Additionally, these factors were predicted to vary based
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on practice site/area with the interactions both facilitating and
deterring participation in these types of trials.
Based on the prior experience of the investigator and the
resources at hand, this project was designed with a mixed-methods
approach and was thought to have a good chance of success.

By

building on the relationships that were already established with
physician/investigators that were participating in the ongoing PCPICT,
the project was predicted to have legitimacy in the eyes of the key
informants, helping to facilitate their acceptance and willingness to
participate.

Since I was conducting research in a familiar setting, the

lack of consensus regarding possible objectivity and potential for role
confusion associated with familiarity in the research setting is noted
and this will be discussed in more detail as it specifically relates to this
project, in Chapter Five. Entrée into the private practice arena was
anticipated to be slightly more challenging; however, referral from a
respected group member was predicted to increase acceptance and
willingness to participate so that the data collection could be expanded
to include the voices of as many private practice/community urologist
offices as possible.
Research Design
Exploratory methods are particularly useful to examine domains
which may be important to the research question, yet not much is
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known. They are also useful to explore a phenomenon in greater
depth, and to measure its prevalence. An exploratory design can also
be useful to generalize the findings of a few individuals (Creswell and
Plano Clark 2011). Mixed methods research is ideal to combine the
exploration of qualitative methods and generalization of quantitative
methods. This merger of modes of inquiry can provide more evidence
and a more complete understanding than either method by itself with
the strengths of one method often offsetting the weaknesses of the
other (Creswell and Plano Clark 2011). Additionally, inductive inquiry
allows for the emergence of processes and explanations that occur
within the complex reality of life (Bradley 2007). Since this may not
necessarily be the way a researcher would expect or predict them,
inductive approaches are useful to examine provider perspectives that
have received little or no previous attention (Hay and Craddock Lee
2009), such as the examination of provider perspectives related to
participation in a PCPICT.

In order to meet the objectives, this

formative, exploratory study employed a mixed methods research
design using qualitative, ethnographic (open ended semi-structured
interviews and participant observation) and quantitative (survey)
methods to examine the individual and structural factors that influence
physician/investigators within the context of participation in a PCPICT.
Glaser and Strauss (1967) suggested that theory building is a
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process of constant comparison of the similarities and differences
between the concepts that emerge in the field. This approach
assumes that theory is “grounded” in data, not specified at the onset
of research and in its purest form there are no preconceived ideas of
importance (Brod et al. 2009). Though it was virtually impossible to
approach this project without any preconceived ideas of importance,
based on the experiences that led me to choose this topic as well as
the comprehensive review of the literature that was conducted, a
grounded theory approach was useful to consider. This methodology
has been suggested as a useful strategy to study the chronic illness
experience (Charmaz 1990) and has also been utilized by
anthropologists to study home birth (Cheyney 2008). Likewise it was
an important methodology utilized with this research as well.
While challenges to recruitment in clinical trials have been well
documented, the specific role of physicians in prevention intervention
clinical trials was yet to be examined using ethnographic methods prior
to this project and such methods can be especially useful to explore
the cultural and social patterns and meaning within a particular
context. Most notably, the hallmark iterative technique the constant
comparison of emerging concepts was very important as fieldwork
was conducted at the various sites for this project. The use of this
technique allowed for the analysis or emerging themes and categories
36

while in the field, at times shaping the subsequent data that was
collected and leading me in directions that were not anticipated, a
benefit of this technique also noted by Charmaz (1990). This
methodology was also useful when determining the point of saturation,
when no new themes emerged from data collection (Guest et al.
2006).
Additionally, this approach allowed for an in-depth exploration of
individual experiences and meanings related to cancer prevention and
participation in cancer prevention intervention clinical trials while also
paying attention to the larger and unavoidable structural factors that
impact the practice of medicine, particularly as they relate to
participation in a PCPICT.

A better understanding of the specific

“how’s” and “why’s” would not have been easily obtained through
other methodologies and was necessary to glean a better
understanding of all of the factors influencing this challenge and to
inform future research efforts. Crabtree et al. (1998) utilized similar
methodology (observation) to study the medical office as a whole
system and explore competing demands within the primary care
setting and noted physician and practice level constructs influencing
the delivery of preventive services in this context. Similarly, Jaen et
al. (2001) utilized mixed methods (observation, interviews and audits
of medical records) to examine compliance with smoking cessation
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practice guidelines in primary care practices. Their results
documented that a smoking cessation agenda was frequently
overridden by competing demands seen as a higher priority during the
time limited visit (Jaen et al. 2001). Guided by formative theory, this
novel project utilized anthropological methods to gain a greater
awareness within a very specific context and explore the ways that the
actors (physician investigators) are influenced by multiple competing
demands both at the individual and structural level. I also attempted
to seek solutions to overcome the current challenges faced in this very
specific context: recruitment to PCPICTs.
Sampling
Structured purposive sampling techniques were employed to
recruit physician/investigators who have been participants and nonparticipants in the ongoing prostate cancer chemoprevention clinical
trial. During the design of the study, a pool of thirty potentially
eligible participants was identified from the parent project, from
various practice areas, as Table 1 describes.
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Table 1. Subject Pool
Practice Area
A-specialty (cancer) center
B-specialty (cancer) center
C-specialty (cancer) center
D-VA medical center
E-VA medical center
F- VA medical center
G-Academic/teaching hospital
H-Academic/teaching hospital
I- Private practice (community)

# of Key informants
2
1
2
1
1
1
1
1
20

Eligibility Criteria
In order to participate, the following eligibility criteria were
required: (1) Physician/investigators were involved or considered for
participation in the prostate cancer chemoprevention clinical trial; (2)
English speaking (as this is was the common language spoken by
researcher and all participants); (3) Willing and able to provide
informed consent; (4) Willing and able to participate in the open ended
semi-structured interview and/or complete the survey.

Any potential

participant not meeting eligibility criteria one through four was
excluded from participating.
Subject Recruitment
Participants were recruited via direct inquiry, using the
recruitment letter /script found in Appendix A or B, depending upon
their participation status in the ongoing clinical trial. Current
participants (physicians/investigators) in the PCPICT were contacted
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regarding participation directly via email or letter from me. Physicians
that had inquired about participating in the trial or been asked to
participate or refer subjects but declined (non-participants) and were
not part of a local urological association were also contacted via letter
from me. Physicians that had inquired about participating in the trial
or been asked to participate or refer subjects but declined (nonparticipants) and were part of a local urological association were
contacted first via email from the respected group member/key
informant and then via letter from me.

Prior to scheduling any

interviews, all potential participants were contacted by me to confirm
interest, eligibility and willingness to participate and the details of the
meeting were arranged at that time. A written confirmation was
provided as well as a reminder phone call or email the day prior to the
scheduled meeting time.
Methods and Data Collection
Open ended semi-structured interviews.
Open ended semi-structured interviews are conducted to explore
the multiple angles surrounding an issue and to discover the shared
understandings of the participants (DiCicco-Bloom and Crabtree 2006)
with a goal of achieving thematic saturation of key content areas. As
power calculations and quantitative sample size estimations do not
apply in qualitative research, Guest et al. (2006) noted that
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nonprobabilistic, purposive sampling instead relies on saturation to
determine when enough data is obtained.

Krueger and Casey (2009)

suggested this is the point where you have heard a range of ideas and
are no longer obtaining new information. When using a mixed
methods approach, Creswell and Clark (2011) suggested the use of a
small purposeful sample in the first phase and a larger pool of different
participants in the second phase of research to help minimize bias.
In terms of specific sample size necessary to reach thematic
saturation, there is a great deal of variation reported in the literature.
Romney et al. (1986) reported that small samples, with as few as four
individuals, can sufficiently provide complete and accurate information
within a particular cultural context, if the participants possess a degree
of expertise and competence about the domain of inquiry.

A review

by Guest et al. (2006) showed that though numerous disciplines utilize
the term and encourage saturation of themes, few actually provided
guidelines for sample sizes using nonprobabilistic sampling. The point
at which the research findings have meaningful themes and useful
interpretations yet no new information or themes are observed usually
occurs within twelve interviews, but may occur with as few as six and
it is also suggested that saturation will be reached sooner, the more
similar participants are in their experience with the research domain
(Guest et al. 2006). According to Bernard (2011), sample size may
41

vary between ten and twenty knowledgeable sources, with the goal to
uncover and understand the core categories in a cultural domain.
Creswell and Clark (2011) suggested that the sample size should
relate to the research question as well as the approach used and can
vary widely between one and thirty.
For this project, open ended semi-structured interviews were
aimed at eliciting individual and structural factors influencing the
willingness and ability of physician/investigators to participate in a
prostate cancer prevention intervention trial. They were also used to
identify factors that may be unique to the various practice areas. The
interview guide consisted of seventeen questions, developed by me
and in collaboration with the dissertation committee and other
researchers familiar with clinical trials, after an extensive review of the
literature and with specific consideration of the objectives of this
project in mind. Key informants were asked to describe challenges as
well as share any suggestions to improve future collaborations. Based
on strong existing relationships with the majority of participants at
least a 50% acceptance rate was anticipated prior to the initiation of
the data collection. The length of the interviews ranged from thirty to
ninety minutes, based on the scope of information and responses
shared by each interviewee.
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Participant observation.
Participant observation or learning via exposure (Schensul et al.
1999) was also carried out at the various research sites, where
possible as approved by the local IRB. This collection of data focused
primarily on the interactions between the physician researcher and
research team in order to better understand the internal working
mechanisms of each facility and the process of research at the
healthcare site. Observation occurred primarily in the backstage
(Ellingson 2005) of the clinic environment where staff function “behind
the scenes” and did not include any observations of provider-patient
interactions. An observational checklist was designed to specifically
note structural factors (such as use of a clinical trial alert system),
noted previously in the literature as well as those observed by me to
have an influence on participation in clinical trials, both therapeutic
and prevention focused. The goal for this methodology was that it be
utilized at a minimum of five sites (the non-VA medical center sites
currently involved in the prostate cancer chemoprevention project),
during routine site visits.
Survey.
The survey was developed by me in collaboration with the
dissertation committee and other researchers familiar with clinical
trials, after a review of the literature and with specific consideration of
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the objectives of this project in mind. The survey was used to capture
demographic information such as years in practice, practice location,
prior clinical trial involvement, as well as elicit feedback related to
areas shown by other researchers to be factors in recruitment to
therapeutic and cancer prevention intervention trials such as impact on
primary role and time and financial constraints.

By comparing current

responses across sites and to prior findings it was possible to
determine if similar factors are salient with those participating or
considered for participation in a PCPICT.
The participant survey was administered to the same key
informants (n=12) who were invited and agreed to participate in the
open ended semi-structured interviews. It was also offered to
urologists (n=19) working in private practice within the state of
Florida, primarily the greater Tampa Bay area that had inquired or
been invited to participate in the prostate cancer chemoprevention
clinical trial. Unfortunately direct access to the majority of these
individuals as originally planned was not possible due to an
unanticipated change in the functioning of local business group
(urologists working in private practice in the Tampa Bay area). Access
that was previously offered (invitation to visit a local urology group
meeting) was no longer possible. As a result, these potential
participants were first asked to complete the survey via email request
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(including the survey link) from a respected group member/key
informant and/or via an invitation letter (including survey and return
stamped envelope) from me. A modification of the Dillman Total
Design Survey Method (Hoddinott and Bass 1986) was employed to
maximize response and follow-up postcards (including the survey link)
were sent one week after the initial mail-out. This group was also
offered the opportunity to participate in the open ended semistructured interview as well if desired. Based on the established
relationship with parent study participants and a strong relationship
with a key informant and “insider” with access to this group of nonparticipating physicians, at least a 50% acceptance rate was
anticipated. Table 2 reflects the planned methodology at each site.
Table 2. Planned Methodology by Site
Practice Area/Research Sites

# of Key
Methodology
informants
A- specialty (cancer) center
2
1, 2, 3
B- specialty (cancer) center
1
1, 2, 3
C- specialty (cancer) center
2
1, 2, 3
D- VA medical center
1
1, 3
E- VA medical center
1
1, 3
F- VA medical center
1
1, 3
G- Academic/teaching hospital
1
1, 2, 3
H- Academic/teaching hospital
1
1, 2, 3
I- Private practice (community)
20
3, 1*
1-Open ended semi-structured interviews 2-Participant observation 3-Survey
*If agreeable
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Data collection tools.
The Interview guide can be found in Appendix C, followed by the
content matrix in Appendix D. The content matrix further delineates
how the various questions helped to address the study objectives.
After IRB approval and prior to the initial interview the guide was pretested with one researcher and two physicians familiar with clinical
trials. Following the pre-test some questions were further divided into
sub questions to ease future analysis. The overall content did not
change and since no substantive revisions were needed, additional IRB
approval was not required prior to the initial interview. The participant
survey, consisting of nineteen questions, can be found in Appendix E
and F. The observational checklist used during all participantobservation sessions can be found in Appendix G.
Data Quality and Management
To assure data quality: (1) I conducted all interviews; (2)
interviews were audio-recorded (with permission) using an Olympus
WS-700M digital voice recorder to ensure that no material was missed
during analysis; (3) audio files were downloaded to a secure, personal
laptop computer immediately following all interviews; (4) transcription
occurred as quickly as possible (usually within twenty four hours)
following the interview; (5) analysis was concurrent with data
collection; and (6) all thematic analysis was conducted by me.
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Detailed field notes were transcribed after each observation period and
used to compare observations across sites including items such as the
use of clinical trial alert systems, availability of dedicated research
staff, and communication between staff related to potential eligibility
to participate in a study, that were not collected by other means.
Survey data was entered directly into Qualtrics build 38768
(Qualtrics 2011) by the participants or captured on paper and
transferred verbatim into Qualtrics by me.

All data was stored on a

secure, password protected, single access computer, to which only I
have access.
Data Analysis Plan
Qualitative.
Open ended semi-structured interviews were audio-recorded and
then transcribed verbatim by me with complete transcriptions
completed in two to three hours, depending on the length of the
interview. Each transcript was then reviewed for accuracy, organized
by question and compiled into the research database. Information
collected from the interviews was then analyzed for themes and
patterns via analysis of recurring words and phrases to specifically
address the study objectives and research questions.

The constant

comparative method was used to compare the views and experiences
of respondents from across the various sites to help explain important
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differences (Barbour 2001). Information from the observations was
incorporated were relevant and appropriate throughout the discussion.
Quantitative.
As is standard in qualitative research, the demographic
information collected via survey was summarized, using descriptive
statistics to better describe the population as a whole (Kidd and
Parshall 2000). This data is not linked in any way to the results of the
semi-structured interviews or individual survey responses. The results
from the interviews, observation and surveys was analyzed
independently and integrated for the purposes of interpretation in
order to address the objectives.
Human Subjects
This research adhered to professional guidelines and codes of
ethics for the protection of human subjects. The purpose of the
research was explained to all participants who were provided the
opportunity to ask questions and voluntarily participate in the research
prior to data collection. To ensure the confidentiality of all key
informants, pseudonyms were assigned to all participants and research
sites in the following format:
interview number-site type-participation status (01-S_P)
Site types were designated as specialty centers (S), academic centers
(A), VA hospitals (V) or private practice/community (P). Participation
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status was further delineated as participant (P) or non-participant (N).
Prior to any subject recruitment, the study was approved for
adherence to Human Subjects Protection by the University of South
Florida Institutional Review Board (Pro #7442). A waiver of consent
was received and though the informed consent document was
reviewed prior to all interviews, a signature was not required. For
those that completed the survey only, consent was implied with the
provision of their responses. This project was also reviewed for
scientific merit and approved by the Scientific Review Committee at
the Moffitt Cancer Center, in Tampa, Florida prior to receiving IRB
approval.
Summary
This chapter set the stage and described the impetus for this
research. It then described the qualitative and quantitative methods
utilized in this study to explore the factors influencing a physician’s
participation (or lack thereof) in a PCPICT. The methods included open
ended semi-structured participant observation and survey
administration. This study adhered to professional guidelines and
ethical standards to assure the protection of human subjects. Results
will be presented in Chapter Four and Chapter Five will include a
discussion of these results.
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Chapter Four:
Results
Introduction
The purpose of this analysis was to conduct a constant
comparison of the similarities and differences between the concepts
that emerged in the field during data collection (Glaser and Strauss
1967) and the literature presented in Chapters One and Two. The
methods, study objectives, and research questions were guided by a
consideration of the various theoretical frames and constructs noted in
Chapters One and Two, in conjunction with the use of a grounded
theory approach as discussed in Chapter Three. As previously noted,
grounded theory methodology was also useful while collecting the data
and at times led the discussion between researcher and participant in
directions not anticipated, a benefit of this iterative technique, also
observed by Charmaz (1990). This vantage point was considered
advantageous in order to effectively examine the factors influencing
physicians in their important role as gatekeeper to access to PCPICTs.
An exploration of the disjuncture that exists between the desire to
participate or refer participants and the reality of the cultural and
social factors influencing participation in each local context was
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constantly considered as data emerged. This allowed for an in-depth
exploration of individual experiences and meanings related to cancer
prevention and participation in cancer prevention intervention clinical
trials within the context of the larger and unavoidable structural
factors impacting the practice of medicine, particularly as they relate
to participation in a PCPICT. The analysis was conducted with the goal
of answering the research questions:
1) What individual factors influence a physician’s participation in
a PCPICT?
2) What structural factors influence a physician’s participation in
a PCPICT?
3) How do these factors vary depending on the practice site/area
(specialty centers, academic centers, Veteran’s (VA) medical
centers, community offices)?
Responses are organized by these questions and as they relate to the
study objectives noted previously.

Due to limitations that were

unforeseen at the time of study design (lack of access to a local
urology group meeting, as described in Chapter Three), there was an
unanticipated change in the total sample size for some of the methods.
Additionally, the distribution of participants from various settings was
altered from the original research proposal. These modifications
allowed the objectives, main research questions, and hypotheses to be
addressed though possibly in a more limited manner. The final
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analysis reflects the actual data collected from various methodologies,
as illustrated in Table 3.
Table 3. Actual Methodology by Site
Practice Area
Trial
# of Key
Participant informants
A- specialty
Y
1
(cancer) center
B- specialty
Y
1
(cancer) center
C- specialty
Y
1
(cancer) center
D- specialty
Y
1
(cancer) center
E- specialty
N
1
(cancer) center
F- VA medical
Y
1
center
G- VA medical
Y
1
center
H- VA medical
N
1
center
I- Academic center Y
1
J- Academic center Y
1
K- Academic and
N
1
Private practice
L- Private practice Y
1
(community)
M- Private practice N
1
(community)
N- Private practice N
1
(community)
O- Private practice N
1
(community)
P- Private practice N
1
(community)
1-

Methodology
1, 2, 3
1, 2, 3
1, 2, 3
1, 2, 3
1,3
1, 3
1, 3
1, 3
1, 2, 3
1, 2, 3
1, 3
1, 3
3
3
3
3

Open ended semi-structured interviews 2-Participant observation 3-Survey
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The results presented are divided into four sections. Section I
describes the key informants. Section II reports on the qualitative,
ethnographic findings obtained from the open ended semi-structured
interviews.

Section III reports on qualitative, ethnographic data

obtained from the participant observation.

Section IV reports on the

quantitative data obtained from the completed surveys.

A final

summary concludes the chapter.
Section I- Key Informants
Qualitative.
The key informants for the open ended semi-structured
interviews were physician/investigators who had been either directly
(serving as a co-investigator) or peripherally (referring or asked to
refer patients for participation) involved in the Phase II, Randomized,
Double-blind, Multi-centered Study of Polyphenon E in Men with Highgrade Prostatic Intraepithelial Neoplasia (HGPIN) and Atypical Small
Acinar Proliferation (ASAP) (IRB 105730) trial. All interviews took place
at a mutually agreeable location at a time that was not in conflict with
the interviewee’s work responsibilities. In total twelve interviews were
completed and the informants could be further stratified and described
as nine participants and three non-participants in the larger/parent
clinical trial. Demographic data was not collected for this portion of
the project; however, based on survey responses, all participants were
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male, ranging in age from 30 to >70. Informants were initially asked
describe the organization that they work for, and this is elaborated in
the following responses:
I work at an academic cancer center NCI designated we’re a
tertiary care referral center for patients with genitourinary
malignancies (01-S_P)
A federal hospital. Large volume. Many social disadvantaged
individuals. Significant proportion of minority patients (04-V_P)
We are not considered in the community (to be) a tertiary
medical center, or quaternary medical center. (The) perception
here (is) it doesn’t draw that patient population (for cancer
prevention research); we have to go out and get it. Some of the
things that are unique here is we have to go out and get
patients. If we were absolutely focused on clinical research, we
would go out and do that and we don’t really have the resources
to do that (07-P_N)
The hospital that I work at is closely affiliated with the academic
institution but they are not the same entity. It absolutely feels
more like an academic center than a community hospital
(10-A_P)
This is two parts organization. My own practice, it’s a private
practice but it’s not exactly like a regular community based
practice. We see more complicated cases, do more complicated
surgeries and see a lot of referrals from other urologists.
Basically it’s like an academic practice without being in
academia. We are part of bigger group, which has many
urologists. Everybody has his own office but we work as a group
we share some common business office and some ancillary
services (11-P_P)
Using the criteria originally defined by me, practice sites can be
categorized as follows: Specialty (n=5), Academic (n=2), Veterans
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Affairs (n=3), Private practice (n=1), and both academic and private
practice (n=1). By considering the views of those from the range of
various practice sites that have been directly or peripherally involved
in the trial (participants) as well as those that have not (nonparticipants), a better and more comprehensive understanding of the
factors influencing the actors within their local context was possible.
Quantitative.
The key informants completing the survey included the twelve
noted above that participated in an interview as well as four that did
not (n=16). This group of four additional participants can be further
described as physicians who had been invited to participate or refer
patients for participation in the aforementioned PCPICT but had
declined. Survey administration took place following the semistructured interview for most respondents (n=8). Two surveys were
completed by participants separately from the in person interview and
later mailed to me. Four respondents (2 participants; 2 nonparticipants) completed the survey using the on-line format and two
non-participants completed the survey and mailed it to me. As such,
all responses were entered directly into Qualtrics by the key
informants (n=4) or captured on paper and transferred verbatim into
Qualtrics by me (n=12). In order to be able to make comparisons
across groups, respondents were sub-divided into two groups,
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participants in the PCPICT (n=10) and non-participants (n=6). As is
standard in qualitative research, the demographic information
collected via this methodology is summarized, using descriptive
statistics to better describe the population as a whole (Kidd and
Parshall 2000).
Participants.
These respondents (n=10) report a range of 6 to 32 (mean 15)
years in practice. Medical specialty was reported as follows: urology
(n=5), medical oncology (n=2), urologic oncology (n=2) and cancer
prevention/epidemiology (1). Participants were also asked to report
the country in which their primary medical training occurred with
results as follows: United States (n=5), Turkey (n=1), Canada (n=1),
Ireland (n=1), India and Great Britain (n=1) and Egypt and the United
States (n=1). In terms of demographic information, all participants
completing a survey were male, ranging in age from 30 to 70 years or
older and specific of each category are found in Table 4 below.
Table 4. Participant Age (n=10)
Age range

# responses

%

20-29

0

0

30-39

1

10

40-49

3

30

50-59

2

20

60-69

3

30

70 years or older

1

10
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Ethnicity was self-reported as Not Hispanic or Latino (n=9), with 1
incomplete survey. In response to the question “How would you
describe your race” participants were encouraged to select all
categories that applied and answered as shown in Table 5.
Table 5. Participant Race (n=10)
Race

# responses

%

American Indian or Alaskan Native

0

0

Asian

1

10

Black or African American

1

10

Native Hawaiian or Other Pacific Islander

0

0

White

7

70

Other, Egyptian, Middle Eastern

1

10

Non-participants.
Those non-participants (n=6) who completed the survey report a
range of 2 to 28 (mean 13) years in practice. Medical specialty was
reported as follows: urology (n=3) and radiation oncology (n=1) and it
is noted that not all respondents answered all the survey questions.
Non-participants were also asked to report the country in which their
primary medical training occurred with results as follows: United
States (n=3) and Egypt (n=1), again with missing data noted. In
terms of demographic information, all non-participants that the survey
was sent to were male; however, not all respondents answered this
question. Those completing a survey report an age range of 30 to 49
years, though incomplete data also was reported for this question.
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Ethnicity was self-reported as Not Hispanic or Latino (n=3) and
Hispanic or Latino (1) with incomplete responses to this question as
well. In response to the question “How would you describe your race”
participants were encouraged to select all categories that applied with
three reporting their race as White while one reported as Black or
African American. There were three non-responders for this question
as well.
The surveys were designed to capture demographic information
such as years in practice, medical specialty, and prior clinical trial
involvement so as to better describe who is participating in the
ongoing clinical trial. This is a first step at describing this specific
population, since data on physician participation in prostate cancer
prevention trials has not been previously reported in the literature.
The surveys were also intended to elicit feedback related to areas
shown by other researchers to be factors impacting recruitment to
both therapeutic and cancer prevention intervention trials, such as
impact on primary role as well as time and financial constraints. The
survey data is not linked in any way to the results of the
semi‐structured interviews or individual survey responses.
Section II- Qualitative Findings
Verbatim transcripts of the open ended semi-structured
interviews were analyzed by research objective and question, using
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constant comparison and key words to identify themes and other
findings. The first group of responses reported here relate to research
question one (What individual factors influence a physician’s
participation in a PCPICT?) and an exploration of the individual
provider level factors -explanatory views on prevention, notions of risk
and uncertainty, shared decision-making, and duality of roles- that
influence participation in a cancer prevention intervention clinical trial).
Individual provider level factors.
Participants were asked what factors were influential to them
personally when they made the decision to participate (or not) in a
cancer prevention intervention clinical trial. Academic recognition and
the ability to publish articles was noted by participants from a specialty
center as well as academic/teaching hospital but not by those in
private practice as noted with the following responses:
I think like anything, being in an academic institutionpublication, participation in the study itself (01-S_P)
One gets the objective impressions of contributing to progress as
well as getting academically recognized beyond personal
satisfaction. I think also the data, the theoretical underpinning
for the prevention trials or endeavors, ought to present in such a
way that they raise interest and enthusiasm because that also
facilitates selling the trial to the patients. Authorships and design
(also) entice (04-V_P)
This suggests that motivations for participation could vary between the
various practice sites. Interaction with those within the community
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was also noted by one participant. Responses suggested a
combination of the desire to work together yet also a warning of the
potential for competition as the following response elaborates:
I think also having them (trials) readily available for your
colleagues in the community (is important). To reach out to you,
for participation and putting patients on trials is definitely
something which is key because oftentimes they will call and
they will ask is there a trial you can potentially do for that.
There are certain other cancer centers in our community actively
who have clinical trials in GU and other areas and really doing as
good a job as we are opening trials. I think it’s important for us
to be able to at the very least have comparable type studies and
sorta keep up with the Jones’ (01-S_P)
One participant from a VA hospital simply noted the cost/benefit ratio
as influential with the following response:
The likely benefit of the trial versus how much effort is at stake
(02-V_NP)
Institutional support was noted by one participant in a specialty
center:
Institutional support. (laugh) It goes back to that. That should
be top on the list because our mission reads: contribute to the
prevention and cure of cancer. So, it’s half of our mission. If you
look at it from that perspective, half the resources should be
allocated to that. Or a significant amount of resources should be
allocated (03-S_P)
Personal interest/belief in prevention was noted by several physicians,
at all types of institutions, as the following responses demonstrate:
I think from my perspective those are studies that should be
done (03-S_P)
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If it’s something that I’m interested in. If I don’t have any
interest you obviously can see that there’s no sense in agreeing
to something (08-A_P)
I can see where all this is going and how it makes sense. I
understand what it’s for and so that’s the biggest thing for me to
understand the trial where they are going with it, what it means.
Secondly to make sure it has an endpoint that is of interest to
me and that I well that it’s of interest to me that’s the main
thing. It would be lovely if we could cure cancer and I wouldn’t
have a job. I know that’s not going to happen but if we could do
something that ultimately lead to less people having it then you
know, that’s something I’m interested in too (10-A_P)
The possibility of prevention was noted as well as altruism and support
for the cause was noted in the following responses:
Oh, that’s easy. Because prevention of a disease is always more
attractive option than trying to treat the disease. At a minimum
it might allow disease that’s a very, very early stage perhaps
earlier than the traditionally defined clinical stage and I think
that it will help certainly potential patients avoiding trouble or at
least minimizing trouble down the road. I think, yes there is no
question, prevention is better than therapy (04-V_P)
Well as a provider, honestly if it basically helps the fight against
cancer in any way I think I would be a go anytime. Contributing
to the fight against cancer is the most important (05-V_P)
We try to do trials that meet the greater need (12-S_P)
Additionally concerns for the patient were noted as evidenced by the
following responses:
I think when it deals with prevention if the patients really not
motivated and their concern is quite low I don’t really feel
strongly that I would push for some sort of prevention trial but
when patients are really quite motivated and specifically ask
what can I potentially do to minimize my risk I think those are
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suitable patient especially if they are compliant if they live fairly
close to the institution. I think degree of commitment and
interest is really ultimately the strongest predictor of how
successful they will be compliant with participation (01-S_P)
Well, that’s like several things 1. Is it something I think the
patients need? Is there a definite human need there for some
help (06-S_P)
Must be patient friendly (07-P_N)
Scientific merit and feasibility were also noted as important as
evidenced by the following comments:
And then #two would be, is it a good scientific question (06-S_P)
There must be a rational for prevention (07-P_N)
and #three is it feasible? (06-S_P)
The ability to enroll patients #1 (08-A_P)
Also noted as factors likely to influence participation at the individual
level were the ability to stay current and provide patients access to
new care as the following respondent explains:
I look for the trials to one, kinda keep me current plus. I mean
current with medicine, but a little aware of what might be next.
Not to get way far ahead of where I’m supposed to be making so
many assumptions that I’m actually 5 years ahead of the rest of
the world. We like trials where they bring in new medications not
new that they are phase 1, we’re not too much on the phase
ones we’re pretty much the new phase 2 things (12-S_P)
The most frequently noted response categories related to individual
factors influencing participation in a PCPICT follow below in Table 6.
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Table 6. Individual Factors of Importance (n=12)
Comment
Scientific Merit
Personal Interest in
Prevention
Publication/Academic
recognition
Patient friendly
Patient Need/Altruism
Community engagement
Feasibility
Institutional Support
Cost/ Benefit
Who is running study
Keep current
Adequate funding

Site Type (Frequency)
S (1) A (2) V(2) P (2)
S (1) A (3) V(2)
S (2) A (1) V (1)
A (1)
S (2)
S (1)
S (1)
S (1)
V (1)
P (1)
S (1)
S (1)

P(2)
V (1)
A(1)
A(1)

S-Specialty Center A-Academic Center V-VA Hospital P-Private Practice

Explanatory views on prevention.
To solicit views on prevention, participants were asked about
their general philosophy towards preventive medicine. Based on their
responses there was wide variation in their interpretation of the
question. Some participants spoke of preventive medicine in general
as the following quotes reflect:
I think that as we embark in medicine today I think the
emphasis is sort of moving away from treatment to prevention.
We know that it’s more cost effective. We know from a society
standpoint, if we can prevent something you’re much better.
From a patient standpoint, obviously if you can prevent and not
have to deal with actual malignancy, prevention is the ultimate
goal. It’s what we strive for everyday. So I think that prevention
is the future of medicine (01-S_P)
I think that’s the wave of the future..we talk about hypertension,
diabetes, many of the cancers and now there is a better
understanding for when one could intervene very early (03-S_P)
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I think it should be the main focus of medicine. Better to
prevent than have to treat (06-S_P)
The government wants to put a lot of money into it so there are
opportunities for grants and research regarding it. I don’t see
how you can be against preventative medicine (10-A_P)
Other spoke more specifically about cancer prevention as seen with
the next responses:
I think there’s lots to do with preventive medicine for cancer.
Unfortunately, most of the time we see and treat cancer when
someone’s already got cancer (05-V_P)
Prevention is very important you know whether it is cancer or it
is stones or whether it is infection you know that’s that will cut
the health (care) cost, it will improve the patient well fare.
When you wait for patient to be treated, there is nothing without
a price whether it is a surgery or medications. Even you put the
patient on medication, medicine has side effects too (11-P_P)
Some spoke more broadly about prevention while others noted specific
types of interventions that they thought would be most beneficial as
seen with the following responses:
My general philosophy is that for most chronic diseases like
cancer, heart disease, cardiovascular disease, diabetes, the most
important thing is physical activity and I know my personal
philosophy is that we need to do more studies using
intervention, using physical activity as intervention. And the
second most important thing is diet. The studies investigating a
healthy diet rich in vegetables, low in sugar, fat and salt, those
kinds of things, that’s prevention. To me the most important
ones are (those) that look at exercise and diet especially in
young people, because once those habits get established and if
you’re approaching 50 year old 60 year old people with
prevention studies, it may be too late. They have already their
BMIs already 35 or 40 and you know it’s not easy to get 50 60
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70 year old people to get motivated to lose weight and start
physical activity when all their lives they’ve been couch potatoes
and not eating healthy, not doing enough physical activity. So
my own personal belief (is) that those kinds of studies are very
important (09-S_N)
In general, I think that there’s a lot of screening and prevention
that we do or call preventive medicine, when a lot of screening
potentially may not show benefit for example: prostate cancer.
There’s numerable studies that show benefit of prostate cancer
screening but there’s probably equal as many or more that show
there’s no benefit towards prostate cancer screening. And so
why do I still offer prostate cancer screening to my patients? I
think that if you can prevent a disease than you should, but how
many lives or how many tests do you have to do to perform that
before you know at least when it comes to screening (08-A_P)
There’s a lot to do with preventing cancer with dietary habits,
with having good food habits. So many things, day to day
activities-exercise, good sleep at night. Things like that that
which might sound ridiculous but they do in the long term diet I
think plays a lot of role in cancer. So does exercise. So I guess
that’s important (05-V_P)
One participant suggested that prevention may work better in some
situations than others:
It’s often a good idea. I don’t have a great philosophy. I think in
certain situations it works really well other times it doesn’t it just
depends on all the details of what you are trying to prevent
(02-V_NP)
Another participant challenged the definition of preventive medicine as
well as wellness, posing the question of “when does prevention start”
and suggested that prevention may need to be better defined, as seen
in the following quote:
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That’s a difficult question to answer. In the first place how do we
define preventive medicine? It means that you know that
something can go wrong. The issue is the definition of wellness.
I think in oncology the most important thing is to change the
image of cancer (for) the population (to) understand it’s a
chronic disease which probably is a result of a chronic process of
abnormalities which eventually lead to a malignancy or
malignancies and therefore just like prevention of other
diseases, nutritional changes, environmental changes, lifestyle
changes, the same should be applied to preventing oncologic
diseases and therefore the definition of when to start ought to be
better defined. And the other issue is where does cancer
prevention start? Could you start to detect molecular fingerprints
of a micro subclinical cancer and prevent that from becoming a
real problem? Is that prevention? Or is prevention trying to
demonstrate that you prevent even the early oncogenic steps?
It’s a matter of target of definitions. So it’s not so simple to
design these studies (04-V_P)
Overall participants can be described as supportive of preventive
medicine and a summary of the range of responses can be found in
Table 7.
There was generally similarity in responses across all groups
with themes such as cost effectiveness, preference of prevention to
treatment and recognition of the value of prevention based on
expanding medical knowledge noted. Several participants mentioned
prevention as the “future” of medicine. Interestingly, some that were
surgeons felt that their role in prevention was limited though could
certainly see the value of prevention as the following response
elaborates:
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You know I constantly counsel my patients towards smoking
cessation for example. (Those) that don’t have physicians want
to treat their blood pressure and cholesterol and all that so I set
them up and tell them they need to do that at their age, if it’s
appropriate for that. But what do I do with my practice to
prevent things? I guess I really don’t. So if asking what my
philosophy is, I guess it is that I support it. It’s hard for a
urologist to practice it but I do try and talk to them about
smoking cessation and get them hooked up with appropriate
primary care (07-P_N)
Table 7. Explanatory views on prevention (n=12)
Comment
Supportive of it
Prevention better than treatment
Doesn’t work well for all cases, depends what
trying to treat
Future of medicine
Challenging to define when prevention starts
Challenging to design prevention studies
Should be main focus of medicine
Hard to practice in my arena
Need more prevention studies because they are
important
I don’t see how you could be against preventive
medicine
Government has put a lot of money into it

Site Type
(Frequency)
S (3) A (2) V(2) P (2)
S (2) A (1) V(1) P (1)
V(1)
S (2)
V(1)
V(1)
S (1)
P (1)
S (1)
A (1)
A (1)

S-Specialty Center A-Academic Center V-VA Hospital P-Private Practice

Following their initial response, participants were asked if what
they stated was based on what they had learned in their training or
was more influenced by their professional practice or even personal
experience. The responses varied with most noting influence from one
area or more as seen with the following responses:
I think I am more attuned to prevention then my training got me
thinking about. I’ve evolved into more prevention (07-P_N)
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It’s evolved since then. But, that question may be a little bit
unfair because I went to med school in foreign county X. Let’s
just say that, preventive health may not have been a priority
there (08-A_P)
It’s pretty much what I’ve learned in my training. And it’s pretty
much what life teaches you in a bit of time. You’ve seen people
die and born in front of you and grow up into men and women in
front of you and people who were adults when you were children
you see them pass away by the time you are in this age that I
am so it kind of gives you a broader perspective of life. Plus
what I’ve learned in medicine as well. So both personal and
professional influence the broader perspective (05-V_P)
Interestingly, there was varied commentary as to the past and current
preventive training specifically with reference to American medical
schools as the following statement:
Well, in the days that I trained we weren’t really taught about
the importance of prevention, diet, exercise and all of that.
More recently, they are becoming more into focus and in medical
schools and in the scientific community. Fifteen years ago,
people were very skeptical about diet and exercise so the
accumulating data is clearly showing that these are very
important for the past couple of decades. You know there’s more
and more realization that you’ve got to make real changes (to
prevent) disease, chronic disease. These are the things we have
to change (09-S_N)
We don’t do a lot of preventive training (with our) surgical
training. Med school yeah, in terms of primary care they talked
about preventive strategies, not necessarily preventive
medications or chemoprevention, things of that sort. Healthier
living and eating and not smoking and not drinking and things of
those sort. You know being fit, exercising. Those things are
stressed and prevention from that point. Healthy lifestyles to
prevent you from getting cancers and other disease but that’s
about it (10-A_P)
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A summary of the responses related to the influence of professional
practice and personal experience on views about prevention follows in
Table 8.
Table 8. Influence of personal and professional experience on views on
prevention (n=12)
Comment
Personal
Professional
Changed over time

Site Type (Frequency)
S (3) A (2) V(3) P (2)
S (3) A (2) V(3) P (2)
S (1) A (3) V(2) P (1)

S-Specialty Center A-Academic Center V-VA Hospital P-Private Practice

Following this, participants were asked to consider how they
thought their philosophy towards preventive medicine may influence
their willingness to participate in a PCPICT.

Responses varied in

specifics; however, there was some homogeneity with all participants
noting at least some positive influence, regardless of their practice site
as the following responses demonstrate:
More and more, I am finding that prevention is probably one of
the most important components in healthcare and to move it up
in the agenda to be not the all encompassing but very, very
important (03-S_P)
I think it influences it in the positive for sure because I think it’s
a good thing to be able to prevent disease processes from
occurring in the first place (10-A_P)
Well I’m absolutely for it, yeah. Being in the trenches, seeing
what disease is at the other end, what is worth preventing
(04-V_P)
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Notions of risk.
Notions of risk came up in various responses, and were
expressed as a means to determine who may be a good candidate to
participate in a prevention intervention trial in general as suggested by
one participant:
Probably the ideal patient is somebody who has a risk factor for
a major disease and I think that’s the incentive for getting them
involved in the first place (06-S_P)
As well as a consideration by clinicians as to when follow-up care may
be provided, as the following response suggests:
The high risk feature on a path report might influence how
aggressive we are together in terms of repeat biopsy. I might
biopsy them at 6 months but most of the guys don’t get biopsied
until a year after diagnosis. I’m not convinced that high grade
PIN (prostatic intraepithelial neoplasia) is perfect just like PSA
(prostate specific antigen) is not perfect. So I use PSA, the
presence or absence of PIN. I use you know patient individual
factors to say ok, when are we going to do another biopsy and I
prepare them prior to initial biopsy that we may end up doing
some more biopsies as time goes by (07-P_N)
As well as who may be offered or encouraged to participate in a
prostate cancer prevention intervention trial as explained by another
participant:
Depending on which condition it is, premalignant condition, if it’s
something which has a significantly increased risk of cancer
development I definitely think that they’re at a significant higher
risk of cancer developing then I’m a little more strongly positive
influenced or motivated to try to encourage patients to
participate in a trial. I think that if it’s something which I think
the risk is potentially increased but only slightly increased I think
that I’m very clear to the patients in terms of what the likelihood
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is of developing a condition and then sort of leaving it up to the
patient based on how they feel whether they want to participate.
I think I discuss it with them really keeping that specific relative
risk really at the as an essential component of the discussion
(01-S_P)
The interpretation of risk within the medical community and how it
may influence participation in a prostate cancer prevention
intervention trial was also discussed as the following responses
elaborate:
You know the other thing that’s detrimentally affecting
particularly prostate cancer I think is the ambiguity in the
medical community about the significance of prostate cancer and
the significance of prostate cancer treatment and if we can’t get
our sh** together at the end of the day, patients think nothing
why do I even have to prevent it? So, I think that we have to
start from there but if the consumer thinks that prostate cancer
is a non-entity then in reality why are we doing the study? That I
think is probably the biggest nut for the consumer to swallow.
They don’t realize the significance of prostate cancer. I as a
surgeon feeling more and more pressure to discuss active
surveillance with patients and so the consumer hearing that also
feels perhaps more and more that they may have a cancer of
little significance and that being said, do I need to do anything
about it? (08-A_P)
I personally think one of the keys is the urologists, and how do
they want to deal with the reporting of prostate biopsy showing
PIN. One of them over there will refer because he just doesn’t
say it’s benign we’ll see you in six months and recheck your PSA
and exam. He will actually spend an extra minute and say it’s
benign but there’s changes that I think you better go talk to
them they have an interesting, and I do believe he uses the
word interesting trial based on green tea. But he’s got three
partners not a one of whom has ever sent anything over
(12-S_P)
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A summary of the various ways in risk was considered by the
respondents can be found in Table 9.
Table 9. Risk (n=12)
Comment
Influences who is offered/encouraged to
participate in a trial
Helps determine who is a good candidate to
participate in PCPICT
Perceived risk determines clinical care
Physician’s perception of cancer risk
Overall risk level (safety) of trial impacts
participation
Patients perceived risk and how it influences
trial participation

Site Type (Frequency)
S (4) A (2)
S (3) A (1)
S (1) A (1) P (2)
S (3) A (1)
S (1) V(1)
P (1)

S-Specialty Center A-Academic Center V-VA Hospital P-Private Practice

Uncertainty.
Participants were asked to reflect upon times that they had
decided to offer participation in a clinical trial and to consider how the
possibility of uncertainty in the plan of care may have played a role in
their decision to offer the trial. For those working at a specialty
center, the possibility of uncertainty did not seem to play a role in the
decision to offer the trial. One participant described the
comprehensive approach taken when considering a patient for a trial
and another noted that an unknown end is indeed the nature of
research:
So you know depending on the patient, on their overall medical
condition, their general well-being, I discuss it very clearly with
them that we don’t truly know what the results are going to be
of a study and potentially they may develop complications from
the chemopreventive agent or the additional procedures that
they need to undergo. I think it’s important not to sort of
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minimize those and make it very clear that at the end of the day
we don’t know what the results are going to be and it’s
important to discuss with them the study design and what
additional tests are going to need to be done and what the
commitment is going to be from their end of things (01-S_P)
No. this is not a factor (03-S_P)
No, I think when you do research you don’t know what’s going to
be the end (06-S_P)
Similarly, respondents from two academic institutions noted that
familiarity with a study protocol helps to eliminate uncertainty as a
factor of influence when offering a trial and one recognized that too
much uncertainty could be a factor impacting participation as seen
with the responses that follow:
No. I would say that I am if the studies that I enroll patients in, I
for the most part know the study inside and out (so that
uncertainty is minimized) (08-A_P)
I feel like I understand the protocol well enough in the beginning
that I know what the plan is going to be so I don’t feel like
there’s that much uncertainty. If there was that much
uncertainty in the plan I probably wouldn’t participate (10-A-P)
Those from the VA medical centers had not experienced uncertainty in
the plan of care though similarly to the prior comment, one participant
did note that if present it could influence the likelihood of offering
participation:
If there’s uncertainty then I think it’s less likely (that I would
offer it). If it’s not a large uncertainty then it doesn’t matter.
Only if it’s a big difference (02-V_NP)
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If one has a large or sufficient patient population which might fit
recruitment to studies, not offering the population access or
studies shortchanges science (04-V_P)
Finally, those participants working in private practice noted that
uncertainty in the plan of care was not a factor of influence when
considering whether to offer trial participation to a patient. Instead
they noted the absence of harm and similarity to usual treatment plan
as more important as evidenced by the following statements:
No, I don’t think so. I think as long as the intervention isn’t
gonna cause harm, I don’t think that that’s an issue (07-P_N)
It (participation) did not change my treatment plan. This is what
I usually do. If I get a protocol that does not make sense to me I
don’t participate but this particular study, it did not change the
treatment plan. If a study design was completely different than
my usual care it would impact my decision to participate
(11-P_P)
Participants were then asked how has the possibility of
uncertainty in the outcome associated with participation in the trial,
played a role in their decision to offer the trial. There was little
variation both between and within groups. Those participants working
at a specialty center suggested that uncertainty in the outcome was
not influential and even suggested the imperfection of medical
knowledge, importance of rationale for a study and the suggestion that
uncertainty is the nature of science as demonstrated in the following
responses:
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No, on the contrary because one of (the) things with prostate
cancer is that most of the knowledge we have is imperfect and
sometimes it can be erroneous and we are assuming that that
knowledge is the real truth, which it is not (03-S_P)
You don’t want to do something just blindly, guessing or hoping
this will do something, you need to have a rational for it
(06-S_P)
It doesn’t really affect my participation because I think by
definition that we know that there is uncertainty when you do
research, otherwise why would you do the research if you were
certain of the outcome? I believe only through clinical trials
we’re going to find the truth so there is going to be uncertainty.
That is a given. It’s the nature of science (09-S_N)
There was some heterogeneity in the response from those practicing
at an academic center with one noting that uncertainty would influence
the way a patient was counseled as well as noting his “patient first”
perspective as the following responses demonstrate:
If there was uncertainty it would make it harder for me to
counsel patients in an unbiased way. You have to dissect them,
have to be interested enough in the trial and the outcomes to
know. And, I guess I put my patients first always so I you know
if the patients aren’t going to benefit, I won’t even look at those
trials (08-A_P)
Another disregarded uncertainty as influential and similar to other
respondents suggested that it was inherent to the nature of research:
(That’s) why it’s called a trial, we don’t know what is going to
happen at all. No, that hasn’t influenced it at all. I would think
that for prevention it would be less of an issue because we’re
trying to prevent the disease process. If it works great; if it
doesn’t we’re right back in same boat that you were in before.
As long as doesn’t make it worse but we’re monitoring it to make
sure it doesn’t make it worse (10-A_P)
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Those at the VA sites also did not report uncertainty as a factor
associated with participation in the trial and similarly to other
respondents noted the importance of safety as evidenced by the
following comment:
If there are no significant safety risks, no. Prevention is looking
towards avoiding something which might be defined only once it
comes up, while therapy you already have the target, it’s well
defined. (When) preventing cancer, I think that the metrics are
a little bit less well defined because ideally you should not
prevent what we now define as established cancer (04-V_P)
Another respondent discussed honesty and communication with the
patient as important means to deal with the possibility of uncertainty
as noted in the following response:
I think if you are honest with your patient, with your potential
recruit, upfront and tell them this is a possibility. You might get
some side effect or if it’s a double blinded trial you may get a
placebo or exact medicine we don’t know. So (this way) the
patient knows they might or might not benefit or might get side
effect or they might have to stop the medication, things like
that. I think as long as you are up front from the very beginning
I don’t think I see a problem with that. Patients understand
(05-V_P)
One participant in private practice made similar comments to others
regarding harm or risk with the following remark:
If it doesn’t help it’s not going to hurt, you know. I have no
problem with doing that (11-P_P)
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Various perspectives regarding uncertainty were noted during the
interviews. A summary of the range of responses related to
uncertainty follows in Table 10.
Table 10. Responses related to uncertainty (n=12)
Comment
Not a factor
Participation less likely if there is uncertainty
Not an issue with cancer prevention studies
Not an issue because understands study
“inside and out”
Uncertainty lessened because know what plan
of care/course of treatment will be when on
study
No uncertainty if not significant safety risks
Communication with the patient reduces
uncertainty
When you do research you don’t know what is
going to be at the end
There is uncertainty in research, it’s the nature
of science
Rational for prevention reduces uncertainty
Uncertainty would make it hard to counsel in
an unbiased way
“That’s why it’s called a trial. We don’t know
what is going to happen.”

Site Type (Frequency)
S (1) P (1) V(3)
V(1)
V(1)
A (1)
A (1)
V(1)
A (1)
S (1)
S (1)
S (1)
A (1)
A (1)

S-Specialty Center A-Academic Center V-VA Hospital P-Private Practice

Shared decision-making.
In an attempt to solicit perspectives regarding shared decisionmaking, participants were asked two separate lines of questions. One
sought to address possible issues relevant to sharing decision-making
with another provider, as may be necessary if a patient participated in
a trial at a location away from their usual care. The other question
dealt with how participation in a cancer prevention trial impacts the
physician-patient relationship. First, participants were asked to
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describe their thoughts about sending their patients to another facility
to participate in a cancer prevention intervention trial. Participants
were next asked about alternatives to referring their patients
elsewhere such as having outside study staff come to their office or
work place. Another alternative presented was the provision of
support to train their own staff so that patients could participate in a
cancer prevention trial but did not have to leave their usual office.
Many considerations were noted by participants, with factors
influencing all possible scenarios noted. A summary can be found in
Table 11.
Table 11. Considerations when trial not available
(n=12)
Comment
Would consider referring out /would not be a
problem
If it was of significant benefit to my patient
If the trial could take precedence over
standard treatment
If patient willing
If supports future research
The protocol must be logical

at site of usual care
Site Type (Frequency)
S (1) A (1) V (2) P (1)
S (2) A (1) P (1)
S (1)
V (1)
V (1)
P (1)

S-Specialty Center A-Academic Center V-VA Hospital P-Private Practice

Themes that emerged were the importance of patient benefit,
financial concerns, the detailed work of running a clinical trial,
ownership and time. In particular, those that were agreeable or
supportive of referring patients for participation at another site
similarly identified themes such as the possibility of a positive
experience or benefit for their patients and were agreeable to make
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the referral due to and lack of availability at their own institution as
the following responses demonstrate:
Yes, I would. I wouldn’t say no just for the sake because we
don’t have something available here in our facility as long as the
patient is happy doing that. If patient is willing and it helps,
helps research for the future I would say yes, definitely yes
(05-V_P)
Yeah. I wouldn’t mind that (08-A_P)
Absolutely. If I have a patient who is eligible for a prevention
trial somewhere else and if I don’t have something for that
population I would send them. Wherever there is a good study
for the patient, we send them (09-S_N)
Yes, because it’s something you don’t offer here and they
potentially could benefit from participating at another place
(10-A_P)
I would be if I felt that the agent or the trial being considered
was potentially quite appealing from a biological standpoint and I
thought there may be a significant benefit to my patient
(01-S_P)
The possibility of “losing” patients or having them “stolen” was noted
by several participants. Variance occurred across the types of sites
where participants worked, with those working at academic centers
and in private practice more concerned than those working at specialty
centers, as the following responses suggest:
No, in the sense that you are sending your patients somewhere
else and they may not come back. So, why should they? It’s
almost like saying that if you’re not cutting edge enough to have
their research trial at your institution so why should I come back
to you? (10-A_P)
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One of the major reasons that people do not like to participate in
the project done in centralized area is that they lose control of
the patient (11-P_P)
Well, we don’t worry about people stealing our patients. I think
that’s probably the big thing. So we wouldn’t mind sending them
(06-S_P)
Comments by another participant suggest that the tenure of
experience may also influence the likelihood that this is a concern:
You ask a guy like me, I’m not just beginning out in this
business. I’m not as threatened by sending off as some might
be. So no, I wouldn’t have trouble with that. If you talk to
someone who’s trying to build a practice they might be less
inclined to do that (12-S_P)
Concerns related to the coordination of all the details involved in
referring patients outside the site of usual care was expressed in
several different ways, in the following responses:
I’m always more in favor of keeping patients within my
institution. All of us have a fear that when patients leave here,
(are) sent out, they can be lost in the paperwork and the shuffle.
Therefore, if there is an opportunity to have some coordinators
come here and patients being managed on a trial and kept here
that would definitely be more suitable or ideal (01-S_P)
It would find that to be overtly cumbersome. That’s nothing I
would encourage (08-A_P)
I think that would be ok. The only problem I guess is just
logistics. Who and when are they coming to visit the patient?
You have facility fees involved, things of that sort that would
have to be worked out on a higher level. Those things are
important because if they’re occupying a clinical room then that
means another patient is not there so potentially losing money.
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It always comes back to money. I would much rather have it
done here (10-A_P)
A summary of concerns that were noted when a trial was not available
locally and referral to another site was possible are found in Table 12.
Table 12. Concerns related to referral to another site (n=12)
Comment
Logistics are challenging
Losing patients to other providers
Lack of transportation to other locations
“Overtly cumbersome” nothing I would
encourage
Someone is going to be losing money
I would much rather have it done here
Volume of patients
Complexity of the trial
Adequacy of current staffing levels to support
volume of work
Patients “lost in shuffle” when “sent out”
No concerns at all about this

Site Type (Frequency)
A (1) V (1)
A (1) P (1)
S (1) A (1)
A (1)
A (1)
A (1)
P (1)
P (1)
S (1)
S (1)
V (1)

S-Specialty Center A-Academic Center V-VA Hospital P-Private Practice

The possibility of training current staff in order to keep the
project at their own site was appealing, yet limitations were noted in
the following responses:
It would be in theory. I know that some of the major constraints
we have today is the number of research staff that we have and
(the) ability for them to participate in all of our active trials. I
think if we ever (are) to do that we would need to increase our
research staff. If we did that then yes, that would definitely be
suitable (01-S_P)
So from the research point of view you are better off sending
your own people because they dot their I’s and cross their T’s.
All the things that these people don’t care about. If you are not
sitting next to me by the time the patient left half of the things I
didn’t do because I am doing my own stuff (and forgot)
(11-P_P)
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Depends on what the trial is. I mean if it’s really complicated
that’s one thing. If it’s not that complicated then I think we can
handle that. A lot depends on if it involves a whole lot of
technology, it just depends on the details (12-S_P)
With the following statement, one participant was quick to clarify that
the concern was not related to training, but rather the lack of time:
The training is not a problem, the time to do it that’s the issue
(02-V_NP)
Participants noted that these options were not mutually exclusive and
may actually be complementary and/or interrelated as suggested by
the following responses:
I think the three are not exclusive. They are complementary
(03-S_P)
I think that they are interrelated, they are not exclusive. That
they’ll occur even within the same site and there will be different
reasons for why patients can or can’t be referred- distance,
neighborhood, whatever (08-A_P)
Interestingly, one noted that prevention trials may not be appropriate
for the patient population served at their facility, with the following
response:
If you’re talking about prevention trials they don’t come up very
often in our discussions because the people I am seeing already
are sick, they already have cancer (09-S_N)
Physician-patient relationship.
The second line of questioning was designed to elicit feedback as
to just how participation in a cancer prevention trial impacts the
physician-patient relationship. Those participants who practice at
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specialty centers all noted it as a positive experience with some
indicating that it fostered trust, the sense of a common goal and
allowed for the provision of involvement at a different and more
holistic dimension, and allowed for a continuum of care as the
following responses demonstrate:
I think it positively impacts it because patients are realizing you
are trying to strive for minimizing their risk of cancer
development that you are offering them treatments that they
would potentially not be getting anywhere else so I think it
fosters a degree of trust and of a common goal trying to be
achieved (01-S_P)
I think it makes it better because it’s more holistic. (You) get
involved with that particular person at a different dimension, a
different perspective which is a perspective that many things
many conditions can be prevented and we just scratching the
surface of that. And that would make the relationship more solid
because one is starting to know the patient very early. You know
them for longer periods of time. There’s more continuation of
care (03-S_P)
It was a positive, that’s about all I can say (06-S_P)
Any clinical trial I don’t think there is any negative effect on
physician- patient relationship. You know most of my patients
are participating in clinical trials they understand how important
they are and some of them are very very happy that they are
participating because they feel that not only are they potentially
helping themselves but may be helping other people too through
their participation (09-S_N)
Those at an academic institution also note a positive experience that
allowed for a more comprehensive level of care as described in the
following responses:
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I speak of this only because of what I have heard from patients
is that they are actually very happy to come to the university
setting to hear about nutritional changes. Patients time and time
again have made the comment that these are things that are not
talked about with them at other institutions or whether it be in
the community or what have you. Or they actually seek that
they want that knowledge and I think that the fact that we do
participate in these trials helps the patient physician relationship
and it also lets the patient know on a different level that we are
concerned about their overall health (08-A_P)
I think it’s a positive thing because you can tell the patient that
you are participating in that type of a trial that kinda lets them
know that you’re not just the surgeon that can’t wait to cut on
you. It lets them know that you are interested in overall patient
care and so this is something I can offer you besides just waiting
for your next biopsy to come up. An opportunity to for me to
intervene again, so there’s something I am interested in doing
that might help you not need that intervention. So I think it’s a
positive thing for the patients. I think they appreciate that
(10-A_P)
Response from those participating from the VA medical centers was
the most varied, yet also overall considered participation to have a
positive and rewarding influence on the relationship as well as benefits
to the patient in respect to contributions to the greater good as
evidenced by the following responses:
Oh it’s wonderful because the patients are interested. Nobody
wants to get sick. They would like as much as possible to
participate. Once your patient is in trials even when participation
is completed, I still see them in my research clinic and you know
it’s actually (a) very good rewarding relation. Some get
recycled; they enter new trials, similar disease spectrums. Oh
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it’s very rewarding. Wonderful relationship with this patient. It’s
fun. Absolutely (04-V_P)
I think patients by and large appreciate that as a physician you
are trying to do something for the betterment of humanity. I
think the patients feel good about it as well themselves because
they feel that they are doing something which is helpful for the
future generations. As a physician patient relationship I think it
makes you feel good, that’s my personal feeling. You get to
know them. They come every so often so you get to see them
(and) often you develop a relationship with the patients. Both
the physician and the patient know that it’s something which
goes beyond the day to day activity, something for the
betterment of humanity. (It’s) definitely a positive experience,
different than the normal (05-V_P)
The participant working in private practice reports no change in
physician-provider relationship and suggests that overall patient
satisfaction is dependent on multiple factors as seen in the statement
which follows:
Nothing changes. They depend upon the outcome you know; if
the patients have good outcome and good experience they are
happy. If they didn’t have a good experience they come back
and express their dissatisfaction. Does (the) patient leave me
because I sent him to the study? No. Is (the) patient mad at me
because I sent him to the study? No. Some of them they feel
that it is good, that it is better because they have more frequent
check-up, more frequent lab work. Some of them see this as a
risk and (some) as a reward you know? (11-P_P)
A summary of the impact of participation in a PCPICT on the physicianpatient relationship can be found in Table 13.
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Table 13. Impact of participation in PCPICT on physician-patient relationship
(n=9)
Comment
Positive Impact
Doesn’t change/impact it
Makes it better, more holistic

Site Type (Frequency)
S (2) A (2) V (2)
S (1) P (1)
S (1)

S-Specialty Center A-Academic Center V-VA Hospital P-Private Practice

Duality of roles.
Prior research suggests a possible conflict when a provider plays
the dual role of advocate for the patient and for the research. To
address this, participants were asked how their ethical responsibilities
as a physician change when a patient participates in a cancer
prevention intervention trial.

Many noted that ethical responsibilities

did not change as seen in the following responses:
I don’t think they ever change. I mean I think that the patient
comes first. I don’t think they ever change (08-A_P)
I don’t think they change at all. I have the same responsibilities.
Whether they are in a trial or not you still are working under the
same ethical premise I would think (02-V_NP)
One informant commented more specifically in relation to the ongoing
trial and introduced the concept of risk. Additionally, he suggested
that the goals of chemoprevention and therapeutic trials may be
different as elaborated in the response below:
Good question. I think that they ultimately remain the same.
One of the premises of being a physician is do no harm. So I
think that you need to be very clear that when you discussing a
chemopreventative trial that the goal remains the same as do no
harm and potentially prevent cancer, but that there are risks.
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Those risks are what you need to discuss, what those relative
risks are in terms of percentages of the various complications
you may have with them. So, I think your role as a physician
doesn’t change but (patients) need to understand clearly you’re
ultimately not knowing what the results are going to be for that
specific intervention, which is a little bit different from when you
treat a condition, when someone has a physical malignancy that
you are treating. So, obviously you are earlier in the spectrum of
disease but the goal is the same-minimizing the progression of a
condition (01-S_P)
Several informants did reference the scientific merit of a study and
how that may be a factor in minimizing any potential conflict related to
duality of roles as seen in the following responses:
I think it’s part of the ethics of the practice of medicine. As long
as the science is sound and makes sense (03-S_P)
Well, one has to be objective about the study design. If the
study is well designed with appropriate controls; reasonable
ethical eligibility criteria, does not push the envelope, does not
promise hyperbolic outcomes I don’t see ethical issues, no
(04-V_P)
One participant did not report ethical conflict; however, did make
reference to the fact that a research participant may be treated
differently than a non-research as seen in the statement which
follows:
I am doubly careful about the patient because he has voluntarily
agreed to do something which may have deleterious effects on
him. So, I am doubly careful with my research patients to ensure
that no harm comes to them and that’s true for any patient
which we would deal with but more so with our cancer research
patients. One does tend to be a bit extra careful with the details
and everything else (05-V_P)
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There was overall no variance in response across types of sites with
informants from several referring to the Hippocratic Oath and
physician’s responsibility to first do no harm. Interestingly, one
physician working in private practice suggested a potential difference
between pharmaceutical and prevention trials with the following
remark:
I think that exists a certain extent in pharmaceutical trials where
there’s dollars coming in. I suppose that the same could hold
true for a prevention trial depending upon what the budget
might or might not allow (07-P_N)
A summary of the responses related to changing ethical responsibilities
is found in Table 14.
Table 14. Ethical responsibilities (n=9)
Comment
Ultimately remain the same, premise of being
a physician is to “do no harm”
They don’t change at all. I have the same
responsibilities
No ethical concerns as long as the science is
sound and makes sense
No ethical concerns as long as the study
design is good
“Doubly careful” with research patients to be
sure no harm comes to them
No change
“They don’t ever change. The patient always
comes first”
They don’t change
“I’m not sure they really do. You still have to
be the doctor and do your best.”

Site Type (Frequency)
S (1)
V (1)
S (1)
V (1)
V (1)
P (1)
A (1)
S (1)
S (1)

S-Specialty Center A-Academic Center V-VA Hospital P-Private Practice
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Next, participants were asked to discuss any experiences related
to role conflict when they played the role of advocate for the patient
and for research simultaneously. Two responded yes and provided the
following explanations:
I have, yeah. Some trials where I’m a PI and I’m discussing the
study and I make it very clear to the patient what my role is in
the study, I am really forthright about it. I tell them since I am
the one that designed the study that obviously I may be a little
biased that I think this study may be beneficial to you, but I
make it very clear to them what the pros and cons are going to
be and I make it very very clear to them that the end of the day
whatever decision they make does not change ultimately how I
treat them and they will ultimately get the best quality care
they can but obviously (it) may vary depending on whether they
participate or not (01-S_P)
I would say yes, you know when these LFTs (liver function tests)
are elevated, how elevated? Is it elevated enough to take them
off the study? Is the drug doing some harm? So yeah, every
time there is something (like that) you have to consider (that)
there’s conflict. It’s a balance, ok is he really being harmed or is
he not being harmed? Is he being harmed enough to come off
the study or not? Those kinds of things, I just make the decision
that’s best for the patient. Always do what you think is best for
the patient (10-A_P)
Others reported that they had not experienced conflicting roles
commenting how factors such as financial interest and IRB oversight
may be influential as noted in the following responses:
No, I think they come together and it comes with an
understanding that the research is part of care and is an
enhancer to the care (03-S_P)
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I feel that my role is primarily being (an) advocate for the
patient. So if I don’t see any conflict of interest or ethical
problems participating in the research. I’m (honoring) my
responsibility of being an advocate for my patient. I would do it
if I were the patient myself so I don’t see any conflict there
(09-S_N)
No, if I don’t have any financial interest or financial benefit and
(it) is a study I am convinced to do, I don’t think it changes
anything. Also (if) the study passes the IRB, you know that (it is
ethical) (11-P_P)
While others noted that though they had not personally experienced
role conflict, they could imagine how it was possible as the following
responses illustrate:
I could see how that would happen, I haven’t really had any
personal conflicts but I could definitely see how that could be an
issue (02-V_NP)
Well, I think that there can be, I wouldn’t say coercion but
motivation of interest on both sides, if one is willing to accept
monetary advantages. Some people have to bring in their
dollars for research resources and percentage of time and so
forth that might be squeing a little bit the balance but for me
personally that has not been an issue (04-V_P)
I have not personally, but I can see how that could happen. I’ll
give an example: there’s a big group here in town who has a
whole wing on their building that is dedicated to clinical research
for profit so while it has not influenced me, I can see how that
how that potentially could influence people (07-P_N)
A summary of the responses related to duality of roles and possibility
of role conflict is found in Table 15.
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Table 15. Duality of roles/role conflict (n=12)
Comment
Yes
When PI (Principal Investigator) that helped
to design
When labs abnormal
No
Have not experienced
As long as I don’t have financial interest or
benefit
Not if the study passes IRB
Can understand how it could be an issue

Site Type (Frequency)

S (1)
A (1)
S (2) A (1) V(3) P (1)
S (1) P (1)
P (1)
S (1) V(2) P (1)

S-Specialty Center A-Academic Center V-VA Hospital P-Private Practice

Changing relationships.
Participants were also asked to describe changes that occur
when a patient converts to research participant. On multiple
occasions, the informants stated that the actual care of the patient did
not change. However, specific changes were noted with the
coordination of care, workload and documentation requirements, as
the following responses demonstrate:
I think that when someone becomes a research participant there
are more people involved in their active care so there is an
additional component of coordination that needs to be involved
(01-S_P)
There is a heck of a lot more paperwork. That’s I mean that’s
really the main thing but you know typically we’re doing the
same things for similar reasons (02-V_NP)
Well, once the patient becomes a research participant we have
to follow everything that is written in the protocol to the minute
detail because if we don’t do everything exactly as it’s written
you get a lot of protocol deviations…That’s the only thing that
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changes once a patient becomes a study subject.
patient’s care it never changes (09-S_N)

As far as

Additional comments hinted at necessary changes in the level of
patient commitment or ownership of their care when participating in a
trial, as the following responses suggest:
Their treatments or the way they are being cared for is more
rigorous and requires more of a commitment from them as well
(01-S_P)
Well I think it makes the patient take more ownership of the
care and the other thing about prevention trials is that the
ownership of the individuals care starts earlier down the
continuum of care (03-S_P)
The importance of the relationship between the patient/research
participant and the research team, as well as hints of possible changes
in this relationship was suggested by the following responses:
You have to be willing to understand that the research subject is
a special patient. For technical reasons there are certain
(protocol) parameters that have to get fulfilled. One cannot cut
corners and by the same token if the research team does not
pay attention to the details and accommodate a patient, one
ends up with noncompliance, drop outs, etc. So, the research
patient has to be accommodated and (the team must) pay
attention very very close because otherwise one loses him. One
has to be flexible (04-V_P)
I’m trying to look for a change but the only thing I see
sometimes is that the patient physician (bond) may become
stronger (08-A_P)
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Variance in response could not be associated with a specific site type
as similar themes were noted by participants from specialty, academic,
VA and private practice sites.
Participants were also asked to describe any changes that
occurred when the research participant completed the study and
converted back to patient again, at the time of study completion.
Responses by all participants varied, with not all reporting changes.
Themes that were noted ranged from possible changes in terms of
trust to a reduction in paperwork and documentation requirements as
evidenced by the following remarks:
Sometimes patients, if they’ve had side effects (they) may be a
little bit skeptical about what you are offering them next. I think
you need to discuss with them why their complication happened
or ultimately outline for them what our treatment goals are
going to be going forward. But there may be some challenges in
terms of the trust (01-S_P)
Of course, once they if they are off study then you don’t have to
worry about the deviations anymore. You just do your usual
standard, good clinical practice (09-S_N)
We track them less because we don’t have to see them so often
(10-A_P)
The most commonly noted change in the physician-patient relationship
was a strong and lasting bond or attachment between the two as
reflected in the following responses:
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You get the impression that they have a stronger bond (08-A_P)
One gets attached to patient and patient gets attached to PI… I
think it becomes almost like (a) family apparatus or relation,
which it’s actually very rewarding. Very rewarding (04-V_P)
We do develop a good rapport once being a study subject and it
carries on after they are off the study (05-V_P)
A summary of responses can be found in Table 16.
Table 16. Changing relationships (n=9)
Comment
People (patients) are more involved in their
care
Additional coordination is required
Trust may be challenged depending on what
happens during the study
Hope the patient becomes a better health
consumer

Site Type (Frequency)
S (1)

Patient-physician bond strengthened
Keep them happy so they stay on the study
PI-Patient attached like a family apparatus
Nothing. We do the same things for similar
reasons
We develop a good rapport
Patient is special and has to be accommodated
or you will lose him

A
A
V
V

S (1)
S (1)
S (1)
(1)
(1)
(1)
(1)

V (1)
V (1)

S-Specialty Center A-Academic Center V-VA Hospital P-Private Practice

Preferred time of involvement.
Participants were then asked at which point in the research
process they prefer to become involved, (i.e., conception/design,
implementation, etc.). Those working at specialty centers all preferred
to be involved early at the conceptual and grant writing stages as
opposed to becoming involved later and gave very concrete and
specific reasons for this as the following responses elaborate:
94

Early on. I think if possible at the conceptual level because I
think it gives (me) the ability to give some input from a clinical
standpoint in terms of what may be important to look at, what
may be hindrances to the study itself (01-S_P)
As early as possible. Prevention is (a) very complex issue which
requires a lot of multi disciplinary approach from the research
(team), from the basic research, from the translation from the
clinicians. And in order to develop a trial all have to be involved
from the very beginning and not only to understand the trial
better to be sure that it makes sense and to be sure that
downstream when has been designed and more importantly
implemented there is a very clear understanding of what the
objectives are from the get go (03-S_P)
The earlier the better because if I’m going to be participating in
a study I would like to be involved in the planning stages. You
know, even writing the grant. Having more people involved early
on you can identify pitfalls and potential problems or even
assess feasibility better if you have people involved (then)
(09-S_N)
The responses from those working at an academic center were more
split with one experienced participating at all levels yet expressing
benefits of participating early as well, especially with trials involving
multiple sites as seen with the following response:
I have participated in all levels. The ones that I find the most
valuable are the ones with design (of the study)… I think that it’s
valuable that if you are thinking of involving 10 institutions that
they all participate at design level or at least get input at design
level (08-A_P)
This response was similar to those noted by physicians working at
specialty centers.

Another physician working at an academic center

mentioned preferred involvement at the activation and recruitment
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stage; however, noted that earlier involvement may be beneficial, as
seen with the response below:
I like…where I was brought in (to the project), kinda I guess
towards the end... because there’s less to do besides just enroll
the patients. But, I don’t think I would mind at all being
consulted earlier on regarding the clinical aspects that could
potentially play a role later on. My perception is just that the
physician probably was not as helpful as (he) could have been
(with this study) because (he was) so busy (10-A_P)
Those working at VA medical centers expressed the most variance in
their responses with one noting that it would depend on the trial yet
was unable to elaborate and provide more specific details for his
response. Another theme observed though not expressly stated,
seemed to be associated with tenure and prior experience as a
researcher as the following participant elaborates:
Well, I believe that after decades in the field, probably some
individuals like myself might be able to contribute some
impressions and some valuable details in the planning phase of
such projects. Not based on just lab experience (but from)
being in the trenches, seeing what disease is at the other end-what is worth preventing and what perhaps is not worth
preventing (04-V_P)
One physician from private practice preferred to be involved with study
activation and initiation and not in the planning stages as seen with
the following response:
I like to join a study at the beginning. I don’t necessarily want to
be involved in study design (07-P_N)
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The physician who has had tenure in both academia and private
practice noted that several factors influenced when he would prefer to
become involved:
It depends upon the study itself and the investigators and my
degree of how much I know him how much I don’t. I have a big
academic background so I don’t mind looking at a study (early
on to provide input) (11-P_P)
Different from responses to the prior questions, there was greater
heterogeneity between but not within the types of sites. A summary of
responses follows in Table 17.
Table 17. Preferred time of involvement (n=12)
Comment
Design/conception
When initiating new sites, training and
recruiting
It depends on the trial
“I’m a clinician. I want to be involved in the
clinical part of it.”
Analysis
All depends on who the investigator is

Site Type (Frequency)
S (4) A (1) V(1)
S (1) A (1) P (1)
V(1)
V(1)
S (1)
P (1)

S-Specialty Center A-Academic Center V-VA Hospital P-Private Practice

Future participation.
I will remind the reader that participants were previously asked
which factors were important to them when considering whether or not
to participate in a cancer prevention intervention clinical trial. In the
final question to address research question one, participants were
asked what would help to increase the likelihood of participation in
cancer prevention clinical trials in the future. This question was
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designed to focus on factors at the individual, provider level not at the
broader institutional or structural level. However, the responses
addressed factors at both levels as well as some specifically related to
their patients. I will focus on the individual factors here (though it is
sometimes difficult to separate the two) and address the larger more
structural issues in a different question.
Those participating from specialty centers especially discussed
larger structural factors and also offered some solutions but none
noted specific individual or personal level factors that may influence
their participation in future trials. This could be a result of the fact
that due to their high level of specialization (surgical and medical
oncology) it is challenging to imagine a role for prevention with their
particular patient populations. Responses from those at academic
centers ranged from individual factors such as personal motivation or
interest and patient factors to academic recognition as seen with the
responses that follow:
I thought for a while there that if I… personally became more
motivated towards nutritional treatment for disease that that
might also drive my patients to do so too, but I didn’t
necessarily see that panning off in that they would be
participating in clinical trials. They may be taking matters into
their own hands but why they’re not choosing (to participate), I
don’t know why. Maybe because they don’t feel that the end
product for them is tangible, that’s their lack of desire to
participate. If there is something tangible they knew that they
could say hey…I can hang my hat on this. But there’s no science
there to support anyone making those statements so you can’t
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make a leap of faith in order to try to get them to buy in
(08-A_P)
I enjoy participating in the trials. I’m in academia so I enjoy
being on the papers… So, certainly having publications…I mean
the only reason to be involved besides your own personal
interest if in academia is the fact that you can get your name on
some papers and if you’re interested can be involved in some of
these cutting edge evolving things. That’s what it is for me, just
kinda the personal interest. I like research (10-A_P)
Larger, structural factors such as funding were also noted as influential
by seen with the following response:
I think one of the most important factors is if I join as a coinvestigator in a trial will there be enough funds for us to do the
trial? … And if the clinical trial is providing you that money then
you know, I would be more inclined to participate and
institutionally also they will not obviously support a study that’s
underfunded. That’s one of the things they look at: does the
study have funding? Adequate funding. So that’s number one
and also …the second thing that would be important to me is, is
it something that I am interested in personally? You know if I’m
interested personally in that clinical trial design or the
intervention then I am more likely to participate in it… If I am
not interested in the trial or don’t think it’s a good idea then
obviously I am not likely to participate (09-S_N)
Responses from two participants not working in private practice
provided potential insight into factors that may be influential to a
physician who was, noting finances and perceived benefit of
participation in the statements below:
I don’t know how you would incentivize a guy in private practice
to participate in trials like this. It would almost have to be
completely financial somehow. There are some big groups in the
country who do participate in trials like that. They present it at
meetings and they talk about how financially lucrative they can
be. And a lot of those are pharma trials. Chemoprevention like
99

this I just don’t know how you would incentivize them because
you have to have extra visits, you know for research and you
have the IRB stuff to go through. I don’t know how you would
incentivize them (10-A_P)
I think most of it would come down to what urologist’s
perception of the benefit (whether or not he/she would be
involved) (12-S_P)
In sharp contrast to factors suggested as influential to physicians
working in private practice, those from the VA centers responded
differently with both academic and scientific recognition as well as
more altruistic factors suggested as likely to influence their future
participation as seen with the following responses:
You know getting proper credit for contributing patients I think is
important. It’s not money; it’s academic and scientific credit
(04-V_P)
If the study appeals to my mind, that the study is going to be
something good for the betterment for the future, in my little
field. If I can kind of help things along or kind of change things
fighting cancer that would be one of the factors. It really gets
down to nuts and bolts, the crux, what is the study trying to
achieve? Are we helping the future? Are we helping the cause,
fighting against cancer? That is the bottom line. This would be
the primary thing. Everything else is secondary (05-V_P)
One participant working in private practice noted some similar factors
to those working in other areas with the following response:
I have to be interested in the type of cancer that we are trying
to prevent so that’s number one. It has to be an organ system
that I work with closely. Then the prevention itself has to have
some rationale, something that seems reasonable and the last
thing it has to be very simple. The other thing, I suppose it has
to be somewhat appealing to patients (07-P_N)
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Personal and professional interest in the topic of study, patient related
factors and funding were all noted as important by participants. The
range of responses regarding personal factors influencing future
participation in a prevention clinical trial can be found in Table 18.
Table 18. Personal factors/future participation (n=12)
Comment
I must be personally interested in the trial
Time
“What is the study trying to achieve, will it
help for the future?”
More federal funding for prevention
Must be patient friendly
Must be a type of cancer that I am interested
in preventing
Must be an organ system that I work with
“Fewer steps for the patient makes it more
appealing to me”
Will there be enough funding for me to do the
trial?
Publications
Must be a trial that patients are interested in
participating in
Academic/scientific credit
If it appeals to my mind and is for the
betterment of the future
Urologist’s perceived benefit
There must be a tangible measure that the
participants can see

Site Type (Frequency)
S (1) A (1)
V(1)
V(1)
S (1)
P (1)
P (1)
P (1)
P (1)
S (1)
A (1)
S (1)
V (1)
V (1)
S (1)
A (1)

S-Specialty Center A-Academic Center V-VA Hospital P-Private Practice

Structural level factors.
The next participant responses are related to research question
two (What structural factors influence a physician’s participation in a
PCPICT?) and explore and document structural -organizational and
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infrastructural- considerations that influence participation in a PCPICT,
with a comparison of factors across types of sites.
Influence of sponsor.
Participants were asked to consider how organizational
infrastructure may facilitate and constrain participation depending on
the sponsor and to consider how some sponsors are preferred over
others. There was great variance in the responses both within types of
centers and when making comparisons across them. Disjuncture
between organizational mandate and allocation of resources was noted
by an informant from a specialty center:
From the organizational level our mandate is to do research.
There is a difference between what is expected and the
resources provided and the expectation that we would have to
provide the resources and the organization somehow is the
coordinator of those resources without allocation of resource. I
understand the organization needs to be fiscally conscious and to
be sure that we carry the business but if the organization doesn’t
allocate the resources that we would need on top of what our
responsibility is to fund some of that research, they are not
proportional (03-S_P)
The response from another key informant was suggestive of
infrastructure related factors that may be influential when considering
those physicians working in private practice, that are not
participating:
If I have to use my infrastructure, I don’t have anyone in the
office so I have to go through the hospital or I have to hire
someone. Hiring someone for a small project is not a good idea.
You have to have the infrastructure, that’s why I think the
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community guys shy away from research, there’s too much
paperwork to do. Even through the paperwork, your examination
is different, your documentation is different, your labs that you
will draw is different (11-P_P)
Funding was reported as influential, serving as both an institutional
barrier and facilitator to participating in research by several
participants as the following responses elaborate:
A non-funded trial gets minimal effort from the clinical trials
support staff (08-A_P).
The institution wants money coming in the door. So I think
we’re getting away from research for the sake of research for
sure but looking more at research that can pay because if it
doesn’t pay it just can’t happen long term. There is just not
enough money going around to pick-up the slack (10-A_P)
The pharma trials, they basically give more money to do it, so
sometimes it is easier to find those resources that you need to
get the job done (02-V_NP)
At the specialty centers there was a clearly stated preference for
federally funded trials or those that had gone through some type of
peer review as opposed to pharmaceutical trials as the following
responses demonstrate:
So my experience has been typically trials that are organized at
the federal level are typically pretty rigorous and well designed…
when studies are done at (the) federal level a lot of the
administrative type responsibilities are not necessarily present.
It is easy just to put the patient on and then everything else is
taken care of…the flow is a little bit smoother and the effort is a
little bit less. We like to participate with some of the big
oncology groups SWOG (South West Oncology Group) for
example is one. I definitely think any studies that are being
conducted directly through the NCI we actively try to participate
in as well in urology, the SUO (Society of Urological Oncology),
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has developed a consortium group …. and they have developed a
couple of trials and I think those are trials we actively try to see
if we can participate because we know that being open to lot of
major cancer centers, accrual should be good…(the) likelihood
of achieving accrual goals is definitely there (01-S_P)
Well our mandate of trials that are preferable are the
investigator initiated trials which go through a(n) outside peer
review, which is basically federal or it could be at the state level.
Then you have the pharmaceutical sponsored trials and they are
at different levels. Definitely, there’s discouragement of doing
post marketing trials. But there’s a hierarchy of preference that’s
the expectation and I think pretty much everybody knows about
the expectation (03-S_P)
We always give precedence to studies that are NIH funded
studies and investigator initiated studies and then if there is
room then industry sponsored studies are supported. So NIH
funded, grant funded studies, always take precedence and then
followed by investigator initiated studies which may or may not
be grant funded and then following them you have a drug
company studies. Of course you know when the funding is
getting tougher to get you may have more pharmaceutical
studies but it doesn’t change the rules that we use to activate
studies (09-S_N)
These types of trials were noted by other sites as well but for different
reasons noted in the responses that follow, such ease of
accommodation:
Federally funded studies are easier to get accommodated then
commercial studies based on fiscal and intellectual property,
legal (type) aspects. Some organizational related federal funds
might be rather accommodated than others like VA cooperatives
have priority over NIH/NCI studies and certainly over
pharmaceuticals. VA cooperatives take precedence but without
the infrastructure to necessarily support them (04-V_P)
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Additionally, funding limitations at the federal level and the specific
impact on clinicians interested in doing research locally were noted:
They say that they (the institution) want us to get federal grants
because those are more prestigious, even sometimes they don’t
quite pay as much by the time you get all the directs, indirects
and those kind of things. At the same time, to get federal grants
many times you have to have at least 40% dedicated research
time and that makes a lot of clinicians not eligible. So, if we say
we can’t get these big grants from the government because we
don’t have research time, rather than give us more research
time then I think the shift is just to say, well try to get these
other grants the pharma grants, and such that don’t have that
requirement (10-A_P)
A respondent also suggested that sometimes the prioritization of
research projects shifts as seen in this response:
Well, for one thing it’s very hard to get federal funding now. At
least in terms of RO1 type grants for investigator initiated
(studies). The cooperative group trials are not such a problem.
Our infrastructure has influenced that a little bit, we participate
in SWOG and to do that we have to put in a certain number of
patients in studies every year. Just recently our director gave
notice to everybody that we are not putting enough patients on
SWOG and to quit putting patients on the drug company
sponsored studies unless there was really some unusual patient
oriented circumstances. It does change over time because if we
are doing really great on SWOG (as) in just a few years past
then it was ok to go out and get the other sponsors (06-S_P)
The range of responses related to the influence of sponsor can be
found in Table 19.
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Table 19. Influence of sponsor (n=12)
Comment
There is a hierarchy of preference
Investigator initiated then pharma trials
Post-marketing trials discouraged
We have a directive and it changes over time
Currently cooperative group trials preferred
over pharmaceutical trials
NIH funded, investigator initiated then
pharmaceutical
Funded preferred over non-funded
Institution just wants money coming in the door
but federal are more prestigious
Federally funded are easier to get
accommodated based on fiscal and intellectual
property issues
There is no preference
I don’t see a difference
Not a good hierarchy, each department does its
own thing
Pharmaceutical can be easier because I don’t
have infrastructure

Site Type
(Frequency)
S (1)
S (1)
S (1)
S (1)
S (1)
A (1)
A (1)
A (1)
V (1)
V (1)
V (1)
P (1)
P (1)

S-Specialty Center A-Academic Center V-VA Hospital P-Private Practice

Additional infrastructural barriers such as limited staffing and time
were also noted by participants across several sites, as evidenced by
the following responses:
We are assigned nurse coordinators and it appears that the
nurse coordinators are always playing catch-up because they are
so busy. And the institutional perception is that there are too
many and they have to be rationed. So we have many studies
that we want to get going and there is a push back institutionally
because they say there are only so many nurse coordinators that
you can use and you can allocate and you have to pay for it
(03-S_P)
Faculty, they are all incredibly stretched thin. I think their
limitation is similar to our limitation in terms of time (07-P_N)
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One participant elaborated on the barrier of time in the following
response:
It’s got to be a trial that a doctor is willing to remember. And
then not only willing to remember but willing to spend some of
their pressured time to bring up in the conversation with the
patient. If it’s something where the doctor says I don’t mind you
having that trial but he’s thinking to himself I don’t care about
that then he’ll never offer it to anybody. Will be aware but
barely remember. Will be aware of it and he would remember it
on multiple choice questionnaire that it’s there but not probably
not remember to spontaneously bring it up when he’s in front of
it. And so you have to know the personalities of the doctors and
what they are interested in doing (12-S_P)
This insight may be particularly relevant to those in a community or
private practice setting and should be considered in the design of
future prevention trials.
Financial loss.
Next, participants were asked about concerns related to financial
loss if a patient moved care to participate in a prevention intervention
trial as well as for suggestions to mediate if it was a concern. There
was much heterogeneity in the responses both within and across
groups as reflected in some of the responses from those working at a
specialty center:
(Financial loss is) not really (a concern). I guess in theory there
is but not really. I think ultimately that in prevention trials we
really want to try to offer patients what we truly think
biologically makes a lot of sense and as long as you continue
following your patient I think that wherever a trial would be the
most suited for someone is ultimately the best place for them to
go (01-S_P)
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Well it depends how you look at it…from the very bottom but
irrational business level, yes because you are losing one patient
but if you set up a system with the view of abundance in which
you have scarce resources and the thinking is you need to
rationalize more and keep the resources to yourself …I think if
you have a good trial, subjects will come in…with the
complexities of the trial you can get it going (and) trials that you
thought would not accrue at all you start (and get) 20-30%
which is more than the zero percent. And I think if you have a
well designed trial, well coordinated if you look from that
perspective you could be adding, more enlarging than restrictive.
So if looking at that bigger view then not just business model, if
you have a bigger network it ultimately becomes advantageous
then because it becomes available to more people (03-S_P)
No, not at all. For others, I don’t know of any way other than
financial inducement (06-S_P)
As well the responses from those working at an academic center:
I’m an employee of the university I don’t feel a big loss if
patients move. I look at it, and this is my opinion to the same
extent if I think someone would be better served to have a
treatment somewhere else, I’ll refer them there and so that
being said, that’s probably bigger money loss then perhaps
revenue generated through office visit for a clinical trial (08-A_P)
Yes. There’s no way I would send my prostatectomy patients to
another facility. No way. The only thing I can think of is if it was
a disease process that was not very easy to take care of or if it
was something that like a lot of the community doctors didn’t
want to deal with then that would be a good excuse for them to
send the patient away and have someone else deal with it but
prostate cancer for example is so pervasive. That’s potentially a
big money maker. Not only for surgical reasons but you have the
biopsy involved, you have the follow-up clinical visits to follow
the PSAs. You know, all kinds of things so if you lose a prostate
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patient you have potentially lost a lot a of money over time even
(10-A_P)
Those working at a VA hospital had the most homogeneity within all
groups, as well as the least concern regarding financial loss as
evidenced by the following statements:
Usually not. I mean I could see how there could be. At a VA
there’s not, at all (02-V_NP)
No. We have so much volume that they don’t care about that
(04-V_P)
One participant hinted at the variance between clinical and business
perspective, both of which cannot be ignored when planning future
chemoprevention trials as the following quote demonstrates:
(This) might be a little difficult question for me to answer
because I don’t know the financials. At my level, I’m a plumber
you know? What I do is a bit of urology or go to the operating
room or go to clinic do my procedures and don’t think too much
about the finance part of it. I guess no institution would like to
lose a patient because more patients, more procedures, means
more money. That’s as simple as that. From their point of view,
it’s a different ball game altogether. From my side it’s entirely
clinical and that’s finances. So we need to kind of merge the
two, find a median path (05-V_P)
A participant from private practice provided insight into several issues
including loss of control of the patient and financial concerns with the
following response:
It’s not, as long as they are coming back. If you look at bigger
studies you know, you are not going not get the community
involved within the design. But if you want to finish it early and
get the cases, it’s your job to send it to them. You can do this
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without them losing their control of the patient. The community
physician does not like to give up the case because this is how
they make their money (11-P_P)
These could be possible reasons for the lack of referrals from
community physicians for the current trial. These reflections should be
considered for future projects as well. A summary of the range of
responses can be found in Table 20.
Table 20. Financial loss (n=9)
Comment
I guess in theory there is but not really
No
It depends how you look at it
At my level no but I don’t think too much
about the finance part of it
We have so much volume they don’t care
about that
Usually not
I’m an employee of the university, I don’t
feel a big loss if the patients move
Yes
Not a concern as long as they are coming
back

Site Type (Frequency)
S (1)
S (1)
S (1)
V (1)
V (1)
V (1)
A (1)
A (1)
P (1)

S-Specialty Center A-Academic Center V-VA Hospital P-Private Practice

Future participation-institutional perspective.
The physician participants were next asked to consider factors
from an institutional perspective that would increase the likelihood of
participation in cancer prevention clinical trials in the future.
Responses were varied and though this question was designed to elicit
factors from an institutional perspective, both individual and structural
factors emerged as evidenced by the following responses:
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(Having) dedicated staff. I think that’s the critical point, need to
have dedicated staff (and) that institution feels is important to
do prevention trials and allocate them. Institutionally (03-S_P)
Talking about developing cancer trials, we need more faculty in
cancer prevention and control (06-S_P)
Being willing to set up and open dedicated clinical research units.
Which means clinic space, clerical staff, study nurses, and
research staff support with the regulatory process. Currently,
everybody does it by himself or herself, the investigators. It
stifles progress. There are lots of patients who are interested in
trials but (there are) insufficient resources to help investigators
bring trials to patients and accommodate patients in trials
(04-V_P)
I’m not in that division (but) I think that the only thing that
prevents them from doing more studies is the lack of funding. If
they had more funding I think they would be doing more
(09-S_N)
A summary of themes that developed included increased
infrastructural support ranging from staff (both clinical research
coordinators and faculty) to dedicated clinic space, as well as the
necessity of funding and can be found in Table 21.
Also mentioned were the current economic climate and its
impact on healthcare as well as the interconnectedness of clinical
activity and research as evidenced by the following response from one
participant:
I think that the financial climate…in the US overall right now is
…with the recession, plays a role because right now people aren’t
going to the doctor much because they don’t have as much
income. People are fighting for funded patients to come in. The
clinical activity is what pays for research really… it keeps the
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doors open and the research dollars don’t keep the doors open
it’s the clinical dollars that do and so we’re encouraged to do
more clinical activity and the thing that suffers of course is the
things that don’t make money. Research typically doesn’t make
the type of money, clinical does. So, that is not encouraged as
much I don’t think as it could be. What is encouraged, I think
sometimes are doing clinical trials that pay like some of the
industry sponsored things. That’s more encouraged because
that’s going to put some money in the bank so to speak. I don’t
feel like there’s always a genuine interest in the research itself. I
think it’s in the dollars that research can bring in. I think that
clinical research is more of a priority because we do more clinical
work here and then even a higher priority is doing clinical trials
that pay (10-A_P)
Table 21. Institutional factors/future participation (n=12)
Comment
Increased advertising
Dedicated staff
Dedicated research units with dedicated
research staff
Increasing patient awareness about trials
Financial incentives for the patients
Less paperwork
Need more cancer prevention faculty
There has to be funding to pay for it
Less ambiguity regarding significance of the
disease and it’s treatment in the medical
community
It’s ultimately going to depend on the
urologist’s perception of the benefit.”
The institution has to feel it’s important to do
prevention trials

Site Type (Frequency)
S (1) V(1)
S (1) V(1)
V(1)
V
V
V
S
A
A

(1)
(1)
(1)
(1)
(1)
(1)

S (1)
S (1)

S-Specialty Center A-Academic Center V-VA Hospital P-Private Practice

The importance of incentives and advertising were also noted by
participants as the following responses demonstrate:
For (the) institution it would be an incentive to work harder and
recruit more subjects (05-V_P)
I think making sure they are publicized more (01-S_P)
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The final responses related to research question three (How do
these factors vary depending on the practice site/area (specialty
centers, academic centers, Veteran’s (VA) medical centers, community
offices?) and consider how practice area may impact the feasibility of
participating in a prostate cancer prevention intervention trial.
Influence of the organization.
Participants were asked to discuss how the organizational
infrastructure both facilitates and constrains participation in
research/clinical trials.
Facilitation.
Responses related to the facilitation of research included a
consideration of the types of patients seen at each site and the
appropriateness for them to participate in prevention clinical trials as
the following responses demonstrate:
We see a fair portion of patients with unique clinical type
dilemmas or genitourinary malignancies or premalignancies,
which allow for participation in clinical trials and often times
patients are seeking trials when they come to us (01-S_P)
There’s a big referral base to the University for treatment, so it
gives an opportunity to accrue patients to clinical trials (08-A_P)
To the importance of integration of the research within usual clinical
practices was also seen as important as evidenced by the following
responses:
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The research is actively integrated within our surgical practices
(01-S_P)
The other thing that we have that works really well from an
infrastructure stand point is that we do actually discuss
prevention (08-A_P)
These trials we’re doing you know are for disease processes that
I’m going to be dealing with anyway so it makes sense. We can
just work it in to the natural flow (10-A_P)
Also reported was the importance of having an environment that
fosters research. The presence of support was expressed in various
ways and includes staffing, regulatory affairs assistance and
administrative backing, as the following responses suggest:
We have research staff that are present in our clinics (which)
makes it that much easier to obtain consents and to conduct
even questionnaires or surveys with patients. I think similarly
we have an active list of our clinical trials and protocols that
we’re that patients may be suitable for in the clinic, and
therefore, anytime we see patients we attempt to see if they
would be candidates for one of these trials. So, I think the
whole environment is fostered to consider participation in studies
when possible (01-S_P)
The organization has mechanisms including a clinical trial office
which facilitates putting studies through to get the required
regulatory requirements...we have a research nurse who also
assists not only in carrying the trial through but putting it
together and thirdly our mandate and one of our missions is to
do research (03-S_P)
An IRB that helps us... research is encouraged by the dean;
there are dean’s grants that are awarded yearly to facilitate and
to encourage research. There’s an office of research affairs that
basically makes sure that every research project that’s going
here is functioning as it ought to and is compliant with you know
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any standards that are put forth either nationally or locally by
the IRB or the office of educational affairs to make sure they’re
compliant (10-A_P)
The importance of building and maintaining positive relationships with
physicians within the community was also noted, as reflected in the
following comments:
I think we do try and maintain a good rapport with referring
physicians in the community in order to keep them aware of
what’s going on (08-A_P)
We also have “friendly physicians” who are not afraid of losing
patients. We can keep the care within our system and the
patients do not have to travel far (to participate in clinical trials)
(12-S_P)
One participant noted that though infrastructure existed, this
only allowed but did not help with the work of the study as seen with
the following response:
There’s nothing really to facilitate in any way. There’s
infrastructure: IRB, research office doesn’t actually help you do
the study, it just allows you to do it (02-V_NP)
Another participant noted a lack of institutional support with the
following response:
No particular efforts on behalf of institution to facilitate
research…. the institution is not very facilitating (04-V_P)
Constraint.
More specific responses related to the how the organizational
infrastructure constrains participation in research will now be
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presented. The most frequently emerging theme, noted across all site
types was time or lack thereof as noted in the following responses:
I think part of it is clinical volumes being such, sometimes it
becomes difficult to take the time to discuss all of the various
studies that you have available to patients. And sometimes with
the volumes you don’t think about it or consider putting people
on trial. So I think that it’s a little bit of two way street in the
sense that being actively busy gives you opportunities to see
more patients who may be suitable. Similarly (it) makes it
difficult sometimes to actively try to recruit as many patients as
possible for these studies (01-S_P)
Resources would be me actually having the time to focus on
patient recruitment, patient identification and managing that
piece of patient through a study. So when I say we lack
resources we lack that type of resource. It’s not that I’m not
interested but I’m pulled in too many directions. We’re a real
small department and just don’t have that critical mass to do all
things we need to do and still do a really quality job in clinical
research in my book (07-P_N)
Time definitely. Time dedicated to the encounter...sometimes
not having adequate support staff, clinical trial coordinators who
are readily available. If you are scrapped for time and you know
you potentially could accrue somebody, but yet you go to get
somebody and they are not in the office because they are off site
with someone else it’s like ok, we’ll make it a phone call then. I
think that we all know that your best attempt at getting
somebody is after the physician has talked to them and when
they are there in the office and quite often if you can’t accrue on
site, it’s going to be hard to accrue them over the phone or in
any other way without it sounding as though it’s coercive
(08-A_P)
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Additional themes that emerged were documentation
requirements, limited resources and financial related issues. As the
quotes will demonstrate, there is often overlap in these factors:
There is this huge amount of paperwork. Essentially you have to
have someone whose job it is to do the paperwork. It makes it
logistically and monetarily harder to do it (02-V_NP)
High volume of nonresearch patients strains all resources—time,
space, laboratory, radiological and pharmacy resources...
(Research), it’s a side kick to the general operation of the
hospital. It’s not a research institution. It’s accommodated on
an individual base based also on available monetary resources
(04-V_P)
We need more support.... More clinical trials personnel....more
coordinators and regulatory (staff). It constrains because we
don’t have enough staff. Lack of adequate personnel, it can slow
things down. You need clinical trial support to help with
screening, consenting, regulatory and also obviously once the
patients are on study making sure everything is done right. In
other words, the more clinical trials support you have the more
patients you are likely to put (09-S_N)
I think it’s just that everybody is so busy clinically that it makes
it difficult sometimes to participate in research to the extent that
you could. We can’t make ourselves less busy, because need to
be busy to pay the bills (10-A_P)
We have some infrastructure that could facilitate (research) if
people wanted to do it. The problem, the difference between me
doing this (and others in private practice) is that I send my
cases (to you). I don’t need any financial support. This way I
can participate as I want but don’t have to put investment into it
(11-P_P)
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Then and now.
Participants were also asked about participation in research at
other institutions they had worked and to describe similarities and
difference to their current place of employment. Not all had
participated in research at other institutions. Those currently working
at specialty centers noted some similarities in the responses below:
I think on the whole scheme of things the framework is
essentially the same. We have research coordinators, we have
research statisticians that we work with… clinical questions may
vary but at the end of the day when you put them together it is
close to similar. (That) made it that much easier (when I came
here) (01-S_P)
(I am) coming Europe and North America because I came from
Europe…I don’t see it as a whole lot of difference. Basically the
bottom line is the same (05-V_P)
And differences were noted across most site types. Most commonly
noted was variance in support staff and other resources as the
following quotes suggest:
I will say that I think at the current institution there is less
support staff. So I think PIs have to take a more proactive role
and be involved with more of the day to days of how a study is
conducted and the way it’s being registered and the way patients
are followed and following specific end points or study (01-S_P)
At the previous VA I worked for (had) internal administrative
constraints, a lower staffing to patient ratio, much more limited
diagnostic services, availability, significantly inferior parking
facilities for patients (04-V_P)
Well, at the NCI, it’s the government’s branch of medicine so
resources were essentially unlimited while you were there
because everything done there is done on protocol. So it’s
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already approved so to speak ...it’s all intramural. It’s almost like
having a credit card for research (10-A_P)
Changing with the times.
Those working in specialty centers also noted changes over time,
most notably changes in funding as well as regulatory requirements as
described in the following response:
As time goes by there is less and less and less money. (When I
started) resources were almost limitless and you could do any
research you wanted because there was a lot of money. Now
money is very tight. (Previously) one could do research on
almost anything and now it is more tough and one has to
prioritize. The point is that there are less and less resources
available (03-S_P)
Things have gotten more complicated for everybody now with
HIPPA, IRB and all the regulations (06-S_P)
Appropriateness.
Participants were also asked if the trials that were available to
them were appropriate for the population that they serve and to
elaborate as to how this was or was not so. Emergent themes and
factors considered were the appropriateness of available patients for
trials, risk, resource demands, reception by potential participants and
the ability to “work” the study in to the usual care routine as noted
with the following responses:
We definitely should do a better job in looking at more
innovative trials. About 10-20% of my patients are seen
possibly for screening, they are somewhat more appropriate in a
sense that they already are at the higher at the level where the
risk of having prostate cancer is higher, and they are in the
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system. There are biomarkers that one can use now to then
define whether there is cancer or not (03-S_P)
Yes, so far. They are relatively low risk and did not require
extraordinary resources for execution. Regarding prostate
cancer prevention (we’ve had a) relatively good reception among
potential candidates (04-V_P)
Yeah, I think so; it allows me to participate in research that has
a translational bent and also be able to work it into my regular
routine of seeing patients (10-A_P)
Disruptions and integration.
In the final question to address this objective and research
question, participants were asked about their experience enrolling a
patient into a clinical trial and encouraged to discuss any disruptions
related to enrolling them at their current site of healthcare delivery as
well as referring them elsewhere. In regards to enrollment at the
current site of healthcare delivery, it is not generally seen as disruptive
mainly due to the structure and resources already in place and
integration with current or usual care. Enrollment in research was also
seen as a way to provide a more comprehensive level of care. These
results were reported across all site types, as seen with the responses
below:
I think if you integrate it into your discussion when you see a
patient and similarly as long as the logistics of the trial are such
that you have research coordinators that are readily available (it
is not disruptive). I really don’t think it hinders or impacts the
flow of a clinic or how it’s integrated into your practice. In fact I
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think it makes it that much more comprehensive and appealing
to patients (01-S_P)
Not that disruptive if you have a good coordinator (02-V_NP)
The way we do it here, it’s not very disruptive. They come to the
clinic and they have a problem already and we’re seeing them
and the physician can say by the way we have this study (you
may want to consider) (06-S_P)
I don’t think it disrupted my care with them at all because these
particular trials didn’t affect what I did at all (10-A_P)
One participant clearly noted that it could be disruptive yet this was
lessened with flexibility and dedicated staff as elaborated with the
following comment:
Trying to fit (research patients) between other patients, in order
to accommodate them or research candidate patients is often
cumbersome. And (it) requires significant flexibility not just on
my behalf but on other ancillary staff: study nurses,
coordinators, secretary check-in check-out people, research
pharmacy, labs, etc. We cannot have a research clinic every day.
It’s not a research institution. The research patient has to be
treated personally with special attention. (He) cannot be left to
generic clinics and non dedicated staff. It backfires. (04-V_P)
Another participant expanded on the previously mentioned notion of
time, as well provided a possible model to consider for future trials
with this response:
I don’t know about the word disruptive but it takes more time.
The current study is not disruptive for us because the person
comes in who already has the time set aside for the
conversation. Basically what happens is the urologist does the
biopsies (and) when he gets the biopsy back and it shows that
it’s PIN he’s going to do one of two things: he’s going to say
that’s benign we’ll see you in 6 months just to follow up…or he’s
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going to say well, it’s benign but you know it’s kinda worrisome
we’ll send you over to the cancer center… they have some trials.
But if one doctor was doing all that and they had three minutes
to talk to you, their talk would be well it was benign see you in 6
months versus a long(er) conversation about green tea. You
know which way they are going to have to go. Otherwise if they
(spend) 45 minutes (instead of three) then however many
people they were going to have to see in those 45 minutes, they
are backed up (12-S_P)
In regards to referring patients to other sites for participation, there
was vast heterogeneity in responses with positive and negative
scenarios noted by respondents from all site types:
It involves much more effort... there’s more opportunities for
things to go awry... any time you add variables that could go
wrong, it can go wrong (01-S_P)
There are different types of constraints because they have to
package the patient information including PHI and test results
and so forth in such a way that it can be it becomes portable and
sometimes there are hybrid situations. One has to be creative.
One has to be willing to be flexible and work with all systems,
but that’s the price for clinical research (04-V_P)
There’s a couple of variables there, it would depend on the
facility where I am sending them to. How much confidence I
have in that facility and I guess if I had to do that the best way I
would do it is to speak to the person whom I am referring him to
that facility so that he or she knows that I am getting a patient
from XXX this is what he is supposed to be doing so that you
know we communicate (05-V_P)
Some at risk populations, it is disruptive because they have to
do something they wouldn’t normally do to be seen. So, it does
change their daily routine (06-S_P)
It’s just an email and phone call to the coordinator. When you
have a good coordinator, that’s easy to do. Patient doesn’t get
lost they have one point person you know, they know exactly
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what you need they send it to you. They call the patients. You
know, the transition was smooth (11-P_P)
In closing, participants were asked if there was anything else
that hadn’t been discussed that they felt was important for me to
know. Perhaps most notably, the issue of limited time and the
importance of infrastructure surfaced again as evidenced by the
following responses:
No, I think the set up that we have here is very is ideal. It
makes it easy for me to do it. There’s really very little for me to
do regarding the trial and that influences my participation more
than anything else because I am busy taking care of patients.
The last thing I want to do is have to do a lot of paperwork to
keep people on the trials and so that would be the thing that
made me not participate-if we somehow lost the infrastructure
that we have I’d be less likely to participate because I just
couldn’t keep up with all the paperwork (10-A_P)
Don’t underestimate how busy the doctors are. Another thing to
consider for future prevention trials, that they have that
dedicated slot, coming in to talk specifically about trial versus
something being added on to what was already in place so if
planning for future trials maybe keeping that type of thought
process in place might help (12-S_P)
Also relevant was commentary related to increasing participation from
the community at large as noted by this participant:
If you need bigger participation from the whole group it has to
be a little but more organized. It has to be presented to the
group and it may have to go through the research coordinator. If
you want bigger, you are dealing with many urologists and every
one of them sees 100-120 patients a week. If you want this
volume you have to talk with the organization itself (11-P_P)
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Additionally, they were asked if there any other factors that influenced
their willingness or ability to participate in cancer prevention
intervention trials that had not yet been discussed.

Some

respondents reinforced comments made earlier such as:
I think at the end of the day my drive to want to put patients on
specific chemoprevention trials is believing that they are at
increased risk of something developing and that ultimately from
a biological standpoint (the) chemoprevention agent makes
biological sense and is being given or administered at a time
point where prevention is possible (01-S_P)
I think the willingness to participate in general with the
practitioners is an understanding of what it means, prevention.
Because many don’t understand it, that there are different levels
of prevention. It could add to the quality of care, participating in
those trials and (also) to understand the mechanisms of the drug
because many don’t understand them (03-S_P)
Others noted regulatory challenges and difference in priorities that had
not been noted previously as seen with the next response:
Well, there are organizational problems I guess you could say.
Difficulty with the regulatory affairs certainly…difficulty dealing
with people within the institution who don’t care about research
and patient care. That’s a big one right there. And I think that’s
getting more of an obstacle. It’s just the volume of work. It’s
business versus patient care and research, totally trying to meet
different ends. And then the whole regulatory thing, the HIPAA
and all the regular stuff, it gets impossible (06-S_P)
Also not specifically noted previously was the influence of the
physician’s interpretation of biopsy results and how this may influence
participation in a cancer prevention clinical trial as described by one
participant:
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What makes or breaks whether a physician will even mention a
trial is their interpretation of how significant the biopsy findings
are. So if they think HGPIN -it’s benign it’s one thing. But (if)
interesting finding- it’s going to be a whole different
interpretation and sense of what needs to be done. And then I’m
sure it’s also comes down to what the doctor’s interpretation of
what the patient wants to hear. If you are going to design this
type of trial I think you really need to get feedback from the
people that are going to be involved in it, at least on a PIN sort
of prevention trial. (And) the urologist because they’re the ones
who do the biopsy, they’re the ones who interpret it. They’re the
ones whose name is on the pathology report. And then it comes
to how they interpret or respond to that, if they’re one that will
that it’s not cancer so instead of yearly we’ll see him at 6
months or if they say whoa something’s starting up (12-S_P)
Possible challenges at the institutional level between the dual role as a
surgeon and researcher and financial considerations were also noted in
the following response:
Nobody is going to give a physician 40% research time, a
surgeon, when I can go bill in a quarter what the grant is going
to be for the whole 3-5 years. The institutions like, you gotta be
kidding me, my surgeon’s going to the OR. I think that prevents
a lot of good research from happening and it prevents a lot of
physicians who have an interest in research from being able to
pursue that as their career goes on. And, you have physicians
who have done a lot of preparation in terms of research
preparation and to be in academia who eventually fall out of
academia for that very reason. The bottom line (is) I can’t get
the grant because I’m too busy taking care of patients. And
that’s what research is for, supposedly (10-A_P)
Finally, some comments shed light into the private practice
arena, suggesting a role for future urological prevention studies, and
noting future potential challenges when involving those physicians in
private practice in future cancer prevention intervention projects:
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A urologist can’t back down from the bread & butter urology that
men need. So I have 2 groups of patients. I have patients that
have cancer that I operate on and follow them along and guide
them through that whole process and that’s what I like to do and
that’s why I do what I do. But I’ve got this whole cohort of
patients that I follow for prostate cancer screening and BPH and
they come see me on a regular basis. They get to know me and
how the practice is. I think definitely the group that I develop
the relationship with over time is most appropriate place for a
prostate cancer prevention trial. And so the cancer prevention, I
don’t think should be focused on tertiary/cancer surgeon but
more on my primary role as a urologist. So that’s where cancer
prevention (needs to be) and with primary care doctors as well.
But getting them interested, that’s a whole different story I
suppose (07-P_N)
The important thing, the way to do that is you have to have a
protocol that is logical. People like it and agree upon it and want
to participate. One of the major reasons that people do not like
to participate in the project done in centralized area is that they
lose control of the patient (11-P_P)
Section III-Qualitative, Ethnographic Findings from Participant
Observation
This collection of data focused primarily on the interactions
between the physician and research team in order to better
understand the internal working mechanisms of each facility and the
process of research as it occurred at each local healthcare site.
Observations were conducted in the backstage (Ellingson 2005) of the
clinic environment, not in the presence of any patients or study
participants. For consistency in data collection, an observational
checklist was used to compare observations across sites and included
items such as the use of clinical trial alert systems, the availability of
126

dedicated research staff, and communication between staff related to
potential eligibility to participate in a study that were not collected by
other means. During this time I was also fortunate to be able to
engage in conversations with research coordinators, a research nurse,
a regulatory specialist, a grant administrator and a research manager.
I was also able to draw upon my familiarity and comfort level in the
clinical arena and report on observations that were made beyond what
was originally planned. Due to privacy and other considerations, this
methodology was not utilized at VA medical centers or any private
practice/community offices. At these sites this information was
obtained when possible directly from the key informant during the
semi-structured interview or via informal conversations with the
parties noted above.
Use of Clinical Trial Alert system (CTA).
None of the specialty centers used a CTA system to alert
practitioners about trials for which a patient could potentially be
eligible. During the observations I had the opportunity to speak with
coordinators and research nurses. When asked about the use of such
a system, several expressed some concern that though a CTA may
alert the physician regarding potential eligibility to participate in a trial
(therefore increasing awareness), it would only be a starting point to
enrolling a patient and would not eliminate the detailed screening for
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eligibility that would follow and was usually completed by them, prior
to physician involvement with the patients. Echoing comments from
the coordinators and research nurses, the physicians also expressed
reservation about the potential for a system (CTA) to accurately
identify the appropriate patients for participation, noting that some
element of human involvement would still be needed to verify the
system’s results. Several physicians voiced an interest in this type of
alert during the interview; however, also expressed skepticism as the
following quote reflects:
(It) May be my own lack of exposure but I’ve never seen one
that would work well, you have to pull together a lot of data
points. Not saying it’s not possible, it’s just not easy (02-V_N)
Respondents from one center did note a “flag” that was
supposed to be used to identify subjects currently participating in
research projects. Not all staff at this facility was aware of this feature
suggesting that it was not universally or consistently utilized.

Another

specialty center did not use a CTA; however, the participant noted that
their recent transition to an electronic medical record (EMR) would
make it easier to keep referring physicians abreast of what was
happening with a patient that had been referred for clinical trial
participation:
With the new electronic medical records and computerized scans
you know you can do a lot just looking at that which should
make it easier to stay in contact (12-S_P)
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All respondents from VA sites reported that a CTA was not
utilized and two out of the three also reported that a “flag” specifically
identifying research patients was not in use. One VA site participant
did report the use of such a system as the following response
demonstrates:
I have patients details on the electronic medical record (EMR)
(and) the first thing that pops up is (notification that) this is a
research patient (05-V_P)
The physician at this site was not aware of how accurate or
consistently this feature of the institution’s EMR was used. However;
the responses suggest variance even within one type of system. The
academic centers were not utilizing any form of CTA system or even
an EMR at the time of data collection.
Dedicated research staff.
The importance of dedicated research staff cannot be
understated as was evident from the interviews and observation
conducted for this project. Participants at all sites noted the critical
and valued role of research staff as the following responses
demonstrate:
All that matters is who your research coordinator is. That’s
basically 99% of it. The other things may differ a little but the
research coordinator is all that matters (02-V_N)
I think the set up that we have here is very is ideal…(the
coordinator) takes care of everything and there’s really very little
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for me to do regarding the trial and that influences my
participation more than anything else because I am busy taking
care of patients. The last thing I want to do is have to do a lot of
paperwork (10-A_P)
When you have a good coordinator, it’s easy to do (11-P_P)
Clinical trial coordinators were noted most often followed by regulatory
support staff with participants often noting that without this support,
participation in clinical trials would not be possible as the following
response illustrates:
That would be the thing that made me not participate-if we
somehow lost the infrastructure that we have I’d be less likely to
participate because I just couldn’t keep up with all the
paperwork (10-A_P)
There were various ways that this staff was structured and utilized
depending on the site. Some were integrated within the surgical
department while others were supported via a clinical research or
other research department within the institution. Even within systems
that would seemingly be similar (VA hospitals) there was no one way
to participate in research. The participant in private practice did not
have his own dedicated staff; however, noted that depending on the
trial they were available via various scenarios allowing him to make
participation in research projects a part of the comprehensive care
that he provides to his patients.
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Communication between staff.
During the time that participant observation was conducted
there was minimal discussion between physician and research staff in
regards to the possibility of participation or enrollment of specific
patients in a clinical trial. In one instance a clinical trial coordinator
made the physician aware that a patient was potentially eligible to
participate in a clinical trial and then reminded him of the inclusion
criteria before the physician entered the patient room.

When

research coordinators were observed in the clinic setting, it was
noticed that they functioned very independently from the physician,
relying more on communication from nursing and other staff (other
coordinators, scheduling specialists, medical assistant, etc.) regarding
patient status and other details necessary to identify patients that may
be eligible to participate in a particular research study. In one
specialty center there was a very collegial atmosphere between the
research coordinators who often made each other aware of the
specifics about a patient, which were then used to help determine
potential eligibility.
At some sites it was difficult to discern if the minimal discussion with
the physician could be attributed to the presence of an “outsider” with
the usual flow of practice interrupted by my presence or if indeed this
was the norm in that particular setting. Utilizing the observation
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checklist as a guide, a summary of the data collected during actual
observations can be found in Table 22 below.
Table 22. Participant observation (n=6)
Criteria
Use of CTA
Dedicated research staff
Consideration of patient for
participation in research
study by physician
Consideration of patient for
participation in research
study by other staff
Communication between
staff related to eligibility to
participate in a trial
Definitive plans to present a
clinical trial to a patient

Site type (times observed)
S (0) A (0)
S (3) A (3)
S (0) A (0)
S (4) A (0)
S (2) A (1)
S (0) A(0)

Beyond the checklist.
During my time in the various clinics, observations were made
that were not initially included on the observation checklist; however,
further expanded my understanding of how research was conducted at
each of the various sites. This helped to identify the variances at each
location and to glean insight as to what best practices for a future trial
may be. Of great interest to me was that though research
infrastructure was in place in varying degrees at all of the sites where
observation occurred, many of those involved in the work of research
(nurses, coordinators, physicians) found the structure to be more
prohibitive than helpful. This was mainly due to the many levels of
documentation that needed to be completed at varying steps in the
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research process. Though thorough documentation was recognized as
necessary and important, many coordinators in particular felt that
there were redundant steps that could be stream lined, resulting in a
more efficient use of their time while still adhering to the necessary
guidelines that are considered good clinical practice.
Also of interest was that though the study had a very specific list
of inclusion and exclusion criteria that was to be used in identifying
and pre-screening appropriate subjects for participation, one
coordinator reported, “We have our own set of pre-inclusion criteria”
This was echoed by study teams at several of the sites who reported
that things like overall health history and presence of other
comorbidities, transportation, flexible job schedules (which would allow
for adherence to required monthly study visits), family support,
education level and perceived patient interest were often considered
before the actual study inclusion/exclusion criteria were reviewed or
the possibility of participating was presented to the patient. This
unofficial set of criteria often eliminated potential subjects that
otherwise may have been interested and/or eligible to participate in
the trial. It is unclear from the data collected for this research how
this ultimately impacted the screening and recruitment numbers
reported by each site in the ancillary study; however, it did most likely
result in the underreporting and elimination of potential participants.
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A final observation was that research visits occurred primarily in
one of two modes at the different sites. One model was that patients
were identified by research coordinators or physicians and approached
about participation in the trial in clinic on the same day that they were
present in clinic for another reason. If approached then about trial
participation, the result was often a conflict of time for all parties
involved. If interested in participating, the visit was then extended
and longer than the patient and staff had planned resulting in a
competition for time and clinic space as well. The second model was
that patients were identified in advance, while away from the clinic and
then contacted about participation. If they expressed an interest and
met initial criteria then a research specific visit was scheduled.
Patients then came to the clinic for a future appointment where time
and space were dedicated to them. The second model seemed to work
more effectively in that the patient as well as the research team was
better able to prepare for the visit. This lessened the competition for
time and space at the initial visit. Subsequent visits were all arranged
in advance and there seemed to be less competition for resources
because of this.
An awareness of these additional factors may help to further
identify the best sites for future cancer prevention trials and should be
considered in the design of upcoming trials. Additional insights about
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the overall clinic environment, the patient population at the various
research sites and how each may influence future trials are found in
Chapter Five.
Section IV-Quantitative Data from Surveys
Participants.
Participants were asked about involvement in clinical trials and
all reported previous involvement in one or more
(range: 3-100) clinical trials. Types of involvement ranged from
recommending that a patient participate in a clinical trial to actually
participating in the design of a clinical trial. The range of responses
and more specific descriptions about the types of involvement are
further described in Table 23. The reasons for involvement in clinical
trials were also captured and the variance in responses can be found
below in Table 24. The main reason noted for participating fell into
four broad categories including altruism and benefit for patients (n=4),
advancing medical science/scientific knowledge (n=4),
education/keeping current (n=1) and personal interest in clinical trials
(n=1).

More specifically in regards to participation in prevention

trials, participants reported prior participation in a range of 1-12
(mean=3.5) trials each. The reasons noted for participating in
prevention trials are found in Table 25 and the main reason for
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participation in prevention clinical trials verbatim as reported by
participants can be found in Table 26 below.
Table 23. Types of involvement in clinical trials (n=9) (
Types of involvement in clinical trials

#
responses

%

I have participated in a clinical trial
(therapeutic or prevention) in other ways. If
so, please explain

3

33

I have had patients inquire about clinical trials
(therapeutic or prevention)

5

56

I have participated in the design and
implementation of a clinical trial (therapeutic
or prevention).

5

56

I have recommended patients participate in a
clinical trial (therapeutic or prevention)
administered by others.

6

67

I have had patients enroll at a clinical trial
(therapeutic or prevention) at another location
because it was not locally available.

7

78

I have recommended patients participate in a
clinical trial that I administer.

8

89

Table 24. Reasons for involvement in clinical trials (n=10)
Reasons for involvement in clinical trials

# responses

%

Advancing Medical Science

8

80

Providing access to a novel treatment

9

90

To expand available services

4

40

Challenge

3

30

Variety

1

10

To earn extra income for my practice

1

10
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Table 25. Reasons for participating in prevention trials (n=10)
Reasons for participating in
prevention trials

# responses

%

Advancing Medical Science

9

90

Providing the best possible care

5

50

Providing access to a novel
treatment

5

50

To expand available services

3

30

To earn extra income for my practice

1

10

Table 26. Main reason for participating in prevention clinical trials (n=9)
Main reason for participating in prevention
clinical trials
Advancing Medical Science
Interest in their effect
Impact a premalignant condition before it
develops into malignancy
Prevent cancer suffering
Prevent cancer
A personal belief in the benefits of prevention
To offer patient chance to prevent disease
Improve healthcare delivery for mankind

%

# responses
4
1

44
11
11

1
1
1
1
1
1

11
11
11
11
11

Somewhat in contrast to work by Weinberg et al. (2004) that
reported survey participants would be much more likely to enroll
patients to treatment than screening, diagnostic or prevention trials,
this group of respondents was interested in participating in prevention
trials for the reasons noted above. The factors influencing the
participants and their decision to participate in any type of clinical trial
are found in Table 27.
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Table 27. Factors influencing participation in any clinical trial (n=10)
Factors influencing participation in any
clinical trial
Influence on clinical care process
Time
Financial Incentives
Cost to you/your institution
Paperwork requirements
Staffing
Concern for your patients well-being
Introduction of another care provider or
decision maker
Requirements of the research protocol
Institutional support

%

# responses
6
6
1
3
4
4
7

60
60
10
30
40
40
70
10

1
7
4

70
40

These factors reported by participants and noted in Tables 24-27 as
influential in their participation in all types of clinical trials are similar
to those previously reported in the literature such as the presence of
incentives and disincentives (Cohen 2009; Yates 2003), staffing
challenges (Meropol et al. 2007), documentation and paperwork
requirements (Comis et al. 2000; Crosson et al. 2001; Orozco 2009;
Weinberg et al. 2004) and the presence of research infrastructure or
support (Al Refaie 2011; Somkin et al. 2005).
Non-participants.
Non-participants were also asked about their prior involvement
in clinical trials and this ranged from addressing patient inquiries about
clinical trials to participating in the design and implementation of trials.
The responses related to involvement in all clinical trials can be found
in Table 28.
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Table 28. Types of involvement in clinical trials (n=4)
Types of involvement in clinical trials

#
responses

%

I have had patients inquire about clinical trials
(therapeutic or prevention)

3

75%

I have recommended patients participate in a
clinical trial that I administer.

1

25%

I have recommended patients participate in a
clinical trial (therapeutic or prevention)
administered by others.

4

100%

I have participated in the design and
implementation of a clinical trial (therapeutic or
prevention).

1

25%

I have had patients enroll at a clinical trial
(therapeutic or prevention) at another location
because it was not locally available.

1

25%

Of those responding to survey question seven, two respondents
reported participation in one or more therapeutic or prevention clinical
trial while two reported no prior participation. Reasons for
involvement in clinical trials as noted by respondents are found in
Table 29 which follows.
Table 29. Reasons for involvement in clinical trials (n=2)
#
responses

%

Advancing Medical Science

1

50%

To expand available services

1

50%

Challenge

1

50%

Variety

1

50%

To earn extra income for my practice

1

50%

Reasons for involvement in clinical trials

Similar to participants in the PCPICT, advancing medical science,
expanding available services and earning extra income were all noted.
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Additionally, non-participants note challenge and variety as two
additional reasons for prior involvement in clinical trials. The main
reasons noted for participation were to earn income for the practice
(n=1) and advancing medical science (n=1).
Two non-participants reported that they have participated in
prevention trials as an investigator or other study personnel noting the
reasons shown in Table 30.
Table 30. Reasons for participating in prevention clinical trials (n=2)
#
responses

%

To earn extra income for my practice

1

50%

Providing the best possible care

1

50%

Advancing Medical Science

1

50%

Reasons for participating in prevention clinical trials

The main reasons reported for previously participating in prevention
clinical trials were earning extra income for the practice and providing
the best possible care, which were different than the main reasons
noted by participants who most commonly reported advancing medical
science.

This differential would benefit from further exploration if

more direct inquiry (interviews) with non-participants was possible.
Additionally, factors influencing the decision to participate in any type
of clinical trial can be found in Table 31.

140

Table 31. Factors influencing the decision to participate in clinical trials (n=2)
Factors influencing the decision to participate in
clinical trials
Time
Cost to you/your institution
Paperwork requirements
Staffing
Concern for your patients well-being
Institutional support

#
responses
1
1
1
1
1
1

%
50%
50%
50%
50%
50%
50%

Staffing, documentation and paperwork requirements, and research
infrastructure or support are factors similar to those reported by the
participants in the PCPICT and prior literature as discussed above. The
concern for patient’s well-being is a factor influencing participation
which has been previously identified by Weinberg et al. (2004).
Concerns related to time and cost were also identified in the interviews
as the following quotes reflect:
I think that the biggest constraints are time (12-S_P)
As time goes by there is less and less and less money.
(Previously) resources were almost limitless and you could do
any research you wanted because there was a lot of money. Now
money is very tight (3-S_P)
One respondent provided a reason for not participating in clinical trials,
whether therapeutic or preventive in nature, writing in that “clinical
trials not part of the practice model that I joined”. Unfortunately due
to the nature of reporting via survey, this response could not be
expanded upon; however, commentary from one participant may
provide some perspective:
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Most (physicians) are in private practice for a reason. ..If I was
in private practice, I would have to think of myself as not as
someone who is not interested in academics. I’m not interested
in research. Why would I do this? (research) I got a tee time at
(1), you know? I wouldn’t do it (10-A_P)
The various medical practice models and ability as well as desire to
participate in clinical trials should be an additional consideration when
determining future recruitment sites for prevention trials. The overall
response rate to the surveys was not significant enough to consider
additional analysis using SPSS. The results from the interviews and
surveys were analyzed independently and will be integrated in chapter
five for the purposes of interpretation in order to address the research
objectives.
Summary
This was a formative, exploratory study conducted to provide an
in-depth understanding of the individual and structural factors
influencing a physician’s participation in a PCPICT, a topic with little
documented research to date. A mixed methods research design using
qualitative, ethnographic (open ended semi-structured interviews and
participant observation) and quantitative (survey) methods was
employed to examine factors of influence within the context of an
ongoing PCPICT.
This chapter provided the results of the data that was obtained
from the open ended semi-structured interviews, participant
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observation, and survey methodology employed. Analysis was
conducted in order to identify individual and structural factors
influencing a physician’s participation in a PCPICT with a consideration
of factors that may vary across practice site/area and to identify ways
to improve collaboration between researchers and physicians to
improve the success of this and future projects. The ethnographic
detail within the context of an ongoing project that would not have
been obtained via other means can be used to inform the design of
future cancer prevention studies requiring multi-site participation in
order to recruit participants reflective of our diverse population.
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Chapter Five:
Discussion and Conclusions
Introduction
This chapter discusses the responses of the
physician/investigators who participated in the open ended semistructured interviews, findings from participant observation where
possible, as well as the results of the quantitative surveys as related to
the research objectives, questions and hypotheses. The reader will be
reintroduced to the model proposed initially as well as a modified
version, reflecting the data collected with this study. The contributions
of this research to theory, applied anthropology, and biomedicine will
be elucidated. The implications of the research with recommendations
for future cancer prevention clinical trials will be discussed and
recommendations for future research directions will be presented. The
limitations of this study will be delineated including those related to
my vantage point and familiarity in the research setting prior to
completing this work.
Research Question 1
This question attempted to explore and document individual
provider level factors such as explanatory views on prevention, notions
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of risk and uncertainty, shared decision-making, duality of roles, and
other individual factors influencing a physician/investigator’s
participation in cancer prevention intervention clinical trials. Physician
involvement is thought to be essential for the provision of many
preventative services with the physician serving a critical link in the
chain of events leading to the delivery of preventative services (Jaen
et al. 1994).
Explanatory views on prevention.
A personal interest and/or belief in preventive medicine and
cancer prevention in particular were motivating factors for participants
in this study and this was observed across all site types. As one
participant remarked:
I think that as we embark in medicine today I think the
emphasis is sort of moving away from treatment to prevention.
We know that it’s more cost effective. We know from a society
standpoint, if we can prevent something you’re much better.
From a patient standpoint, obviously if you can prevent and not
have to deal with actual malignancy, prevention is the ultimate
goal. It’s what we strive for everyday. So I think that prevention
is the future of medicine (01-S_P)
Preventive medicine was recognized for its potential cost savings and
preference over treatment of disease and participants had been
influenced by their training as well as professional and personal
experiences. This is exemplified in the following quote by one
participant:
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It’s pretty much what I’ve learned in my training. And it’s pretty
much what life teaches you in a bit of time. You’ve seen people
die and born in front of you and grow up into men and women in
front of you and people who were adults when you were children
you see them pass away by the time you are in this age that I
am so it kind of gives you a broader perspective of life. Plus
what I’ve learned in medicine as well. So both personal and
professional influence the broader perspective (05-V_P)
Support of preventive strategies was also noted to positively
influence the willingness to participate in the PCPICT though
interestingly, some felt that their role in prevention was limited due to
their role as surgeons:
The cancer prevention, I don’t think should be focused on
tertiary/cancer surgeon but more on my primary role as a
urologist. So that’s where cancer prevention (needs to be) and
with primary care doctors as well (07-P_N)
This response mirrors work by Hall et al. (2010) who found that
though oncologists were interested in referring patients to prevention
trials, they felt that they did not have access to eligible (i.e., healthy)
patients in order to do so. Similarly, as noted in the review of
literature, Crosson et al. (2001) reported how the preference of
primary care physicians (PCPs) to refer their patients to an oncologist
for discussion of cancer treatment may extend to discussions related
to cancer prevention trials as well. This perspective would benefit
from further exploration prior to the design of future prostate cancer
prevention intervention trials. A consideration of the most appropriate
referral source for future studies is critical in an era of healthcare
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reform and limited funding for research, to assure fiscal responsibility
and that accrual goals are met in a timely fashion.
Notions of risk and uncertainty.
As previously noted in Chapter Two, anthropologists Douglas and
Wildavsky (1982) consider risk perception to be the beliefs, attitudes,
judgments and feelings in addition to the socio-cultural disposition that
people adapt towards both hazards and their benefits. Risk perception
grounded in culture and the cultural theory of risk is one way to
interpret how and why individuals make judgments about danger,
pollution, or threat (Tansey 1999). Since risk may have varied
meanings to different groups, all risk must be understood within the
larger social, cultural and economic context that it occurs (Douglas and
Wildavsky 1982). This is an important consideration in a discussion
about prostate cancer prevention and risk within the culture of
biomedicine. In this study, risk perception and assessment were
observed at two distinct levels, that of the patient, as the following
quote demonstrates:
If the consumer thinks that prostate cancer is a non-entity then
in reality why are we doing the study? (08-A_P)
As well as that of the provider, as suggested in the following quote:
I personally think one of the keys is the urologists, and how do
they want to deal with the reporting of prostate biopsy showing
PIN? What makes or breaks whether a physician will even
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mention a trial is their interpretation of how significant the
biopsy findings are (12-S_P)
Similar to risk and “risk status” as reported by Hunt et al. (2006), the
“risk of cancer development” had multiple meanings that were
understood differently by the physicians participating in this study.
Although the patient voice was absent from this research, its influence
in relation to study participation was mentioned by the participating
physicians and cannot be ignored.

In reality, the decision to

participate or recommend that a patient participate in a cancer
prevention trial is likely influenced by factors at both levels. A
consideration at the patient level may be used to determine which
patients would be willing (based on their perceived risk of disease) as
well as those that could benefit (based on the provider’s interpretation
of risk) from participation. A lack of consistency in the definition of
risk within the medical community and ambiguity in the current
management of prostate cancer and its precursors was noted as
exemplified with the following statement:
You know the other thing that’s detrimentally affecting
particularly prostate cancer I think is the ambiguity in the
medical community about the significance of prostate cancer and
the significance of prostate cancer treatment (08-A_P)
The overall subjectivity in determining risk is important to recognize,
as it may influence trial participation as well.
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Hales et al. (2001) noted that physicians may experience
discomfort disclosing uncertainty in clinical management, as may be
required as part of the participation in a clinical trial. Since this
research was with a therapeutic trial, exploration in regard to cancer
prevention, intervention trials was warranted. In this research, neither
uncertainty in the plan of care nor the outcome associated with
participating in the clinical trial was negatively influential.

Uncertainty

was seen as the “nature of science” with participants across sites
offering suggestions (such as honesty and communication with
patients) as a means to deal with the possibility of uncertainty.
Shared decision-making.
Similar to the findings of Hunt et al. (2005), disparate starting
points related to the perceived problem (or lack thereof) and how to
prevent or control it may greatly influence what treatment options are
considered in this context as well. The lack of consensus and
subjectivity in determining risk as noted above, in addition to variance
in clinical priorities may influence the information and treatment
options that are shared with each individual patient, as abnormal
biopsy results are identified. This likely influences the process of
shared patient decision-making between the patient and physician, as
it relates to participation in prevention trials.
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As would be anticipated considering the focus with this project,
shared decision making was contemplated at the level of the provider.
Questions were situated to elicit feedback related to various scenarios
where research efforts may be coordinated with actors beyond their
local site, in an effort to increase participation opportunities for their
patients. Participants expressed a variety or responses and shared
decision making was indeed a salient factor, but not in the ways
anticipated by me during project design. Considerations such as
logistics were pointed out as shown in the quote below:
The only problem I guess is just logistics (10-A_P)
As well as the importance of coordinating the details of care as one
respondent noted:
All of us have a fear that when patients leave here, (are) sent
out, they can be lost in the paperwork and the shuffle (01-S_P)
Also the importance of considering the benefit to the patient was
mentioned:
If I have a patient who is eligible for a prevention trial
somewhere else and if I don’t have something for that
population I would send them. Wherever there is a good study
for the patient, we send them (09-S_N)
And interestingly, the possibility of losing control of patients was
mentioned as the following quote demonstrates:
No, in the sense that you are sending your patients somewhere
else and they may not come back. So, why should they? It’s
almost like saying that if you’re not cutting edge enough to have
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their research trial at your institution so why should I come back
to you? (10-A_P)
Heterogeneity in responses varied depending on the practice site as
well as the tenure of experience. The following suggests that those
with an established medical practice may be less concerned about
losing control of their patients than those still in the process of
establishing their practice:
You ask a guy like me, I’m not just beginning out in this
business. I’m not as threatened by sending off as some might
be. So no, I wouldn’t have trouble with that. If you talk to
someone who’s trying to build a practice they might be less
inclined to do that (12-S_P)
These findings are similar to prior work by Cornuz et al. (2000) who
suggested factors such as age, gender, specialization, and the
physician’s own health habits influenced the likelihood of preventative
care.
Duality of roles/role conflict.
Hunninghake et al. (1987) suggested that clinical trials may be
seen as a competing service to clinical care and noted challenges with
role delineation and personal integrity when serving as both clinician
and investigator. More recently, Ruffin IV and Baron (2000) suggested
that conflict may arise between the physician’s role as care giver and
that of scientist. The possibility that varied and separate roles may
contribute to conflict related to the ultimate goals and populations
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targeted in clinical research have also been noted by others (Frayne
2001; Hales et al. 2001; Orozco 2009).

Ka'ano'i et al. (2004)

identified conflict between the roles of clinician and research advocate
as physician-related barriers specific to participation in cancer
prevention clinical trials. Prior to this study, it was unclear how salient
this was specifically in relation to a PCPICT.
Participants at all types of sites noted that their ethical
responsibilities did not change when a patient participates in a cancer
prevention intervention trial.

One noted that this could be a unique

difference between pharmaceutical (treatment) and prevention
focused trials. In terms of role conflict, this had been experienced
specifically in regards to participation in the ongoing trial by at least
one participant working at an academic center when the course of
action required by the protocol deviated from the usual care he would
have provided, as he stated:
When these LFTs (liver function tests) are elevated, how
elevated? Is it elevated enough to take them off the study? Is
the drug doing some harm? So yeah, every time there is
something (like that) you have to consider (that) there’s conflict
(10-A_P)
For others, at all site types, it was not an issue with some
noting protective stops in place such as the IRB oversight and lack of
financial interest or benefit as possible factors contributing to the lack
of conflict. This is reflected in the following quote:
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No, if I don’t have any financial interest or financial benefit and
(it) is a study I am convinced to do, I don’t think it changes
anything. Also (if) the study passes the IRB, you know that (it is
ethical) (11-P_P)
Other factors of influence.
Additional individual factors influencing the likelihood of
participation in cancer prevention intervention trials were noted such
as personal motivation and/or interest in research, scientific
recognition and altruism. The following quotes provide examples of
response from the participants:
It’s not money; it’s academic and scientific credit (04-V_P)
If the study appeals to my mind, that the study is going to be
something good for the betterment for the future, in my little
field (05-V_P)
These were noted by participants across all site types. In general, the
participants were willing to consider multiple means of participation in
trials such as patient referral to outside facilities, training their own
staff and utilizing staff provided by the research sponsor in order to
provide the best possible care options for their patients. Ka'ano'i et al.
(2004) identified changes in the doctor/patient relationship as
physician-related barriers specific to participation in cancer prevention
clinical trials. This was not observed in this research and the impact of
participation in the trial on the physician-patient relationship was
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generally seen as favorable across all types of practice sites as the
following responses demonstrate:
I think that the fact that we do participate in these trials helps
the patient physician relationship and it also lets the patient
know on a different level that we are concerned about their
overall health (08-A_P)
It’s actually (a) very good rewarding relation. Some get
recycled; they enter new trials, similar disease spectrums. Oh
it’s very rewarding. Wonderful relationship with this patient. It’s
fun. Absolutely (04-V_P)
A glimmer of insight.
Perhaps most informative for consideration in the design of
future trials was insight by providers as to why physicians in private
practice may be hesitant to participate in prevention trials:
I don’t know how you would incentivize a guy in private practice
to participate in trials like this. It would almost have to be
completely financial somehow…Chemoprevention like this, I just
don’t know how you would incentivize them because you have to
have extra visits, you know for research and you have the IRB
stuff to go through. I don’t know how you would incentivize
them (10-A_P)
The need to incentivize in some way, excessive regulatory
requirements without the infrastructure such as adequate staffing to
support the required work, a consideration of the benefit of
participation as perceived by the urologist, and potential loss of control
in decision-making were all important factors that were suggested to
influence the likelihood of participation in a prostate cancer prevention
intervention trial. These proposed barriers and facilitators to research
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participation should be explored in further detail to improve the
success of future endeavors.
Research Question 2
This question aimed to explore and document the structural
(organizational and infrastructural) considerations that influence
participation in a PCPICT and to provide a comparison of factors across
types of sites.
Resources and other support.
As noted in the prior chapter, there was heterogeneity in the
responses both within types of centers and when making comparisons
across them. A disjuncture between the organizational expectation to
participate in research and the resources provided was noted by an
informant working at a specialty center, as he said:
From the organizational level our mandate is to do research.
There is a difference between what is expected and the
resources provided (03-S_P)
Similarly, a participant in the VA system noted insufficient resources
“stifling progress” in clinical research:
Currently, everybody does it by himself or herself, the
investigators. It stifles progress. There are lots of patients who
are interested in trials but (there are) insufficient resources to
help investigators bring trials to patients and accommodate
patients in trials (04-V_P)
The presence of research infrastructure was a critical component noted
by those in private practice as well. These findings are similar to work
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by others (Roberts 2002; Ruffin IV and Baron 2000; Somkin et al.
2005) where organizational support and other health care system
related factors were noted as predictors of enrollment as well as
barriers to participation in treatment trials, with infrastructural support
(including support staff) noted as critical.
Similar to work by Ka’ano’i et al. (2004), staffing and time
constraints were potential infrastructural factors noted as important
considerations influencing participation by these key informants.
Funding not only to support research efforts but to contribute to the
institution’s bottom line was noted as relevant across all site types
though not as significant within the VA system. A clear preference to
participate in funded research over non-funded research was observed
across all site types. This was a more important factor than the actual
sponsor at most sites though all noted a preference to participate in
investigator initiated, federal or state and cooperative group trials over
pharmaceutical trials. As evidenced by the following remark from a
participant:
We always give precedence to studies that are NIH funded
studies and investigator initiated studies and then if there is
room then industry sponsored studies are supported (09-S_N)
Interestingly several reported changing priorities as a result of the
current economic environment as the following responses
demonstrate:
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Of course you know when the funding is getting tougher to get
you may have more pharmaceutical studies (09-S_N)
So, if we say we can’t get these big grants from the
government … I think the shift is just to say, well try to get
these other grants, the pharma grants and such that don’t have
that requirement (10-A_P)
Research Question 3
Cancer clinical trials recruitment has historically occurred in
academic settings (Nguyen et al. 2005), with community and
nonacademic hospitals less likely to participate (Al Refaie 2011).
Pinto et al. (2000) suggested a strategy for increasing enrollment in
clinical trials is to improve communication and outreach with
community physicians; however, it is also noted that increasing
participation in screening and prevention activities would require more
attention be given to logistical barriers and an increased awareness of
cancer information and research services (Ka'ano'i et al. 2004). Since
much, but not all, of the prior research has focused on therapeutic
trials, this question was addressed by considering how practice area
(specialty centers, academic centers, Veteran’s (VA) medical centers,
community offices) may impact the feasibility of participating in a
prostate cancer prevention intervention trial. The results from the
various modes of data collected in this study suggest that for a variety
of reasons, some sites may be better suited than others to participate
in the prevention trials of the future.
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The right place.
As previously noted, practice site influenced not only the
facilitation of research (due to the absence or presence of
infrastructure) but also the types of patients that were seen at each
site. This is problematic since research done primarily in university or
teaching centers may result in unintended subject bias due to the
population seeking care there (Carbone et al. 2005). Additionally,
since the opportunity to participate in trials may not be a reality for all,
Azevedo and Payne (2006) have suggested that differential access to
research opportunities due to structural or other barriers may
disparately impact certain populations. The unavoidable reality that
patient pool was influenced by other factors such as the presence or
lack of insurance and unofficial “pre-inclusion” criteria at some sites
warrants further exploration. This is especially important in the face of
impending health insurance reform, since the standard of care in many
medical treatment regimens are the direct result of clinical research.
The reality of unequal access could have implications for many
conditions and is not simply limited to the spectrum of cancer care.
All participants reported limits in access to the resources
necessary to participate in research, even those specifically designated
as research centers. This was reported by key informants during
formal interviews as well as by other members of the research team
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during participant observation. Suaveness and creativity on the part
of the physician/investigators made it possible for the current project
to occur at their facility. Some respondents reported better support
than others and a physician at one private practice site had found a
way to access resources beyond his own in order to expand the types
of services that were available and offer participation in clinical trials to
his patients, despite the lack of his own research infrastructure, as
described in the following response:
There’s a research coordinator at XXX Hospital. We can use her
and that’s another way we can take advantage of (the) XXX IRB
and their research coordinators. If I have to use my
infrastructure, I don’t have anyone in the office so I have to go
through XXX or I have to hire someone. Hiring someone for a
small project is not a good idea. You have to have the
infrastructure, that’s why I think the community guys shy away
from research, there’s too much paperwork to do. It’s a lot of
paperwork to do (11-P_P)
The right time.
Across all sites the common theme noted by all was time,
broadly speaking, and the influence it had on their ability to participate
in research as seen with the following responses:
The time to do it that’s the issue (02-V_NP)
I think their limitation is similar to our limitation in terms of time
(07-P_N)
Don’t underestimate how busy the doctors are (12-S_P)
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Time was seen as both a positive and negative influence on
participation. When trial requirements were in-line or able to be
incorporated into the usual schema of care this was seen as positive
factor making participation more feasible as the following respondent
explains:
It allows me to participate in research that has a translational
bent and also be able to work it into my regular routine of seeing
patients (10-A_P)
However, when time related to fitting a discussion about research into
a time slot that was previously established for a clinical encounter; the
time allotted by administration as dedicated for research (vs. clinical
care); the time required to document research participation or even
the time for a patient to see a research coordinator because they were
present and readily available in the clinic, it was seen more as a
negative factor of influence. Despite the negative time factors noted,
this was not seen as a finite barrier making physicians unwilling to
participate in this and future projects, yet is definitely a factor that
should be considered in future trial design and resource allocation.
The ways in which conflicts for time and space were handled varied in
each of the research sites; however, a consideration of the two
models noted during participant observation may help to lessen the
competition for time and space often reported by these key
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informants, observed in the clinic and noted in prior research, further
reducing this challenge in the future.
A Comparison of Results
When considering the quantitative results for a comparison of
responses from those who are currently involved in the clinical trial
and those that are not, similar responses were noted by both groups.
Reasons for participation in clinical trials included advancing medical
science, expanding available services, providing challenge and variety
and earning extra income noted by participants in both groups. These
results are similar to work by Crosson et al. (2001) who reported
comparable reasons for participation in clinical trials. As would be
expected based on total accrual, there was unequal representation
between groups (participant and non-participant) with a greater
number of participant responses in most categories.
The reasons noted for participating in prevention trials was also
similar (advancing medical science, providing the best possible care,
earning extra income for practice) among the groups. The participants
also mentioned other motives such as providing the best possible care
and access to a novel treatment. In terms of overall participation in
any type of clinical trial, similarities between participants and nonparticipants included the influence of time, cost to individual or
institution, paperwork requirements, staffing, concern for patients
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well-being, and institutional support. Factors reported by participants
but not non-participants also included the influence on the clinical care
process, financial incentives, the introduction of another care provider
or decision maker, and the requirements of the research protocol.
Overall, the groups had more similarities than differences in this area
and there was consistency when triangulating the findings generated
by qualitative and quantitative means. One reason for the similarity in
findings could be that though respondents were not currently
participating in the PCPICT, most had participated in research
previously. It is likely that a disjuncture between the individual
willingness or interest in participating and limitations at the structural
level (due to practice site, medical practice model or lack of
infrastructure or resources) existed, ultimately influencing participation
in the current PCPICT.
The primary hypothesis for this study was that both individual
and structural factors intersect and influence both the willingness and
the ability of the physician/investigator to participate or refer patients
for participation in a PCPICT as shown in Figure 2:
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Figure 2: Proposed Model: Individual and structural factors influencing
physician participation in cancer prevention, intervention clinical trials




Dark blue boxes represent individual factors believed to impact the
physician’s participation in cancer prevention intervention clinical trials
Light blue boxes represent structural factors believed to impact the
physician’s participation in cancer prevention intervention clinical trials

Additionally, it was hypothesized that these factors would vary
based on practice site/area and the interactions will both facilitate and
deter participation in these types of trials.

The results of this study

show that the hypothesis is supported and that both individual and
structural factors intersect, influencing the willingness and ability of
physician/investigators to participate or refer patients for participation
in a PCPICT. Individual factors such as explanatory views on
prevention, notions of risk and uncertainty, shared decision-making
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and duality of roles appear to have a greater influence on the
willingness of physicians to participate while structural factors such as
staffing, other resources and time are more influential in regards to
the ability to participate. Though individual and structural factors did
vary across sites to some degree, there was more heterogeneity
among various physician/investigators than across the different site
types. What was not examined in this project and would be a next
logical step, is to further explore how willingness and ability was
reflected in the actual accrual at the various sites participating in the
PCPICT.
Contributions to Theory
An adaptation of the theory of competing demands that included
a theoretically-grounded exploration of individual provider level factors
(notions of risk and shared decision-making, explanatory views on
prevention, and duality of roles) as well as structural level factors
(practice area and organizational/infrastructural considerations) that
as noted in previous chapters, were shown to be salient in other types
of research, was proposed for this project. Within this framework, I
was able to draw upon both micro and macro level factors of influence
to provide a more holistic understanding of the multitude of individual
and structural variables influencing the physician’s participation in a
PCPICT. Jaen et al. ( 1994) proposed a three-part model to better
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understand the delivery of preventative services in the primary care
setting. Components of the model included the physician, the patient,
and the practice environment. My research expanded this concept via
mixed methods exploration to show that these factors are similarly
influential in the delivery of services associated with participation in a
PCPICT.

Willingness and desire to participate on the part of the

physician was unfortunately not always enough to result in actual
participation since the ability to participate was influenced by
constraints within the practice environment such as competing
demands for time, space and personnel.
As noted previously, Joseph and Dohan (2009) suggested that
enrollment in therapeutic cancer clinical trials is shaped by biomedical
and social factors. Similarly, this research has revealed that these
factors are also influential as physicians consider participation and
enrollment in a PCPICT.

Biomedical factors such as risk perception

and scientific rationale; as well as social factors such as explanatory
views on prevention, concerns for their patient’s well-being, and prior
personal and professional experiences were reported as salient and
influential by participants in this study.

As with the prior research,

the intersection of these individual, social and biomedical (physician
and patient) and structural (practice environment) factors influences
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not only the willingness but the ability of physician/investigators
creating barriers as well as facilitators to participation in a PCPICT.
The factors of influence identified following a review of the
literature and proposed in the original model were supported by the
findings of this research. With the results of this study, a much better
understanding of the intersection of these various factors within this
particular context is now possible. As noted in the results section,
individual factors such as explanatory views on prevention, notions of
risk and uncertainty, shared decision-making and duality of roles
appear to have a greater influence on the willingness of physicians to
participate in a PCPICT. Structural factors such as staffing, access to
other resources and time are more influential in regards to the ability
to participate. This research did not examine how physician
willingness and ability ultimately influenced actual recruitment to the
PCPICT as compared to the project goals. This would be a valuable
consideration and could add overall insight to better understanding the
greater challenge of recruitment to prevention clinical trials within
each of the four contexts. Further examination would also further
delineate if some factors were more influential than others. The
following, revised model (Model 2) demonstrates the interactions of
the various individual and structural factors influencing these
physicians as they function as gatekeepers in access to the PCPICT.
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Figure 3: Revised Model: Individual and structural factors influencing
physician participation in a PCPICT

These factors served as both barriers and facilitators to the
physicians as they considered participation in a PCPICT. The findings
from this project show that factors previously shown to influence
participation in therapeutic clinical trials are influential within the realm
of prevention trials as well. Though all key informants were interested
and willing to participate in the PCPICT due to individual factors, not all
were able to due to the structural constraints of their specific practice
environment. While this project focused on a very specific contextprostate cancer prevention intervention clinical trials- a consideration
of these factors and how they may influence the willingness and ability
of physicians to participate in other types of prevention trials should be
considered by investigators that seek to design this unique and
challenging type of study.

Additional exploration of the intersection of
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factors within each local environment would add additional insight and
investigators designing such projects are encouraged to consider how
the various factors may or may not be relevant depending on their
planned recruitment site (specialty center, academic center, VA
hospital, private practice).
Contributions to Applied Anthropology
This research provides an in‐depth and nuanced understanding
of the individual and structural factors that influence a physician’s
participation (or lack thereof) in a PCPICT. It provides a novel
qualitative component within the context of an ongoing research
project, greatly contributing to the literature and expanding the theory
of competing demands into the field of anthropology and prevention
clinical trials. The results can be applied to inform the design of future
cancer prevention intervention trials which require multi‐site
participation in order to recruit participants reflective of our diverse
population, in a timely and cost-effective manner. This is an area that
to the best of my knowledge has not been previously examined
specifically from an anthropological perspective. Anthropological
contributions in the arenas of cancer control, clinical trials, ethics, and
clinically applied anthropology were considered in the design of the
project; however, a direct comparison of my findings is not possible
due to the lack of analogous prior work. My project expands the
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presence of the anthropological voice, making a contribution to this
broad topical area while using a holistic perspective to address
challenges previously identified by other disciplines. The results of this
research provide novel insight and therefore answer Kleinman’s call
(1985) for medical anthropologists to be able to consider the practical
as well as theoretical aspects of health issues. By asking questions
instead of making judgments as suggested by Barnett (1985), it helps
to better understand why practitioners behave and believe as they do
regarding PCPICTs.

By considering physicians as actors in an

ethnomedical belief system, an analysis of their beliefs and the social
and cultural construction of biomedical disease concepts within a
particular context was possible, as suggested by Chavez et al. (1995).
Contributions to Biomedicine
Kleinman (1985) noted that clinically applied anthropologists are
able to consider the divergent views and visions of patients,
professionals and the community, facilitating perspectivism and
contributing to a broader understanding of all relevant issues. This
project was able to elucidate the views and perspectives of
professionals as they relate to participation in a specific type of clinical
trial. Swanson and Ward (1995) identified the need for studies of
physicians’ attitudes and behaviors regarding clinical trial participation,
and prior to this work there was limited literature specifically exploring
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the role of physicians as gatekeepers in access to PCPICTs. This
project contributed to a gap in the literature and allowed for an indepth examination of the individual experiences of the
physician/investigators within the larger social and economic contexts
in which health care is provided.
Al Refaie (2011) reported that infrastructure, realignment of
incentives and compensation, and improved patient and physician
navigation systems have been suggested by surgeons as ways to
improve their engagement in clinical trials. These are also noted as
important among the participants in this study. Similarly, Meropol et
al. (2007) noted that tailoring approaches to a specific practice area
(academic vs. nonacademic) may help to optimize participation. This
research shows that overall the differing practice areas have
challenges that are more similar than different.
Application to future trials
The analysis of these findings provides the opportunity to make
suggestions that should be considered in the design of future prostate
cancer prevention intervention clinical trials, and may be useful in the
design of other types of prevention trials as well. Additionally, this
research identifies and addresses the invisible barriers (named such
due to the lack of formal evaluation or documentation previously) such
as structural and infrastructural barriers, the identification of which
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was suggested as critically important due to the increasing number of
new chemotherapeutic agents needing evaluation (Dilts and Sandler
2006).
The urology clinic is a fast paced and ever changing
environment. The clinical encounter is limited by both time and space
resources, as observed during participant observation and reported by
participants. Dedicated infrastructural support to provide for both may
allow for the successful facilitation of future prostate cancer prevention
research projects. A closer examination of the ways in which patients
are identified and visits are scheduled may have a positive impact on
future recruitment as well as result in a more efficient use of limited
resources.

The patient population at each clinical site influences the

ability to meet recruitment goals, creating yet another structural
challenge if there is a disjuncture between the two and as Sharp and
Pentz (2004) note, the enrollment of adequate numbers of patients,
within a reasonable time period is particularly critical in
chemoprevention trials.

An additional observation is that some of the

types of sites where this project is taking place may not be ideal and
should be reconsidered for future endeavors. Practitioners working in
specialty and academic centers typically have a relatively small volume
of low risk (cancer free) patients which is the population best served
by a prostate cancer prevention intervention trial. Since the VA
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hospitals function more as a primary care facility, there are a
significantly greater proportion of potential patients available at these
sites. Perhaps the best referral source is from within the community,
urologists who are working to provide the “bread and butter” urology
care to their patients over a life time and have an established
relationship well before cancer diagnosis. Each of these sites has
infrastructural challenges as noted previously and they must be
considered within the greater health care structure as it continues to
evolve. Finding ways to bridge paths of partnership with the
community is highly recommended for the success of future cancer
prevention studies.

A summary of the main points from the key

informants which should be considered by any investigator in the grant
writing phase of a project follows:
1.)

Future studies must make biological sense and be for a
condition where the scientific rationale is clear and no
ambiguity regarding the significance of treatment exists

2.)

Protocol requirements must be closely in line with usual
practice for the condition under study to minimize patient
and physician burden

3.)

Dedicated research time and personnel is highly desirable

4.)

Partnerships with “friendly” community physicians must be
forged to extend availability to a wider range of patients

5.)

A collaborative project, available at the site of usual care
delivery when possible with the urologist remaining key
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decision maker (in partnership with patient and research
team) is highly desirable
6.)

Trial must utilize existing resources or provide for
additional so that venture is at least cost neutral for the
institutions involved

As previously noted, though willing to participate, those working
in specialty and academic centers simply do not have access to the
“healthy” and cancer free population that is needed for such a study.
Finding ways to build relationships with community physicians where
they are not threatened by collective work is imperative since these
settings have the potential to recruit a much larger and more
representative sample (Somkin et al. 2005).

This will not only assure

the best use of limited fiscal resources but also facilitate the
recruitment of a wider and more diverse population, representative of
those impacted by the burden of prostate cancer. As well, additional
research should further explore more specifically what financial
incentives would be considered necessary for those in private or
community practice to participate in such a study as well as what
infrastructure is or may be available to support their participation in
prostate cancer prevention clinical trials.
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Limitations
As with all research, this study is not without its limitations.
What follows is a summary of obstacles as well as a brief discussion
regarding non-participants.
1) This study included interviews with twelve
physician/investigators currently participating or asked to
participate in a prostate cancer prevention clinical trial as the
primary research participants. Though the sample size was
sufficient for this dissertation, it is not meant to generalize to all
physician/investigators or even to all types of prevention
intervention clinical trials, instead it was meant to describe the
population within a particular context and provide implications
and recommendations for future research.
2) Though some insight into possible reasons for non-participation
can be gleaned from the responses provided by those who did
participate, their responses should not be considered
generalizable or reflective of the opinions of all non-participants.
Soliciting this voice is incredibly important for the success of
future prostate cancer prevention research projects.
3) Due to a poor response from community physicians, the sample
size of “non-participants” from the private practice setting was
limited. Despite the request to participate from a wellrespected gatekeeper within this community, only 4 nonparticipant surveys and no interviews were completed. Though
response was limited, those that did participate in the interviews
and/or complete the surveys did provide some important insight
that should be examined in future projects.
4) Non-random sampling was the primary means to recruit
participants. The potential for bias in participant response exists
due to the fact that all interviewees had a previously established
working relationship with me prior to the time of data collection.
Due to the specific nature of this project, this sample was
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considered best qualified to address the research questions.
Additionally, this association was thought to positively influence
the willingness of the key informants to talk with me, as
evidenced by the three interviews with non-participants that I
was unable to complete. No physicians with whom a prior
relationship did not exist were willing to be interviewed.
5) All key informants in this project were male and I am female.
While this was unavoidable, it is unclear how this may have
influenced the willingness to participate or the responses
provided.
Certainly the most notably missing voice from this project was
that of the physicians who did not agree to participate in the
interviews or even complete the survey. Unfortunately due to a
change in dynamics in the large, local urology group, I was unable to
administer the survey in person as originally planned. The use of the
modification of the Dillman Total Design Survey Method, using the
letter/survey packet and a follow-up postcard provided little additional
response (n=2).

In person distribution may have increased the total

number of surveys completed but it is unclear how it responses may
have added to the depth of data collected since as noted in chapter
four, little variance was noted between participants and nonparticipants, utilizing this methodology.
Reflecting on Familiarity in the Research Setting
Concerns about the familiarity of researchers in the research
setting have been noted and include a lack of objectivity and possible
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role confusion (Hanson 1994). Arguments have also been made that
acting in familiar role as well as that of researcher may compromise
objectivity (DiCicco-Bloom and Crabtree 2006). Additionally, the
concern that motivates the research and potential to focus attention
on a specific element or issue has been described as both a potential
weakness and a strength when functioning as an ”insider” (Hanson
1994:941) and Preston (1997) suggested that carrying out
ethnography in a familiar culture has the advantages of access and
familiarity of the setting. There is clearly not a consensus on this
issue.
DiCicco-Bloom and Crabtree (2006) noted that establishing trust
and finding out new perspectives is best done by reducing the
hierarchy between informants and researchers therefore, it could be
argued that this may be facilitated more easily in a research setting
with some level of familiarity to the researcher. Hanson (1994) noted
several positive aspects of familiarity including subjective knowledge
and awareness of the cultural norms and values of the health care
professionals involved in the study and suggest these strengths may
be particularly salient when using qualitative methods. Researcher
reflexivity is always essential to acknowledge power differentials and
integrate reciprocity into the creation of new knowledge (DiCicco-
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Bloom and Crabtree 2006) and this was of particular importance when
“studying up” as this project required.
When considering my own agency and the possible
constraints of working in a familiar setting, reflexivity, or the
awareness that the production as well as distribution of knowledge is a
social action (Hahn and Kleinman 1983) was critical during the
completion of this dissertation project.

While developing the study,

familiarity in the research setting and with the challenges facing the
project allowed me to truly apply anthropology to design a project that
would provide a broader and more holistic perspective of the issues;
providing data from the individual actors and within their local context
that would not have been obtained without a mixed methods
approach. Perspectivism and the ability to mediate between varying
viewpoints on the same phenomenon was a valuable skill in the
anthropologist’s toolkit that proved absolutely useful while arranging
interviews and site visits and completing my work in the field.
Conducting the participant observation was the part of the research
process where reflexivity was perhaps the most important. I had to
constantly interpret my findings based on observations, acknowledge
power differentials and integrate reciprocity; however, the sum of my
prior experiences as a clinician, research coordinator and project
manager could not be completely avoided.
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Once the actual data was collected, I was pleasantly surprised to
experience an ease in separation between the professional experience
prior to data collection, my role as scientist during data collection and
the focus required to analyze and elicit the details necessary to answer
the research questions.

A keen awareness of my differing role and a

more analytic focus during my time in the field while maintaining a
collaborative approach as the research questions are addressed was of
critical importance. The data that was collected was sorted and
analyzed from my perspective, based on the totality of my experiences
as is inherent to this type of research.

Anthropological research is an

interactive endeavor and this project resulted in exchanges between
the key informants and researcher that were more rich and detailed
than I could have hoped for. I am not sure that this result would have
been the same, were I not considered to some degree, an insider. In
this particular case, I believe that there were more strengths than
weaknesses with familiarity with the research setting as I was able to
build from existing relationships to focus on the specific details needed
to address the study objectives and research questions. Buy-in to the
project was not problematic and participants were more than willing to
share their time and perspective as the key informants had the same
vested interest in the parent trial’s success as I did.
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Opportunities
The findings from this project offer several prospects to expand
into other arenas for further research and provide suggestions for
training and education related to clinical trials. These include, but are
certainly not limited to contributions to other arenas of prevention
research, development of improved patient-trial identification systems,
and implications for physician education.
Prevention research.
Though this research focused on the specific context of a
prostate cancer prevention intervention clinical trial, the findings are
likely applicable to challenges observed in other areas of prevention
research. Funding agencies, sponsors and investigators involved in
the design and funding of such trials may benefit from a review of the
six main findings reported previously, for applicability to their own
local context.
Clinical trial alert systems.
With advances in technology and the increasing use of the
electronic medical record (EMR), collaborations between researchers,
information technology (IT) professionals and clinicians may increase
the use of CTAs to improve the ease with which participants for all
clinical trial types (therapeutic as well as prevention) are identified at
various medical settings. Ultimately this could improve resource
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utilization, minimize physician burden, boost enrollment and speed the
rate at which new discoveries are tested for efficacy via clinical trials.
Implications for physician education.
Participants in this study had not received specific training or
education related to clinical trials as part of their medical school
curriculum. With few exceptions, most had not had any such training
during their residency or surgical training either. Considering the
importance of clinical trials to continuously improve the provision of
medical care, providing an early introduction of the basic concepts,
and laying the foundation of knowledge regarding clinical trials in
medical school may be an effective means to improve understanding
of physicians, ultimately improving future involvement in trials. This
exposure could occur via workshops provided within the medical school
curriculum or perhaps at conferences and other educational venues.
Dissemination and Future Directions
The dissemination of these findings is crucial to maximize the
application as I intended at the outset of project design. This can
occur through various channels including the preparation of an
executive summary of findings, publication in peer-reviewed journals
and presentation at scholarly meetings. An executive summary may
be most useful to physicians already participating or interested in
participating in prevention clinical trials as well as investigators
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involved in trial design. Publication in peer-reviewed journals could
cater to two audiences, those more in the biomedical arena who may
be interested in the application of the findings (such as trial sponsors,
funding agencies and physician investigators) as well as to
anthropological or other social science journals where the theoretical
contributions may be more valued. Participation in scholarly meetings
in both arenas could also increase the dissemination of results, thereby
reaching a much broader audience.
On a more personal level, I envision future projects at several
different levels. The “work” of research and how in reality it played
out, varied greatly in the different spaces I visited. The physician
clearly serves as a gatekeeper, often providing direct access to the
potential research participant; however, a host of support is occurring
in the backstage. This support varied greatly at each type of research
site and additional research could explore in greater detail the valuable
work of nurses, clinical trial coordinators and regulatory staff without
which, the true work of research would not occur.
An additional expansion from this project is to attempt to
capture the experiences of those physicians who are non-participants
in research, either due to their current medical practice model or other
barriers which have not yet been identified.

I believe this work would

be the most relevant in the private, primary care and specialty setting,
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where potential prevention research patients are seen prior to the
development of cancer and other such conditions. Relationships with
“friendly” physicians in private practice was suggested by those at
specialty centers as a way to increase participation in prevention trials
so this could provide timely insight into the world of “non-participants”
and specifically explore their willingness and ability to participate or
refer patients for participation. Access would remain the largest
challenge since just as was observed in the parent PCPICT, this group
was challenging to reach in my study as well.
A final area of exploration would be to more closely examine the
process of research within a particular setting to better understand the
structural factors that influence a physician’s involvement in research.
This is critical because support such as infrastructure and staffing
ultimately impacts patient recruitment and the attainment of accrual
goals to all types of clinical trials. Findings could contribute to an
improvement in organizational support impacting the recruitment to
and completion of prevention trials in a more timely and cost-effective
manner.

This may be most relevant in the VA setting, where some

level of research infrastructure is already in place and a wide range of
patients are seen for their primary medical care.
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Conclusion
Using an applied anthropological perspective I examined the
individual and structural factors influencing physician/investigators in
their role as gatekeeper in access to a PCPICT. This research extends
work by Probstfield and Frye (2011) to show that physicians also serve
as gatekeepers for participation in a PCPICT, and provides valuable
insights and information related to the reality that is experienced
within each local context where study recruitment and participation
take place. The results fill a void, building from prior work where
Ruffin IV and Baron (2000) recommended further research to not only
better understand barriers unique to prevention trials but to identify
successful strategies to overcome them and used ethnographic
methods to specifically explore the individual and structural factors of
influence impacting physician/investigators in their role as
gatekeepers. I was able to provide applied recommendations for
researchers considering the design of future cancer prevention
intervention projects as well as identify areas where additional
research would be beneficial.
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Appendix A. Recruitment Letter (current trial participants)
Month TBD, 2012
Dear Dr. _____________,
I am contacting you because of your involvement in the prostate
cancer prevention trial: Phase II, Randomized, Double-blind, Multicentered Study of Polyphenon E in Men with High-grade Prostatic
Intraepithelial Neoplasia (HGPIN) and Atypical Small Acinar
Proliferation (ASAP).
I am a student at the University of South Florida, interested in
exploring the factors that influence physician’s participation in a
prostate cancer prevention intervention clinical trial and
identifying ways to improve collaboration between researchers and
physicians, thus improving the success of future projects.
This letter is to invite you to participate in an additional research
study: Physicians as Gatekeepers: Applying Anthropology for a New
Perspective (eIRB#7442) which is being conducted in partial fulfillment
of the requirements for the degree of Doctor of Philosophy and
approved by the University of South Florida Institutional Review Board.
The study consists of an interview and a brief paper or computer based
survey. Both are designed to gain a better understanding of the
factors that have influenced your participation in this project. The
interview will be conducted at your convenience, off site and on your
own time as may be required by your institutional guidelines.
Your expertise is very important and the results will inform my
dissertation research as well as the design of future cancer prevention
studies. In total, participation will take approximately ninety minutes
of your time. To schedule a time for this interview, please contact me
at 813-745-6046 or 813-507-7912. I look forward to speaking with
you soon.
Kind regards,
Theresa Crocker, MS, RD
Doctoral Candidate, Department of Anthropology
University of South Florida
tomaszts@mail.usf.edu
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Appendix B. Recruitment Letter (invited or inquired)
Month TBD, 2012
Dear Dr. _____________,
I am contacting you because of your invitation to or prior interest in
participating in the prostate cancer prevention trial: Phase II,
Randomized, Double-blind, Multi-centered Study of Polyphenon E in
Men with High-grade Prostatic Intraepithelial Neoplasia (HGPIN) and
Atypical Small Acinar Proliferation (ASAP).
I am a student at the University of South Florida, interested in
exploring the factors that influence physician’s participation this
prostate cancer prevention intervention clinical trial and
identifying ways to improve collaboration between researchers and
physicians, thus improving the success of future projects.
This letter is to invite you to participate in an additional research
study: Physicians as Gatekeepers: Applying Anthropology for a New
Perspective (eIRB#7442) which is being conducted in partial fulfillment
of the requirements for the degree of Doctor of Philosophy and
approved by the University of South Florida Institutional Review Board.
The first part of this study consists of a brief paper or computer based
survey which should take no more than thirty minutes to complete.
The completion of this survey will serve as affirmation of your
agreement to participate in this portion of the project. The survey can
be completed at your convenience so as not to interfere with your
usual work duties. Additionally, you will have the opportunity to
participate in a more in depth, interview at a later time, which will take
approximately sixty minutes of your time. The interview will be
conducted at your convenience, off site and on your own time as may
be required by your institutional guidelines. Both are designed to gain
a better understanding of the factors that have influenced your
participation in this project.
Your expertise is very important. To schedule a time for the interview,
please contact me at 813-745-6046 or 813-507-7912. I look forward
to speaking with you soon.
Kind regards,
Theresa Crocker, MS, RD
Doctoral Candidate, Department of Anthropology
University of South Florida /tomaszts@mail.usf.edu
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Appendix C. Interview Guide
Participant ID (Interview number-site type-P/NP): _________
Date: ________
“Thank you for taking the time to meet with me today. I know your
schedule is busy and I really appreciate your willingness to share your
expertise and experiences with me. Please keep in mind that there
are no correct answers to these questions. I am truly interested in
your responses to inform our current project and those in the future.
Every part of this discussion is considered confidential. Your responses
will be identified by using a unique code, not your name or any other
identifying information. You can stop the interview at any time and
there is no penalty if you stop taking part in this study. Do you have
any questions?”
1. a. Can you tell me a little about the organization that you work for?
b. Can you tell me about how the organizational infrastructure
facilitates participation in research/clinical trials?
c. Can you tell me about how the organizational infrastructure
constrains participation in research/clinical trials?
2. a. When considering how the organizational infrastructure may
Facilitate participation, can you talk about what differences may
exist, depending on the sponsor of the trial? [probe: Federal
government, State University, Community Hospital, Private
Industry such as a pharmaceutical company]
b. When considering how the organizational infrastructure may
constrain participation, can you talk about what differences may
exist, depending on the sponsor of the trial? [probe: Federal
government, State University, Community Hospital, Private
Industry such as a pharmaceutical company]
c. How are some sponsors preferred over others?
3. a. Describe how have you participated in research at other
institutions that you may have worked.
b. Can you tell me about things that made it similar to where you
currently work? [probe: are there things that made it
better/worse, easier/more challenging?]
c. Can you tell me about things that made it different from where
you currently work? [probe: are there things that made it
better/worse, easier/more challenging?]
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4. Are the trials that are available to you appropriate for the
population that you serve?
b. If so, how is this so?
c. If not, how is this so?
5. Please tell me your thoughts about sending your patients to another
facility to participate in a cancer prevention intervention trial.
a. Would this be acceptable to you [why or why not]?
b. Would a preferred alternative be study staff coming to your
office or workplace?
c. How you feel about receiving support to train your staff so your
patients could participate but stay at your office/workplace?
6. Tell me about your experience enrolling a patient into a clinical trial.
a. In your experience, to what extent is it disruptive to do this at
their usual site of healthcare delivery?
b. How disruptive is it to refer them elsewhere?
7. a. Is there any concern of financial loss if patients move care to
participate in a prevention, intervention trial?
b. How salient is this concern?
c. Are there ways this can be mediated so that more people can be
involved in cancer prevention trials?
8. From the perspective of your institution, what would help to
increase the likelihood of participation in cancer prevention clinical
trials in the future? [probe: compensation, protected time, staff
training or dedicated study staff, less paperwork, simplified approval
process, personal interest in the trial]
So far we have talked about organizational or structural (bigger
picture) influences, now I am interested more in individual or personal
factors (those factors that are closer to home so to speak).
9. What factors are most important to you, when considering whether
or not to participate in a cancer prevention intervention clinical trial?
[probe: personal interest, participation in the trial design, authorship,
meeting the needs of the community that you serve, other]
10. At what phase in the research process do you prefer to become
involved? [probe: design/initiation/training, analysis, results, other]
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11. From your perspective, what would help to increase the likelihood
of participation in cancer prevention clinical trials in the future?
[probe: compensation, protected time, staff training or dedicated
study staff, less paperwork, simplified approval process, personal
interest in the trial]
12. a. Can you tell me about your general philosophy towards
preventive medicine?
b. Is this similar to what you learned in your training or different?
c. Has this changed due to your professional experience?
d. Has this changed due to your personal experience?
13. How does your philosophy towards preventive medicine influence
your willingness to participate in a cancer prevention intervention trial?
14. Tell me about how participation in a cancer prevention trial
impacts the physician-patient relationship? [probe: neutral, positive or
negative?]
15. Thinking back to times when you have decided to offer
participation in a clinical trial,
a. How has the possibility of uncertainty in the plan of care associated
with participation in the trial played a role in your decision to offer the
trial? If so, can you tell me more about this?
b. How has the possibility of uncertainty in the outcome associated
with participation in the trial, played a role in your decision to offer the
trial? Can you tell me more about this?
16. How do your ethical responsibilities as a physician change when a
patient participates in a cancer prevention intervention trial?
17. Prior research suggests a possible conflict when a provider plays
the dual role of advocate for the patient and for the research.
a. Have you ever experienced this?
b. Can you tell me about what changes when patient becomes
research participant?
c. Can you tell me about what changes when the study is done and the
research participant becomes the patient again?
In this time together we have discussed both organizational/structural
and individual factors that may influence your willingness and ability to
participate in a cancer prevention intervention trial.
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18. Is there anything else that we haven’t discussed that you feel is
important for me to know about?
19. Are there any other factors that influence your willingness or
ability to participate in cancer prevention intervention trials?
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Appendix D. Content Matrix
Explore and document individual provider level factors (such as
notions of risk and shared decision-making, explanatory views on
prevention, and duality of roles) that influence participation in a cancer
prevention intervention clinical trial.
5. Please tell me your thoughts about sending your patients to another
facility to participate in a cancer prevention intervention trial.
a. Would this be acceptable to you [why or why not]?
b. Would a preferred alternative be study staff coming to your
office or workplace?
c. How you feel about receiving support to train your staff so your
patients could participate but stay at your office/workplace?
9. What factors are most important to you, when considering whether
or not to participate in a cancer prevention intervention clinical trial?
[probe: personal interest, participation in the trial design, authorship,
meeting the needs of the community that you serve, other]
12. a. Can you tell me about your general philosophy towards
preventive medicine?
b. Is this similar to what you learned in your training or different?
c. Has this changed due to your professional experience?
d. Has this changed due to your personal experience?
13. How does your philosophy towards preventive medicine influence
your willingness to participate in a cancer prevention intervention trial?
14. Tell me about how participation in a cancer prevention trial
impacts the physician-patient relationship? [probe: neutral, positive or
negative?]
15. Thinking back to times when you have decided to offer
participation in a clinical trial,
a. How has the possibility of uncertainty in the plan of care associated
with participation in the trial played a role in your decision to offer the
trial? If so, can you tell me more about this?
b. How has the possibility of uncertainty in the outcome associated
with participation in the trial, played a role in your decision to offer the
trial? Can you tell me more about this?
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16. How do your ethical responsibilities as a physician change when a
patient participates in a cancer prevention intervention trial?
17. Prior research suggests a possible conflict when a provider plays
the dual role of advocate for the patient and for the research.
a. Have you ever experienced this?
b. Can you tell me about what changes when patient becomes
research participant?
c. Can you tell me about what changes when the study is done and the
research participant becomes the patient again?
Explore and document structural (organizational and infrastructural)
considerations that influence participation in a prostate cancer
prevention intervention clinical trial (with a comparison of factors
across types of sites).
2. a. When considering how the organizational infrastructure may
facilitate participation, can you talk about what differences may
exist, depending on the sponsor of the trial? [probe: Federal
government, State University, Community Hospital, Private
Industry such as a pharmaceutical company]
b. When considering how the organizational infrastructure may
constrain participation, can you talk about what differences may
exist, depending on the sponsor of the trial? [probe: Federal
government, State University, Community Hospital, Private
Industry such as a pharmaceutical company]
c. How are some sponsors preferred over others?
7. a. Is there any concern of financial loss if patients move care to
participate in a prevention, intervention trial?
b. How salient is this concern?
c. Are there ways this can be mediated so that more people can be
involved in cancer prevention trials?
8. From the perspective of your institution, what would help to
increase the likelihood of participation in cancer prevention clinical
trials in the future? [probe: compensation, protected time, staff
training or dedicated study staff, less paperwork, simplified approval
process, personal interest in the trial]
10. At what phase in the research process do you prefer to become
involved? [probe: design/initiation/training, analysis, results, other]
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11. From your perspective, what would help to increase the likelihood
of participation in cancer prevention clinical trials in the future?
[probe: compensation, protected time, staff training or dedicated
study staff, less paperwork, simplified approval process, personal
interest in the trial]
Consider how practice area (specialty centers, VA medical centers,
academic centers and community offices) may impact the feasibility of
participating in a prostate cancer prevention intervention trial.
1. a. Can you tell me a little about the organization that you work for?
b. Can you tell me about how the organizational infrastructure
facilitates participation in research/clinical trials?
c. Can you tell me about how the organizational infrastructure
constrains participation in research/clinical trials?
3. a. Describe how have you participated in research at other
institutions that you may have worked.
b. Can you tell me about things that made it similar to where you
currently work? [probe: are there things that made it
better/worse, easier/more challenging?]
c. Can you tell me about things that made it different from where
you currently work? [probe: are there things that made it
better/worse, easier/more challenging?]
4. Are the trials that are available to you appropriate for the
population that you serve?
b. If so, how is this so?
c. If not, how is this so?
6. Tell me about your experience enrolling a patient into a clinical trial.
a. In your experience, to what extent is it disruptive to do this at
their usual site of healthcare delivery?
b. How disruptive is it to refer them elsewhere?
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Appendix E. Participant Survey (current trial participants)

PARTICIPANT QUESTIONNAIRE
Thank you for agreeing to participate in this project. This portion
contains some general questions to provide a better idea of who we
are working with and what your general research experience has been.
Please do not write any personal information (e.g. your name) on this
form.
1. Please choose the site(s) that most closely represents your
practice location:
[
] Academic Center/Teaching center
[
] Specialty Center, Please specify type ________________
[
] Private practice
[
] Veterans Affairs Medical Center
[
] Other (please specify) _______________
2. How many years have you been working at this location?
[___|____]
3. How many years have you been in practice?

[___|____]

4. What is your area of medical specialty?
____________________
5. In what country did your primary medical training occur?
____________________
6. In your practice, what has been your involvement in any type of
clinical trial? Check all that apply.
[
] I have had patients inquire about clinical trials (therapeutic
or prevention).
[
] I have recommended patients participate in a clinical trial
(therapeutic or prevention) that I administer.
[
] I have recommended patients participate in a clinical trial
(therapeutic or prevention) administered by others.
[
] I have participated in the design and implementation of a
clinical trial (therapeutic or prevention).
[
] I have had patients enroll at a clinical trial (therapeutic or
prevention) at another location because it was not locally
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available.
[
] I have participated in a clinical trial (therapeutic or
prevention) in other ways. _________________________
[
] I have never been involved in a clinical (therapeutic or
prevention) trial.
7. How many clinical trials (therapeutic or prevention) have you
participated in as an investigator or other study personnel?
____________________
If none, please skip to question 14.
If 1 or more, please continue to question 8.
8. What are your reasons for involvement in clinical trials? Check
all that apply.
[
[
[
[
[
[
[

]
]
]
]
]
]
]

Advancing Medical Science
Providing access to a novel treatment
To expand available services
Challenge
Variety
To earn extra income for my practice
Other _____________________

9. What is your main reason for participating in clinical trials?
___________________________________________________
___________________________________________________
___________________________________________________
10.
How many prevention trials have you participated in as
an investigator or other study personnel?
____________________
11.

What are the reasons for involvement in prevention

clinical trials? Check all that apply.
[
[
[
[
[
[

]
]
]
]
]
]

Advancing Medical Science
Providing the best possible care
Providing access to a novel treatment
To expand available services
To earn extra income for my practice
Other _____________________
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12.

What is your main reason for participating in prevention

clinical trials?
___________________________________________________
___________________________________________________
___________________________________________________
___________________________________________________

13.

Which of the following factors influence your decision to

participate in any type of clinical trial? Check all that apply.
[
[
[
[
[
[
[
[
[
[
[
[
[

]
]
]
]
]
]
]
]
]
]
]
]
]

Influence on clinical care process
Time
Financial Incentives
Cost to you/your institution
Paperwork requirements
Training and education
Staffing
Concern for your patients well-being
Impact on primary role
Introduction of another care provider or decision maker
Requirements of the research protocol
Institutional support
Other _____________________

After completion, please skip to question 16.
14.

What are your reasons for not participating in clinical trials

(therapeutic or prevention)?
Check all that apply.
[
[
[
[
[

]
]
]
]
]

Influence on clinical care process
Time
Financial Incentives
Cost to you/your institution
Paperwork requirements
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[
[
[
[
[
[
[
[

]
]
]
]
]
]
]
]

15.

Training and education
Staffing
Concern for your patients well-being
Impact on primary role
Introduction of another care provider or decision maker
Requirements of the research protocol
Institutional support
Other _____________________
What is your main reason for not participating in clinical

trials (therapeutic or prevention)?
___________________________________________________
___________________________________________________
___________________________________________________
___________________________________________________
16.
[
[

What is your gender?
] Male
] Female

17.
[
[
[
[
[
[

]
]
]
]
]
]

What is your age?
20-29
30-39
40-49
50-59
60-69
70 years or older

Note: Please be sure to answer both question numbers
18& 19 about your ethnicity and race.
18.
[
[

]
]

How would you describe your ethnicity?
1. Hispanic or Latino
2. Not Hispanic or Latino

19.
How would you describe your race?
Select all that apply.
[
] 1. American Indian or Alaska Native
[
] 2. Asian
[
] 3. Black or African American
[
] 4. Native Hawaiian or Other Pacific Islander
[
] 5. White
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[
[

] 6. Other (please specify) _______________
] 7. More than one race (mark all that apply)

Thank you for answering these questions
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Appendix F. Participant Survey (invited or inquired)

PARTICIPANT QUESTIONNAIRE
Thank you for agreeing to participate in this project. This survey
contains some general questions to provide a better idea of who we
are working with and what your general research experience has been.
Please do not write any personal information (e.g. your name) on this
form.
1. Please choose the site(s) that most closely represents your
practice location:
[
] Academic Center/Teaching center
[
] Specialty Center, Please specify type ________________
[
] Private practice
[
] Veterans Affairs Medical Center
[
] Other (please specify) _______________
2. How many years have you been working at this location?
[___|____]
3. How many years have you been in practice?

[___|____]

4. What is your area of medical specialty?
____________________
5. In what country did your primary medical training occur?
____________________
6. In your practice, what has been your involvement in any type of
clinical trial? Check all that apply.
[
] I have had patients inquire about clinical trials (therapeutic
or prevention).
[
] I have recommended patients participate in a clinical trial
(therapeutic or prevention) that I administer.
[
] I have recommended patients participate in a clinical trial
(therapeutic or prevention) administered by others.
[
] I have participated in the design and implementation of a
clinical trial (therapeutic or prevention).
[
] I have had patients enroll at a clinical trial (therapeutic or
prevention) at another location because it was not locally
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available.
[
] I have participated in a clinical trial (therapeutic or
prevention) in other ways.
_________________________
[
] I have never been involved in a clinical trial (therapeutic or
prevention).
7. How many clinical trials (therapeutic or prevention) have you
participated in as an investigator or other study personnel?
____________________
If none, please skip to question 14.
If 1 or more, please continue to question 8.
8. What are your reasons for involvement in clinical trials? Check
all that apply.
[
[
[
[
[
[
[

]
]
]
]
]
]
]

Advancing Medical Science
Providing access to a novel treatment
To expand available services
Challenge
Variety
To earn extra income for my practice
Other _____________________

9. What is your main reason for participating in clinical trials?
___________________________________________________
___________________________________________________
___________________________________________________
___________________________________________________
10.
How many prevention trials have you participated in as
an investigator or other study personnel?
____________________
11.

What are the reasons for involvement in prevention

clinical trials? Check all that apply.
[
[
[

] Advancing Medical Science
] Providing the best possible care
] Providing access to a novel treatment
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[
[
[

] To expand available services
] To earn extra income for my practice
] Other _____________________

12.

What is your main reason for participating in prevention

clinical trials?
___________________________________________________
___________________________________________________
__________________________________________________
___________________________________________________
13.

Which of the following factors influence your decision to

participate in any type of clinical trial?
[
[
[
[
[
[
[
[
[
[
[
[
[

]
]
]
]
]
]
]
]
]
]
]
]
]

Check all that apply.

Influence on clinical care process
Time
Financial Incentives
Cost to you/your institution
Paperwork requirements
Training and education
Staffing
Concern for your patients well-being
Impact on primary role
Introduction of another care provider or decision maker
Requirements of the research protocol
Institutional support
Other _____________________

After completion, please skip to question 16.
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14.

What are your reasons for not participating in clinical trials

(therapeutic or prevention)?
Check all that apply.
[
[
[
[
[
[
[
[
[
[
[
[
[

]
]
]
]
]
]
]
]
]
]
]
]
]

15.

Influence on clinical care process
Time
Financial Incentives
Cost to you/your institution
Paperwork requirements
Training and education
Staffing
Concern for your patients well-being
Impact on primary role
Introduction of another care provider or decision maker
Requirements of the research protocol
Institutional support
Other _____________________
What is your main reason for not participating in clinical

trials?
___________________________________________________
___________________________________________________
___________________________________________________
___________________________________________________
16.
[
[

What is your gender?
] Male
] Female

17.
[
[
[
[
[
[

]
]
]
]
]
]

What is your age?
20-29
30-39
40-49
50-59
60-69
70 years or older

Note: Please be sure to answer both question numbers
18& 19 about your ethnicity and race.
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18.
[
[

How would you describe your ethnicity?
] 1. Hispanic or Latino
] 2. Not Hispanic or Latino

19.
How would you describe your race?
Select all that apply.
[
] 1. American Indian or Alaska Native
[
] 2. Asian
[
] 3. Black or African American
[
] 4. Native Hawaiian or Other Pacific Islander
[
] 5. White
[
] 6. Other (please specify) _______________
[
] 7. More than one race (mark all that apply)
20.
If you would be interested in providing additional
information related to your experiences
with clinical trials, please provide the following contact
information:
Name: _____________________________
Contact number: _____________________
Best time to contact: _________________
Email address: _______________________
You will be contacted by the researcher to schedule a mutually
convenient time to meet.
Please note this information will be used for contact purposes
only and will not be linked in any way to your responses.
Thank you for answering these questions
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Appendix G. Observational Checklist
Research Site:
Date:
Time:
Y/N
Use of Clinical
Trial Alert System
Dedicated
research Staff

Observed

Not Observed

Consideration of
patient for
participation in
research study by
physician
Consideration of
patient for
participation in
research study by
other staff
Communication
between staff
related to
eligibility to
participate in a
trial
Definitive plans
to present a
clinical trial to a
patient
Comments:
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Appendix H. IRB Approval Letter
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